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The first α-boryl ether molecular scaffold for the release of alcohols, aldehydes, and 
ketones in the presence of H2O2 is described. Utilizing novel chemistry that gives access to α-
hydroxy boronates as well as methods for their successive etherification and acetalization, 
alcohols, aldehydes, and ketones can be released in vivo in the presence of exogenous and 
endogenous H2O2.   
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v 
The synthesis of potent simplified analogues of Bistramide A, the primary cellular receptor 
for actin and a potent cytotoxin, have been synthesized in 9 steps, an improvement over the 
previous total synthesis of Bistramide A (14 steps).  The key step in the synthesis was 
accomplished using a one pot hetero diels-alder reaction (HDA), 2,3-Dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) oxidation, and an acid mediated cyclization.  
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1.0  THE CHEMISTRY OF BORONATE ESTER AND THEIR APPLICATIONS AS 
OXIDATIVE TRIGGERS FOR H2O2  
Boronate esters have emerged as a unique class of compounds that have shown great utility as a 
tool for synthetic organic chemists and medicinal chemists. The generic structure of boronate 
esters and their derivatives is presented in Figure 1.1 
Historically, this functional group has seen use throughout organic chemistry as a substrate 
for the Pd-catalyzed Suzuki coupling reaction.1  In recent years, boron and subsequently boronate 
esters have become useful diagnostic tools to probe H2O2 in living systems as well as triggers for 
the release of small molecules in living systems that are undergoing overproduction of reactive 
oxygen species (ROS).2 This chapter will introduce the concept of self-immolative linkers, the 
chemistry of boron, and research done on the use of boronate esters as biorthogonal probes for 
H2O2. Additionally, pharmaceutical compounds containing boron will be discussed to demonstrate 
the feasibility of boronate esters as prodrugs. 
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Figure 1.1 Commonly seen organoboron derivatives 
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1.1 SELF-IMMOLATIVE-LINKERS: DESIGN FOR ALCOHOLS, AMINES, AND 
LACTONES 
 Oftentimes, the release of a small molecule in response to specific stimuli in 
biological and environmental systems is desired for the development of targeted 
therapeutic agents and chemoselective small molecule sensors.  An attractive solution is to 
utilize self-immolative linkers that only undergo spontaneous release of the desired cargo in 
the presence of the appropriate stimulus. Small molecules can be designed that contain: 1) a 
targeting group that promotes cellular localization, 2) an inactive version of the desired cargo, 
3) a cleavable group (trigger) that will react under the desired conditions leading to cargo 
release (Scheme 1.1).3 Activation of the trigger generates an intermediate that spontaneously 
decomposes, leading to release of the target molecule.
Self-immolative small molecules rely on several different mechanisms, many of which are 
summarized in Scheme 1.2. 
Scheme 1.1 Small molecule self-immolative linker design 
3 
1.1.1 Cyclization-based self-immolative linkers 
Several self-immolative linkers rely on a cyclization-based approach in which a 
nucleophile is masked until it is in the presence of a specific stimulus. Once the nucleophile is 
unmasked by the stimulus, spontaneous cyclization occurs to release the cargo (Scheme 1.3).  
Typically, the nucleophile is either a free amine or alcohol and the electrophile is a carbonate, 
ester, or amide. 
Scheme 1.2  Mechanisms for self-immolative linkers 
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One of the primary methods to release cargo is via intramolecular lactonization. A classic 
example of a lactonization prodrug system is the tri-methyl lock (TML) approach.4 The TML 
approach utilizes the Thorpe-Ingold effect to enhance the rate of cyclization with the addition of 
geminal methyl groups (Scheme 1.4).5   
The TML scaffold works by forcing the substrate into a conformation that very closely 
resembles the transition state of the cyclization reaction, thus increasing the rate.  This rate 
enhancement is so large that even amides can be used as electrophiles after trigger release.6 The 
TML has been used to mask fluorescence,6 improve aqueous solubility,7 and enhance 
bioavailability.8  
Scheme 1.3 A cyclization-based self-immolative linker 
Scheme 1.4 Lactonization rates for tri-methyl lock approach 
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A similar cyclization system uses coumarin-containing derivatives.9 This design utilizes a 
quick intramolecular cyclization that occurs between a masked phenol and a carbonyl derivative 
containing the cargo.  This lactonization occurs at rates comparable to the TML system due to the 
cis geometry of the double bond locking the phenol into a transition state required for 
intramolecular cyclization (Scheme 1.5).10 Coumarin based self-immolative systems start from 
readily available, affordable starting materials and the byproducts are known to be non-toxic.9 
One of the first examples of a lactonization prodrug was the use of ester 1.1, an analogue 
of the drug pilocarpine.11 Alkyl ester 1.1 acts as a trigger once in vivo leading to an unmasked 
alcohol, which undergoes spontaneous intramolecular lactonization and quantitative release of 
pilocarpine (Scheme 1.6).  Diester prodrug 1.1 has much higher bioavailability then pilocarpine. 
Scheme 1.5 Coumarin derivatives as self-immolative linkers 
Scheme 1.6 A lactonization-based pilocarpine prodrug 
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A recent example of a lactonization-based prodrug is the cyclization-based prodrug for 
propofol, phosphate ester 1.2. Propofol is typically administered as an elimination-based prodrug 
(fospropofol) sedative-hypnotic agent for surgical procedures.12 In this novel system, 1.2 is 
hydrolyzed in vivo to give pendant alcohol 1.3 (Scheme 1.7).  The alcohol then undergoes 
intramolecular cyclization to give butyrolactone and propofol.  Compound 1.2  releases 
propofol, albeit at a slower rate than fospropofol.13 
1.1.2 Elimination Based Self-immolative linkers 
There are several self-immolative linkers that rely on an elimination-based mechanism to 
release their cargo (Scheme 1.8).  These types of scaffolds rely on a masked nucleophile that will 
selectively react within the cell leading to the release of the desired drug along with a quinone 
methide or formaldehyde derivative.  Advantages of this strategy are: 1) ease of synthesis 
compared to cyclization-based prodrugs, 2) cargo release is faster than in cyclization-based 
systems.3, 14
Scheme 1.7 A lactonization-based propofol prodrug 
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One scaffold that has been extensively exploited within the literature is an elimination 
system where the unmasked product is an alcohol or an amine that breaks down to give a quinone 
or aza-quinone methide (Scheme 1.9).  Appendage of the trigger ortho to the cargo leads to 1,4-
benzyl elimination while appendage of the trigger para to the cargo leads to a 1,6 benzyl 
elimination.  Alternatively, an alkene linker can be used, which allows breakdown via 1,8-
elimination.15 
Scheme 1.8 Strategies for elimination-base self-immolative linkers 
Scheme 1.9 Elimination based self-immolative linkers 
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A literature comparison of 1,4 and 1,6-benzyl elimination suggests that there is no 
significant difference in their release rates (Scheme 1.10).16-17 Rates can be enhanced by appendage 
of a linker such as a carbonate which is a better leaving group than an alcohol.  
A seminal example of an elimination based self-immolative linker is the 4-amino benzyl 
alcohol scaffold.14 Starting with 4-amino benzyl alcohol, a simple linker can be synthesized 
(Scheme 1.11). Attaching the trigger and then appending the desired cargo allows the synthesis of 
a self-immolative compound in a few simple steps. Exposure to the trigger unmasks the amine 
which leads to spontaneous 1,6 benzyl elimination and the release of the cargo along with an 
equivalent of p-azaquinone-methide.  This linker system is flexible and has been used to: 1) trigger 
cargo release in a low pH environment by utilization of an acid labile Schiff base, 2) attach 
antitumor drugs such as taxol and doxorubicin to reduce systemic toxicity in vivo, and 3) trigger 
cargo release via specific enzymatic cleavage of an amide bond. 18  
Scheme 1.10 Relative release rates for carbonate and ether linkers 
Scheme 1.11 A 4-amino benzyl alcohol self-immolative linker 
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One disadvantage to quinone-methide and azaquinone-methide elimination systems is the 
high toxicity of their byproducts (Figure 1.2).19 These highly reactive compounds are ultimately 
responsible for the anticancer activity of a number of phenolic anticancer drugs due to their 
powerful alkylating abilities.19 
1.2 PRODRUG DESIGN FOR ALDEHYDES AND KETONES 
 In the previous section, the released cargo is an alcohol, amine, or lactone.  Literature 
precedent for the release of aldehydes and ketones is sparse in comparison and typically relies on 
the use of oximes or acetals. 
1.2.1 Oximes as Masking groups for ketones and aldehydes 
Hydroxyimines are excellent masking groups for ketones and aldehydes in biological 
systems because they are quickly converted to their carbonyl precursors in the presence of 
cytochrome P450 (CYP) enzymes. CYP enzymes are promiscuous with their selection of 
substrates and are found in virtually every tissue of the body; however, they are particularly 
abundant in the liver and intestinal tract.  Hydroxyimines are also easily derivatized as an ester, 
Figure 1.2 Quinone Methide byproducts 
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phosphate, or carbamate; thus providing “double-masked” molecules because they require a two-
step activation process (Scheme 1.12).  
One of the first examples of hydroxylimines being used as triggers for the release of 
ketones and aldehydes was the synthesis and validation of ketoprofen and nabumetone 
hydroxylimines 1.4 and 1.5.  Synthesis of 1.4 and 1.5 was achieved by treatment with NH2OH-
HCl in the presence of pyridine (Scheme 1.13). 
1.4 and 1.5 are hydrolyzed to release their parent carbonyl groups (Scheme 1.14).  Stability 
in aqueous conditions increases as pH increases, with a half life of over 16 hours for pH range 5.0-
9.0.  In human serum (pH 7.4), 1.4 and 1.5 have high stability.     
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Scheme 1.13 Synthesis of HI1 and HI2 from nabumetone and ketoprofen 
Scheme 1.14 Mechanism for the hydrolysis of hydroxylimines 
Scheme 1.12 Synthesis of hydroxylimines and their derivatization 
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As predicted 1.4 and 1.5 are oxidized rapidly to their ketone drugs in liver microsome, thus 
demonstrating the site specificity of hydroxylamine prodrugs.  Activation of 1.4 and 1.5 also 
occurs in vivo in rats. 
1.2.2 Acetals as masking groups for ketones and aldehydes   
Acetals and ketals are excellent functional groups for the masking the functionality of 
aldehydes and ketones.  Classically, these functional groups have been used to protect, 1,2 diols, 
ketones, and aldehydes in the synthesis of complex natural products.  They are easily synthesized 
from the parent carbonyl compound and a diol with the desired protecting group in the presence 
of acid (Scheme 1.15).  
Acetals and ketals are easily cleaved under acidic conditions to give aldehydes and ketones 
respectively; however their utility as triggers for cargo release are limited.  Hydrolysis of ketals 
and acetal in biological systems can occur in biological systems at low pH; however, their stability 
often makes them poor masking groups.  Additionally, their utility as pharmaceutical drugs is 
limited due to the highly acidic conditions found in the stomach. 
Scheme 1.15 Synthesis and deprotection of acetal and ketal protecting groups 
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An elegant solution to this is the use of photolabile aromatic protecting groups.20-22  There 
are several diols that have been developed as protecting groups for aldehydes and ketones that can 
be removed in the presence of light under simulated physiological conditions to release their parent 
carbonyl compounds (Figure 1.3).   
Coumarin diol 1.6 was used to release benzaldehyde, piperonal, acetophenone, and 
cyclohexanone under physiological conditions in the presence of 1- or 2-photon excitation.23  
Additionally, diol 1.7 and 1.8 have seen use as photolabile protecting groups in synthesis.  Using 
diol 1.6, photolabile ketal progesterone derivative 1.9 was synthesized in a single step (Figure 1.4). 
1.9 was used to measure changes in the swimming behavior of single human sperm, demonstrating 
the usefulness of these derivatives under physiologically relevant conditions.24    
Figure 1.3. 1,2 diols used as photolabile protecting groups for aldehydes and ketones 
Figure 1.4. A progesterone protected by a photolabile ketal 
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1.3 THE PROPERTIES OF BORONATE ESTERS 
 Boronate esters are trivalent compounds containing two alkoxy or aryloxy substituents and a 
single carbon substituent.  The three substituents are oriented in a trigonal planar fashion with 
boron’s empty p-orbital orthogonal to its three substituents.  This vacant p-orbital is largely 
responsible for giving boronate esters their Lewis acidic character and unique reactivity. The 
properties of a boronate ester are largely dependent on the nature of the carbon substituent and 
the nature of the alkoxyl/aryloxy substituents. 
1.3.1 The electronic and structural properties of the C-B bond 
Boronate esters are typically classified by the hybridization of their single carbon 
substituent.  Due to boron’s empty p-orbital, substituents that can donate in electron density can 
complete boron’s octet, decreasing its Lewis acidic character. 
C-B bond lengths in alkenyl and aryl boronate esters are shorter than C-B bonds of alkyl 
boronate esters, this suggests that there is π bonding between alkenyl and aryl substituents with 
their adjacent boron atoms.25 Further evidence for π bonding in boronate esters is deshielded 13C 
NMR shifts β to boronate esters that have an alkene as their single substituent compared to 
analogous alkenes.26 This demonstrates that alkenyl boronate esters can be thought of as analogous 
to α,β-unsaturated carbonyl compounds, where contribution of the enolate form is important to 
explain reactivity (Scheme 1.16).  These results explain why alkenyl and aryl boronate esters have 
increased stability compared to alkyl boronate esters. 
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Boron’s Lewis acidic character can also lend itself to intramolecular coordination.  There 
are a number of examples of compounds containing dative bonds between boron and a heteroatom 
(O, N).27 One example where the single carbon substituent plays a role in the formation of an 
intramolecular bond can be seen in Figure 1.5 where there is strong evidence for chelation between 
the boronate ester and the oxygen on the amide.28 
1.3.2 The electronic and structural properties of the B-O bond 
The B-O bond is, as expected, stronger than the B-C bond in boronate esters due to the 
very large electronegativity difference between B and O (Δ = 1.4).  The formation of a new B-O 
bond is the primary thermodynamic driving force for boronate ester oxidation (Scheme 1.17).25 
Scheme 1.16 Resonance stabilized forms for alkenyl boronate esters 
Figure 1.5 Intramolecular coordination between a carbonyl group and a 
boronate ester 
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Since alkenyl and aryl boronate esters are less electrophillic than their alkyl counterparts, 
they also have increased stability to oxidation. Kinetically, hydration of boronate esters by H2O is 
a slow process; thus, most boronate esters are stable and can be handled in ambient air.  The relative 
thermodynamic stability of a given boronate ester is largely dependent on the size and electronics 
of its oxygen substituents.  The stability of a wide range of aryl boronate esters has been studied.29 
The study showed that cyclic boronate esters are more stable than their non-cyclic analogues, and 
six-membered cyclic boronate esters are more stable than their five-membered analogues (Scheme 
1.18). 
1.4 THE SYNTHESIS OF BORONATE ESTERS 
 There are number of methods available for the synthesis of boronate esters, most 
begin with inexpensive boron derivatives or any number of other borylation reagents.  A 
summary of the methods available for boronate ester synthesis is presented in Scheme 1.19.  
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Scheme 1.18 Stability towards hydrolysis for a series of boronate esters 
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1.4.1 The conversion of organometallic reagents into boronate esters 
The ability to convert a Grignard or organolithium reagent into the corresponding 
boronate ester from the borate ester is a common and well-known reaction.30-31 The starting borate 
ester is derived from inexpensive boric acid,32  and a large number of nucleophillic 
organometallic reagents are available (Scheme 1.20).   
Scheme 1.19 A summary of the methods available to synthesize boronate esters. 
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This mechanism follows the reactivity pattern seen in several reactions of boronate esters 
(Scheme 1.21). The borate ester reacts with the organometallic reagent to form a tetrahedral borate 
salt, which loses a ligand to acid to restore the trigonal boronate ester, this first step forms the 
desired C-B bond.  The addition of H2O in the presence of acid leads to formation of the boronate 
acid, which can undergo transesterification in the presence of a alkoxy/aryloxy ligand to form the 
desired boronate ester.  The boronate acid or initially formed boronate ester can usually be isolated 
but one pot synthesis of boronate esters is far more common.25, 33   
A recent example from the literature is the synthesis 2-pyridyl boronate acid surrogates by 
utilizing N-methyliminodiacetic acid (MIDA) as a ligand and an acid (Scheme 1.22).34 The 
addition of n-butyllithium to 2-bromopyridine followed by triisopropyl borate gives a tetrahedral 
adduct. The addition of MIDA leads to the boronate acid, and then transesterification with MIDA 
B
OH
OHHO R OH
H3O
+
B
OR
ORRO
Scheme 1.21 Mechanism for the conversion of borate esters into boronate esters. 
Scheme 1.20  The facile synthesis of borate esters from boric acid 
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forms the boronate ester all in a single step.  This elegant example shows the utility of this method 
to synthesize the otherwise unstable 2-pyridyl boronate acid surrogates. 
The use of nucleophillic organometallic reagents to synthesize boronate esters allows for 
selection of the newly formed C-B bond and the desired ligand.  One major disadvantage is 
incompatibility of the highly nucleophillic organometallic reagent with electrophilic functional 
groups.  One way to circumvent this issue is to utilize transition metals in conjunction with 
borylation reagents. 
1.4.2 The addition of B-H to double and triple bonds. 
The addition of a B-H bond to a C-C double bond is ubiquitous in organic chemistry and 
remains an integral part of course curriculum in undergraduate organic chemistry.  In fact, the 
development of the majority of organoboron chemistry can be traced back to 1959 when Herbert 
C. Brown discovered that the hydroboration-oxidation of terminal alkenes gave primary alcohols
in an anti-Markovnikov fashion (Scheme 1.23).35-36 Since then, the scope of B-H addition to 
unsaturated hydrocarbons has expanded to include internal alkenes,37 alkynes,38 allenes,39 1,4 
dienes,40 and α,β-unsaturated ketones.41 35-36 Since then, the scope of B-H addition to unsaturated 
hydrocarbons has expanded to include internal alkenes,37 alkynes,38 allenes,39 1,4 dienes,40 and 
α,β-unsaturated ketones.41  
Scheme 1.22 Synthesis of 2-pyridyl MIDA boronate ester 
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Hydroboration-oxidation begins with multiple additions of a B-H to an alkene to give an 
alkylborane intermediate, which can be oxidized to the less-substituted alcohol in the presence of 
H2O2 and NaOH.  Some commonly seen hydroboration reagents are shown in Figure 1.6. 
B-H addition of pinacolborane and catecholborane to form a boronate ester is not as facile
as organoborane addition due to the electron-donating abilities of the adjacent oxygens.42 To avoid 
these issues, catalytic methods that utilize Rh(PPh3)Cl as a catalyst for less reactive borylation 
reagents such as pinacolborane and catecholborane.   
The catalytic cycle (Scheme 1.24) begins with ligand dissociation to give the active Rh(I) 
catalyst.  Oxidative addition of pinacolborane gives a 14 e- Rh(III) boryl species.  Alkene 
coordination followed by migratory insertion into the Rh-H bond attaches the terminal olefin; 
finally, oxidative addition regenerates the catalyst and gives the borylated product.   
Scheme 1.23 Hydroboration-oxidation using BH3 
Figure 1.6 Common hydroboration reagents 
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1.4.3 The addition of B-B to unsaturated compounds 
The final method for the synthesis of boronate esters (and the most important in regards to 
the content of this document) is the addition of B-B to C-C and C-heteroatom multiple bonds. 
Bis(boronate esters) have attracted a lot of attention as useful synthetic intermediates due to their 
ability to form multiple C-C bonds in a single step and through functionalization of the C-B bond. 
Scheme 1.24 Catalytic cycle for the hydroboration of alkene by HBpin 
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There are a number of synthetic routes to access bis(boronate esters); however, many 
require the use of specific substrates or harsh reaction conditions.43    The first direct catalytic 
diboration was developed by Suzuki and Miyaura in 1994, when they discovered that a catalytic 
amount of Pt(PPh3)4 resulted in the diboration of alkynes by B2pin2 (Scheme 1.25).44 
The catalytic cycle (Scheme 1.26) begins with ligand dissociation to give the tricoordinated 
16 e- Pt (0) complex. Oxidative addition of the B-B bond results in the formation of Pt-diboryl 
species, which undergoes alkyne insertion into the Pt-B bond.  Finally, reductive elimination 
releases the product and regenerates the active catalyst.  
Scheme 1.25 Pt0 catalyzed diboration of alkynes 
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Alkenes,45 allenes,46 and 1,3 dienes47 are all employable as substrates using Pt (0) to give 
a variety of bis(boronate esters) (Scheme 1.27).48 There are also examples of Rh,49 Ni,50 Pd,51  
Cu52, and transition metal free diborations53 of unsaturated compounds.  
Scheme 1.26 Catalytic cycle for the diboration of alkynes using Pt(PPh4) 
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C-heteroatom double bonds are also employable as substrates for B-B additions, this allows
for the synthesis of boronate esters that have a heteroatom adjacent to the boronate ester.  Aside 
from their utility as valuable synthetic intermediates, boronate esters that contain an adjacent 
heteroatom are key intermediates to access the self-immolative linker described in this document.  
There are several examples of α-heteroatom boronate esters in the literature prior to a catalyzed 
diboration of a C-heteroatom multiple bond; however, their synthesis requires multiple steps and 
has limited scope.  The first diboration of a C-heteroatom double bond from readily available 
starting materials utilized a Pt0 catalyst and B2cat2 as a borylation reagent and aldimines as 
substrates (Scheme 1.28).  Unfortunately, due to the labile nature of the B-cat group, selective B- 
N cleavage was never accomplished.  
Many years later, an N-heterocycle carbene (NHC) copper catalytic system was developed 
that used B2pin2 as a borylation reagent and aldehydes as substrates (Scheme 1.29).54 Synthesis 
Scheme 1.27.  Substrate scope for the catalyzed diboration of unsaturated hydrocarbons 
Scheme 1.28 A platinum catalyzed diboration of aldimines 
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and handling of the catalyst and resulting products require the use of highly inert conditions and 
long reaction times.  
 Synthesis of the diboronate ester products without the use of a glove box leads to 
decomposition into starting aldehyde and pinB-O-Bpin (Scheme 1.30).  Only a single α-hydroxy 
boronate (resulting from selective B-O cleavage) was isolated (derived from pivaldehyde) in 
moderate yield.  
Since the discovery that ICy(Cu)O-tBu could efficiently catalyze the diboration of 
aldehydes, many improvements have been made to simplify the conditions and increase the scope. 
Scheme 1.29 Cu catalyzed diboration of aldehydes using (ICy)CuOt-Bu 
Scheme 1.30 Decomposition pathways of borylated aldehydes 
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Although only a single α-hydroxy boronate ester derived from an aldehyde has been 
isolated, α-hydroxy potassium trifluoroborate salts have been synthesized from aldehydes using 
the (ICy)Cu-OtBu catalyst system (Scheme 1.31).55 The addition of methanol enhances the rate of 
the reaction, allowing full conversion in 1.5 hours. 
The mechanism for the diboration has been well documented (Scheme 1.32).56 The first 
step is formation of a Cu-boryl species by σ-bond metathesis with NaOt-Bu and B2pin2.  The highly 
nucleophillic Cu-B bond adds into the aldehyde by migratory insertion. Density functional theory 
(DFT) calculations have shown that this is the rate determining step.56 The Cu-O bond will then 
undergo σ-bond metathesis with B2pin2 to give the diborated aldehyde and regenerate the catalyst. 
In the presence of MeOH, it has been proposed that the Cu-O-B complex is protonated, giving the 
hydroxy boronate ester and a Cu-OMe complex.  Cu-OMe can then undergo σ-bond metathesis 
with B2pin2 to regenerate the active catalyst.  
Scheme 1.31 The synthesis of α-hydroxy potassium trifluoroborate salts. 
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The scope of the (ICy)CuOt-Bu catalytic system has been expanded to include aldimines57 
and ketones (Scheme 1.33).58 These are particularly useful substrates because the resulting tertiary 
Scheme 1.32 Mechanistic considerations for the diboration of 
aldehydes by (ICy)Cu-OtBu 
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hydroxy and secondary amino-boronate esters can be purified, stored, and used in subsequent 
transformations. 
Armed with the knowledge of the synthesis of boronate esters, this discussion will turn 
towards the value of boronate esters as valuable intermediates to access novel organic compounds. 
1.5 BORONATE ESTERS AS SYNTHETIC INTERMEDIATES 
 Uncatalyzed reactions of boronate esters often utilize the nucleophillicity of the C-B 
bond in its tetracoordinated form. 
Scheme 1.33 The diboration of sulfinylimine and ketones using (ICy)Cu-OtBu 
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1.5.1 Transformations that utilize the nucelophilicity of the C-B bond. 
The primary mode of reactivity that is seen in uncatalyzed reactions of boronate esters 
involves reaction of a nucleophile adjacent to a leaving group (Scheme 1.34).   
The first step is the addition of the nucleophile to boron to form a tetrahedral adduct.  The 
resulting C-B bond is highly nucleophilic and undergoes intramolecular attack on the pendant-
leaving group.  This mechanism has been consistently seen in almost all non-catalyzed reactions 
of boronate esters.  The array of reactions that have been developed using this strategy is shown 
in Scheme 1.35. 
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Scheme 1.34 Mechanistic consideration for uncatalyzed reactions with boronate esters 
Scheme 1.35 Uncatalyzed transformations of boronate esters 
29 
The first examples of nucleophiles with leaving groups reacting with boronate ester (aside 
from H2O2 oxidation) were homologation reactions using Cl2C(H)Li to form α-halo boronate esters 
and subsequent substitutions with organometallic reagents.59 These reactions allow for full 
stereochemical retention.  Enantioselectivity can  be achieved using chiral boronate esters such as 
those shown in Figure 1.7.33     
The Aggarwal group utilized lithiated epoxides and carbamates as pendant leaving groups 
in the synthesis of enantiopure 1,2 diols,60 and tertiary alcohols. 61 
Boronate esters can also participate in what is known as a Petasis reaction which allows 
the synthesis of substituted amines.62 The first step is condensation to form the imminium ion 
(Scheme 1.36), which is catalyzed by the oxophillic character of the boronate ester.  This is 
followed by nucleophilic attack by the tetracoordinated C-B bond to form a tertiary amine. Many 
of the steps for the Petasis reaction are analogous to the Mannich reaction.   
Oxidation of organoboron boron compounds by H2O2 follows the same reaction pattern 
seen in Scheme 1.34. In H2O2 the pendant-leaving group is –OH and the product is derived from 
Figure 1.7 Chiral boronate esters 
Scheme 1.36 The mechanism for the Petasis reaction 
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alcohol hydrolysis of the borate ester.  The mechanistic details of boronate oxidation will be 
presented in 1.6. 
1.6 BORONATE ESTERS AS  PRODRUGS AND PROBES FOR H2O2 
 H2O2 is a non-radical oxidant that is present in aerobic organisms.  Initially H2O2 was 
viewed as a detrimental byproduct of cellular respiration; however, in recent years, a large body 
research has determined that the concentration of H2O2 and other reactive oxygen species (ROS) 
plays a vital role in protein folding and signaling, defense response, and respiration.63 The 
concentration of H2O2 in eukaryotic cells undergoing oxidative stress is disputed in the literature 
and shown to be organelle dependent; with higher concentrations found in the cytosol, 
mitochondria, and peroxisome.  Reported concentrations are typically 0.1-1µM for homeostatic 
base levels and  10-100 µM are typically enough to induce cells into undergoing a physiological 
response. The in vivo quantitation of H2O2 is a challenge due to non-specific reactivity with 
other reactive oxygen species (ROS) by traditional methods and the transient nature of ROS 
in living systems.2  As a result, there has been significant effort to unravel the benefits and 
drawbacks of H2O2 within living systems. 
Boronate esters are attractive as probes for the detection of H2O2 within living systems 
because of their specific reactivity with H2O2 and no other ROS typically found within the 
cell such as superoxide (O2-) or hydroxyl radical (OH).2  The oxidation of boronate esters to 
alcohols is bioorthogonal; any chemical reaction that can occur inside of living systems without 
interfering with native biochemical processes.64        
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The mechanism for boronate oxidations begins with nucleophillic H2O2 reacting with the 
empty p-orbital on boron to form a negatively charged tetrahedral boronate complex (Scheme 
1.37).  This forms a nucleophilic C-B bond that undergoes a 1,2 boryl migration to give the borate 
ester, which rapidly undergoes hydrolysis under physiological conditions to give an alcohol.2   
Since the discovery that the oxidation of boronate esters is compatible with biological 
systems, their utility as a trigger in self-immolative linkers has been demonstrated many times. 
The first example of a of a boronate ester being used as a trigger in self-immolative system was 
reported by Lo.65  In this design (Scheme 1.38), boronate ester 1.10 undergoes oxidation  by H2O2 
followed by a spontaneous 1,6 benzyl elimination to release an equivalent of quinone methide 
and p-nitrophenylaniline (or the fluorescent amino coumarin reporter).  
Scheme 1.37 Mechanism for the oxidation of boronate esters by H2O2 
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Since this discovery several groups have utilized boronate esters as triggers for H2O2.   In 
this section, approaches that utilize boronate oxidation as a probe for H2O2 as well as self-
immolative mechanisms for the development of targeted therapeutics will be discussed to establish 
the framework that led to the novel work performed by the author.  
1.6.1 Boronate esters as fluorescent probes for H2O2 
Boronate esters were first identified as excellent triggers for H2O2  by the Chang group.63 
Their initial design utilizes boronate ester 1.11 shown in Scheme 1.39.    
In the presence of H2O2, 1.11 reacts to form a phenol, which undergoes a quinone-methide 
elimination to open the lactone and release fluorescein.  Since the oxidation of aryl boronate esters 
was found to be compatible with biological systems, the Chang group has introduced a wide pallet 
Scheme 1.39 Fluorescein Derivative as a probe for H2O2 
Scheme 1.38 The first report of a boronate ester based self-immolative linker. 
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of probes to serve several purposes.  This includes probes that turn on in the presence of H2O2 give 
different colors, ratiometric H2O2 probes, probes that localize to specific organelles such as 
lysosomes and mitochondria, and probes for live tissue imaging.2  Figure 1.8 shows the structural 
variations as well as the different probes that are available for imaging of  H2O2 in living systems. 
Compound 1.11 represents the first generation of probes that utilizes bis boronate esters 
and had the ability to detect H2O2 over other relevant reactive oxygen species (ROS) such as tert-
Figure 1.8.  Probes for H2O2 developed by the Christopher Chang group 
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butyl hydroperoxide (TBHP), O2-, NO, -OCl, and ●OH.63 1.11 can image H2O2 at high micromolar 
ranges, a range that is relevant to states of oxidative stress.  1.11 was not sensitive enough for the 
detection of endogenously produced H2O2, which led to the development of monoboronate probes 
1.12 and 1.13.  This next generation of caged fluorophores only require a single H2O2 equivalent 
yield their fluorescent product, increasing sensitivity and allowing detection of endogenously 
produced H2O2.66  Once boronate ester oxidation had been established as biorthogonal, the 
ratiometric probe 1.14 that utilizes fluorescence resonance energy transfer (FRET) was 
developed.67  FRET probe 1.14 allows for the measurement of two signals that change 
differentially with H2O2 concentrations. Probe 1.15 utilizes the triphenylphosphonium salt (known 
as Murphy’s salt)68 as a lipophilic cation for mitochondrial localization.  Probe 1.15 allows for 
visualization of discrete oxidative stress changes confined to the mitochondria.69  Finally,  probe 
1.16 allows for live tissue and animal imaging. 1.16 utilizes the bioluminescent luciferin 
fluorophore as well as a self-immolative mechanism.70  This work demonstrates that boronate 
oxidation is sensitive to the micromolar concentrations of H2O2 found in cells and compatible with 
living systems. 
1.6.2 Boronate Ester based Prodrugs 
Several chemotherapy drugs rely on DNA interstrand crosslinking (ICL) as their primary 
mechanism of action; however, host toxicity continues to be a major problem. Targeted 
chemotherapy inspires the development of boronate ester based prodrugs; this is because several 
tumor cells produce higher levels of H2O2 than healthy cells.71   To overcome this limitation 
boronate ester based prodrug 1.17 was developed to release DNA alkylating agents upon oxidation 
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by H2O2 (Scheme 1.40).  The primary mechanism of action occurs by oxidation of the boronate 
ester to phenol 1.18, followed by a 1,4 quinone methide (QM) elimination.   
DNA rapidly reacts with this intermediate and another elimination occurs to give a QM 
which rapidly forms the DNA ICL.  There are variants of these compounds that can undergo DNA 
cross-linking under oxidative conditions and in the presence of light; these undergo cross-linking 
through the formation of benzylic radicals.  
Another example of a boronate ester based prodrug that releases a DNA alkylating agent 
is compound 1.19 (Scheme 1.41).72 1.19 undergoes oxidation by H2O2 which causes a 1,6 
elimination to release the active mustard reagent.  Without H2O2, the mustard reagent is not 
released and 1.19 does not produce host toxicity. 
Scheme 1.40  Boronate ester oxidation to induce DNA ICLs 
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A recent example of a boronate ester based prodrug uses a different approach (Scheme 
1.42).73  Upon boronate oxidation, 1.20 undergoes elimination, which leads to release of 
fluorophore 1.21 and camptothecin derivative 1.22.  This type of approach utilizes a strategy called 
“theranostics” (a portmanteau of therapy and diagnostics).  1.20 was shown to selectively 
accumulate within metastatic tumors in mice; this strategy allows for cytotoxic agents to be tracked 
in vivo, allowing for advanced image-guided therapy strategies. 
Scheme 1.42 A boronate ester based prodrug that releases cyctotoxic cargo and a fluorophore 
Scheme 1.41 A boronate ester based cancer prodrug 
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During an Ischemia-reperfusion (I/R) injury event, reperfusion of blood flow into ischemic 
tissues induces the formation of a large amount of H2O2, which causes oxidative stress and 
exacerbation of tissue damage.74  Targeted antioxidant therapy directed towards the site of an I/R 
injury offers advantages over classic antioxidant therapy, which suffers from off target effects and 
a lack of bioavailability.75  To circumvent this issue, the boronate ester prodrug (BRAP) of p-
hydroxybenzyl alcohol (HBA), was synthesized (Scheme 1.43). 76  
BRAP can be specifically oxidized by H2O2, limiting H2O2 mediated oxidative stress.  The 
resulting oxidation also releases an equivalent of HBA, which has intrinsic anti-oxidant and anti-
inflammatory activities; particularly in tissues undergoing oxidative stress.  The boronate ester was 
shown to inhibit cell death and exerted anti-inflammatory activity more effectively than HBA 
alone.  This work demonstrates the usefulness of boronate esters as not only a trigger for H2O2 but 
also as an effective scavenger for H2O2; a concept that the author will consider in Section 2.2.1. 
Scheme 1.43 BRAP, a boronate ester prodrug for HBA, a potent antioxidant 
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Synergy between two pharmaceutical agents occurs when a new or amplified effect can be 
produced that neither drug could produce on its own.  Boronate ester prodrugs have been used in 
this fashion to amplify oxidative stress selectively in cancer cells through the release of two active 
agents.  In the example shown in Scheme 1.44, 1.23 undergoes oxidation by H2O2, which leads to 
the release of an equivalent of quinone-methide (QM), an antioxidant scavenger.77 The low pH of 
the cancer cells simultaneously releases cinnamaldehyde, a small molecule that generates high 
amount of oxidative stress.  This combination therapy increases oxidative stress enough to 
selectively kill cancer cells, while leaving healthy cells intact.  More importantly, 1.23 acts in a 
synergistic fashion with the environment within the cancer cells.  
1.7 BORON CONTAINING DRUGS 
 Organoboron compounds ultimately degrade by autoxidation and hydrolysis into 
boric acid (Scheme 1.45), a relatively non-toxic inorganic byproduct, making them useful 
as potential therapeutics.78  
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Scheme 1.44. A dual stimuli-responsive hybrid anticancer drug 
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1.7.1 Boron in Medicinal Chemistry 
Pharmaceutical companies often avoid boron containing compounds because they can form 
reversible covalent bonds with side chains on proteins. Covalent modifications often lead to higher 
levels of toxicity; thus, funding of drug candidates that function through irreversible drug 
modification is a high risk endeavor.79  It is tempting to assume that boron is simply another 
electrophile, similar to acrylates, epoxides, and aldehydes.  Boron is different in that its’s covalent 
modifications are reversible.  Additionally, boron has multiple coordination preferences, this 
differentiates its interactions from typical electrophiles (Scheme 1.46).80  These reversible covalent 
interactions are what gives boron containing molecules unique interactions with their targets. 
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Scheme 1.45 Ultimate degradation of organoboron compounds into boric acid. 
Scheme 1.46.  Boron’s coordination preferences with amino acids 
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Boronate esters can act as bioisosteres for phenols.  One of the earliest examples of a 
boronate ester being modified in this way was the development of a boron-based 4-hydroxy 
tamoxifen derivative 1.24 (Figure 1.9).81  1.24 converts to the phenol forms under oxidative 
conditions in breast cancer cells.  Additionally, boronate ester modified Camptothecin derivative 
1.25 showed increased activity against several cancer cell lines.82  A more recent example 
demonstrates that boronate oxidation can be utilized in living systems. Boronate ester 1.26, a 
modified Bellinostat derivative, showed increased efficacy in treating solid tumors than 
Bellinostat, suggesting its potential in a clinical setting.83  
Figure 1.9. A sample of boronate esters being utilized as bioisosteres for phenols 
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1.7.2 Boron in pharmaceutical agents 
 There are four boron containing therapeutics that have been approved by the FDA (Figure 
1.10). Velcade is widely prescribed for multiple myeloma by oncologists.84  Thanks to a number 
of efforts by the biopharmaceutical company Anacor, Tavabarole was approved as a topical 
antifungal medication in July 2014.85  Crisaborole, also developed by Anacor, was approved for 
eczema in 2016 and is currently undergoing clinical trial for psoriasis.  Vaborbactam, discovered 
by Rempex pharmaceuticals, restores potency to existing antibiotics by inhibiting the beta-
lactamase enzymes that would otherwise degrade them. When combined with an appropriate 
antibiotic it can be used for the treatment of gram negative bacterial infections.86  Vaborbactam 
was approved for use in conjunction with Meropen for the treatment of complicated urinary tract 
infections and pyelonephritis in 2017.   
There several other boron containing drugs going through clinical trials that have the 
potential to be utilized as anticancer, antiviral, and antifungal agents; however, discussing their 
properties is beyond the scope of this document.  The next chapter of this document describes the 
specific contributions that that author has made to this field. 
Figure 1.10 Boron-containing drugs approved by the FDA 
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2.0   THE UTILIZATION OF BORONATE ESTERS FOR THE OXIDATIVELY 
TRIGGERED RELEASE OF ALCOHOLS, KETONES, AND ALDEHYDES 
Previous work from the Floreancig group focused on the development of a novel carrier to deliver 
antioxidants to the mitochondria in an effort to mitigate damage from radiation.87  In this work, a 
series of α-alkoxy carbamates were synthesized using a multicomponent reaction consisting of a 
nitrile hydrozirconation, acylation, and alcohol addition.  These compounds were found to rapidly 
release their respective cargo specifically in the presence of H2O2 via the quinone-methide 
elimination discussed in 1.1.2.   The arylboronates are compatible at biologically relevant 
concentrations, suggesting their potential for use in living systems.  Using the multicomponent 
hydrozirconation, acylation, and alcohol addition sequence; compound 2.1 was synthesized 
(Scheme 2.1).  Compound 2.1 was designed to act as an agent that mitigates radiation damage by 
suppressing the formation of ROS.  Pentamethyl chromanol (PMC), was selected as a simplified 
Vitamin E derivative and potent antioxidant.88 The triphenylphosphonium cation (also known as 
Murphy’s salt) promotes mitochondrial localization.68  Unfortunately, treatment of cells with 
compound 2.1 led to cell death. We reasoned that the toxicity of 2.1 resulted from the release of 
an equivalent of quinone methide, a potent DNA alkylator.19  
Scheme 2.1 An oxidatively triggered boronate ester designed to localize in the mitochondira of cells to release 
an equivalent of quinone methide, and an antioxidant. 
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To circumvent this issue, we reasoned that new synthetic methodology for the synthesis of 
α-hydroxy boronate esters would enable access to novel molecular scaffold for the release of 
alcohols without the release of toxic byproducts.  This led to the development of the first 
oxidatively triggered alkylboronate ester based self-immolative linker (Scheme 2.2).  
2.1 ALCOHOL, ALDEHYDE, AND KETONE LIBERATION AND 
INTRACELLULAR CARGO RELEASE THROUGH PEROXIDE MEDIATED α-
BORYL ETHER FRAGMENTATION  
 The initial design envisioned for the scaffold was based on the ability to synthesize and 
functionalize α-hydroxy boronate esters into carbonates.  We predicted that oxidation of a 
functionalized α-alkoxy boronate ester by H2O2 would give an unstable hemiacetal that would 
rapidly breakdown under biological condition leading to release of the desired cargo.   There were 
several challenges that we faced in establishing a biorthogonal alkylboronate scaffold that would 
eventually lead to a molecular scaffold for the release of alcohols, aldehydes, and ketones.  
Scheme 2.2 A novel scaffold for the release of alcohols that circumvents the release of quinone methide 
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2.1.1 Facile access to α-hydroxy boronate esters 
The first challenge towards the construction of a new scaffold was facile access to α-
hydroxy boronate esters utilizing the diboration chemistry presented in 1.4.3.  Initial attempts to 
access secondary α-hydroxy boronate esters from aldehydes failed due to decomposition of the 
diborated products into the starting aldehyde and pinB-O-Bpin upon exposure to air, as reported 
in the literature.54  Thus, we turned our attention towards the synthesis of tertiary α-hydroxy 
boronic esters from ketones. Initial studies showed that ketones were acceptable as substrates for 
the synthesis of tertiary α-hydroxy boronic esters using the (ICy)Cu-OtBu catalyst system (Scheme 
2.3).58
45 
Unfortunately, (ICy)CuCl and (ICy)O-tBu are not easily accessed and must be handled 
under inert conditions, severely limiting access to the desired substrates.  Since (ICy)CuCl is 
normally synthesized by deprotonation of the starting imidazolium salt (ICy)BF4  by NaO-tBu, we 
envisioned a one pot procedure that utilized a larger mol% of NaO-tBu in the presence of CuCl 
and (ICy)BF4. 
We predicted that this would lead to slow formation of (ICy)Cu-OtBu in situ, and increased 
yields of the diborated products.  Additionally, MeOH was used as an additive because it has been 
shown to increase catalyst efficiency by protolytic turnover in other diboration reactions.55   This 
led us to the development of a novel procedure using (ICy)BF4, CuCl, MeOH, and a larger mole 
Scheme 2.3 Modified protocol for the facile access of  α-hydroxy boronate esters 
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% of NaO-tBu in a one pot fashion.  Another advantage to this method is that the reaction can be 
run open to air, albeit in slightly lower yields.  Facile access to tertiary α-hydroxy boronic esters 
allowed the synthesis of a new class of compounds for the release of alcohols in the presence of 
H2O2. 
2.1.2 α-hydroxy boronate functionalized acetals and carbonates 
Once facile access to α-hydroxy boronate esters was achieved, we turned our attention 
towards developing a scaffold that would release alcohols in the presence of H2O2 under biological 
conditions.  Starting with 2-butanone, α-hydroxyboronate 2.2 was synthesized then functionalized 
as carbonate 2.3 with pyridine and phenyl chloroformate (Scheme 2.4).  
Scheme 2.4. Synthesis of carbonate 2.3 and acetal 2.4 
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We reasoned that the release of CO2 would be entropically favored and phenol would make 
for a better leaving group than an alkyl group, thus promoting rapid release and oxidation.  The 
oxidative breakdown of carbonate 2.3 was monitored in a mixture of 5:1 CD3CN:pH 8.0 phosphate 
buffer to mimic the pH of the mitochondria (Scheme 2.5).   
This sample was treated to achieve a final concentration of 25 mM H2O2 (~10 equivalents). 
Surprisingly, in the presence of H2O2 and biologically relevant conditions, the release of phenol 
was slower than we expected.  Consumption of 50% of the starting material required 22 minutes.  
We predicted that due to an intramolecular bond between the C=O bond on the carbonate and the 
boronate ester blocking the open coordination site, preventing oxidation by H2O2 (Figure 2.1).  
Crystal structures of α-amido boronate esters show this type of coordination.89 
Scheme 2.5 Monitoring the fragmentation of carbonate 2.3 and acetal 2.4 
Figure 2.1 Intramolecular bond coordination between the carbonate and the boronate ester 
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To test our hypothesis, methoxymethyl ether 2.4 was synthesized from α-hydroxyboronate 
2.2 (Scheme 2.4).  As predicted, Methoxy methyl ether 2.4 fragmented rapidly in the presence of 
H2O2 to release MeOH and 2-butanone.  Over 50% of the starting material was consumed in less 
than 2 minutes and complete conversion was achieved in 20 minutes. 
The reaction progress of both methoxy methyl ether 2.4 and carbonate 2.3 were monitored 
by the disappearance of the diastereotopic hydrogens from the methylene group and the appearance 
of the corresponding enantiopic hydrogens in 2-butanone (Figure 2.2). 
Additionally, changing the pH from 8.0 to 7.2 (the pH of the cytosol) has a small effect on 
the rate of boronate ester oxidation despite the diminished peroxy anion concentration required for 
oxidation to occur (Figure 2.3). 
Figure 2.2 Monitoring the oxidation of methoxy methyl ether 2.4 
OH2C
O
B
OO
O
C
H2
49 
2.1.3 Defining the scope: The synthesis and fragmentation of α-boryl ethers, carbonates, 
and acetals 
With a system for the release of alcohols established, the scope for the release of alcohols 
was explored.  Secondary alcohols such as cyclohexanol and menthol are released quickly from 
substrates 2.5 and 2.6 in the presence of H2O2 (Table 2.1, entries 1 and 2).   
Figure 2.3 Oxidation of methoxymethyl ether 2.4 at pH 7.2 and 8.0 
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Table 2.1 Scope of alcohol release for α-boryl ethers. 
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It was demonstrated that a phenolic antioxidant can be released (albeit at a slower rate) 
from compound 2.7 (Table 2.1, entry 3).  Compound 2.7 was synthesized from α-hydroxy boronate 
2.8 and  PMC chloroformate. (Scheme 2.6).  
Since the initial goal of the project was to avoid the release of undesired toxins, especially 
if the cargo is not a cytotoxin; direct release from α-boryl ethers rather than acetals was desirable 
(due to the release of formaldehyde).  Unfortunately, direct Williamson ether synthesis with α-
boryl alcohols leads to a Bora brook rearrangement; which renders the alcohol non-nucleophillic 
(Scheme 2.7).90   
Scheme 2.6 Synthesis of carbonate 2.7 from hydroxy boronate 2.8 
Scheme 2.7. Alkoxide generation leads to bora-Brook rearrangement rather than alkylation 
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To overcome this undesirable result, potent electrophiles must be used to avoid the 
generation of alkoxide intermediates.  This can be accomplished by activating halide leaving 
groups with AgOTf, this allows hindered pyridines to be used as H+ scavengers.91  This is 
demonstrated in the ethylation of  α-hydroxy boronate ester 2.9 to form ethyl ether 2.10.  (Scheme 
2.8).    
Ethyl ether 2.10 fragments smoothly to release EtOH (Table 2.1, entry 4).  If the desired 
halide is unavailable, reductive etherification with BiBr3 is another method for preparing α-boryl 
ethers. 92 Silyl ether 2.11 condenses with isobutyraldehyde in the presence of Et3SiH to give α-
boryl ether 2.12 (Scheme 2.9). 
Scheme 2.8. Etherification to form boronate ester 2.10 
Scheme 2.9 Reductive etherification to form α-boryl ether 2.12 
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α-boryl ether 2.12 fragments rapidly in H2O2 to release 2-methylpropanol (Table 2.1, Entry 
5).  Since the starting material is an ether, this allows for the borylation of aldehydes then 
immediate subsequent protection of 2° α-hydroxy boronate esters to give silyl ethers.  Unlike the 
2° α-hydroxy boronate esters, which decompose rapidly, the protected silyl ethers can be handled 
and purified with ease.  This expanded scope was illustrated in the synthesis of α-boryl ether 2.14 
from α-boryl silyl ether 2.13 (Scheme 2.10). 
α-boryl ether 2.14 fragments rapidly in the presence of H2O2 to release cyclohexanol 
(Table 2.1, entry 6).  The release of a carboxylic acid from an α-boryl ester was far slower than 
the release of alcohols and carbonates (Table 2.1, Entry 7).  Compound 2.15 does show 11B shift 
of 27.0 ppm, slightly lower than a typical α-boryl ether (~30 ppm), this suggests that intramolecular 
coordination is likely to play a role in providing its stability. 
2.1.4 Defining Limitations: Cyclic acetal discovery 
With the scope defined, we looked towards finding a compound that would release a 
fluorophore to probe fragmentation within cells.  While searching for the appropriate compound, 
Scheme 2.10 Reductive etherification to form α-boryl ether 2.14 
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some of the limitations of α-boryl ether functionalization and its compatibility with low 
concentrations of H2O2 was explored.  Initially we reasoned that since carbonate 2.7 fragmented 
so slowly in the presence of H2O2, a new system could be developed that utilizes an acetal to 
release a fluorescent phenol compound.  We reasoned that with a fluorescent phenol quenched as 
an acetal, release of the fluorescent species would occur upon addition of H2O2. Initially attempts 
were made to form an ether from a fluorescent phenol using a Mitsunobu reaction.93  Unfortunately 
(and perhaps unsurprising), the reaction was sluggish and only trace amounts of our desired 
product were formed, even at elevated temperatures (Scheme 2.11).  Even the Mukaiyama 
etherification, which has been used for the synthesis of 3° ethers failed due to decomposition of 
the intermediate product.94 
Since synthesis of the α-boryl phenolic ether was shown to be impractical, we focused our 
attention on the synthesis of an acetal that would release a phenol.  To test our theory compound 
Scheme 2.11.  Attempts to synthesize a 3° aryl-alkyl α-boryl ether
Scheme 2.12.  Synthesis of acetal 2.16 from α-hydroxy boronate 2.2 
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2.16 was synthesized from α-hydroxy boronate 2.2 utilizing AgOTf, 2,6 ditertbutylpyridine, and 
chloromethyl phenyl ether (Scheme 2.12).   
Unfortunately, acetal 2.16 was not stable in pH 7.2 Buffer; thus ruling out its use in 
biological studies.  We reasoned that the acetal was undergoing hydrolysis due to the increased 
leaving group ability of the phenol.  Realizing that the release of a phenol was impractical and 
unlikely to succeed under biological conditions; we turned our attention towards substrates that 
would release fluorescent aldehydes and ketones in the presence of H2O2.  Unfortunately, α-
hydroxy boronates derived from aryl ketones and aldehydes are unstable and cannot be purified, 
limiting the scope. Even attempts to functionalize α-boryl silyl ethers using reductive etherification 
with aryl carbonyl compounds led exclusively to elimination products (Scheme 2.13). 
To synthesize a chloromethyl ether from α-hydroxyl boronate ester 2.17, we discovered 
that rather than the chloromethyl ether, a cyclic acetal was isolated in a high yield (Scheme 2.14). 
Scheme 2.13.  Attempted etherification with acetophenone 
Scheme 2.14 Unintentional synthesis of a cyclic acetal 
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We reasoned that with the appropriate group attached to a cyclic acetal, the addition of 
H2O2 would lead to the release of a fluorescent aldehyde or ketone.  Acetal 2.18 was accessed 
through DDQ-mediated oxidative cyclization from α-hydroxyl boronate 2.17 (Scheme 2.15).95 
Ketal 2.19 was synthesized via removal of the PMB group from 2.17 under hydrogenolytic 
conditions followed by acetal exchange with the dimethyl ketal of benzophenone to give ketal 
2.19. 
Scheme 2.15 Synthesis of acetal 2.18 and ketal 2.19 from α-hydroxy boronate ester 2.17 
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Acetal 2.18 rapidly reacts with H2O2 at pH 8.00 to give an equivalent of anisaldehyde and 
4-hydroxy-2-butanone (Scheme 2.16).  Over 50% of the starting material is consumed within 90
seconds, and complete conversion occurs in 15 minutes.    Although a hemiacetal was not observed 
via NMR, this is the suspected intermediate.  Ketal 2.19 reacts similarly, releasing an equivalent 
of benzophenone and 4-hydroxy-2-butanone.  This advance represents a novel approach for the 
design of compounds that can release aldehydes and ketones under oxidative conditions; previous 
work on this was discussed in 1.2.20, 96 
2.1.5 A novel biorthogonal scaffold for the release of a fluorescent aldehyde. 
With the scope defined, we turned our attention towards determining whether or not our 
scaffold would be sensitive to biologically relevant concentrations of H2O2.  The first step towards 
this was to synthesize an α-boryl ether that would release a fluorescent ketone or aldehyde.  
Starting with α-hydroxy boronate ester 2.8, Noyori acetalization with fluorescent coumarin 
Scheme 2.16 Oxidative breakdown of cyclic acetal 2.18 and cyclic ketal 2.19 
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derivative 2.20 gave caged fluorophore 2.21 (Scheme 2.17).97  Standard Brønsted acid catalyzed 
acetalization gave exclusively protodeboronation products. Compound 2.21 has λem and λex  values 
of 510 and 448 nm98 and compound 2.20 has λem and λex  values of 452 and 402 nm, this was used 
to monitor the oxidative breakdown at biologically relevant concentrations of H2O2.
Compound 2.22 was synthesized to verify the importance of the oxidative trigger in the 
fragmentation (Figure 2.4). Benzylic carbonate 2.23  was synthesized to compare the hydrolytic 
stability of 2.21 to a well-known scaffold used in several biological studies.14 
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Scheme 2.17 Noyori acetalization of aldehyde 2.20 and α-hydroxy boronate ester 2.8 
Figure 2.4 Acetal 2.22 and Carbonate 2.23 
59 
The fragmentation of acetal 2.21 was studied at a concentration of 25 µM at pH 7.4 with 
H2O2 concentrations of 100 and 200 µM (Figure 2.5).  The concentration of fluorophore 2.20 was 
monitored by excitation at 448 nm and emission at 499 nm (due to background from starting acetal 
2.21).  The product released was quantified through comparison to a standard curve.  These 
experiments are visualized in Figure 2.5. Compound 2.22 did not release fluorescent aldehyde 2.20 
upon exposure to H2O2 indicating the importance of boronate oxidation for cargo release. 
Lowering the concentration of H2O2 from 200 µM to 100 µM slowed fluorophore release 
indicating dependency on H2O2 concentration.  In the absence of H2O2, fluorophore release is 
minimal.  Additionally, hydrolytic stability was studied at pH 6.0 and pH 4.5. Fluorophore release 
was slightly inhibited at lower pH values. 
Figure 2.5  Fluorophore fragmentation at low substrate and peroxide concentration and pH stability studies. 
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To demonstrate that hydrolytic breakdown without H2O2 is minimal, the ratio of 
fluorophore release in the presence and absence of H2O2 for carbonate 2.23 and acetal 2.21 was 
compared; the results show that ratio is nearly equivalent (Figure 2.6).  
To test the vulnerability of 2.21 to other ROS, solutions of H2O2, NaOCl, KO2, and t-
BuOOH were prepared and added to a 40 µM solution of acetal 2.21 in pH 7.4 buffer to give final 
concentrations of 200 µM for each oxidant (Figure 2.7).  Additionally, solutions of hydroxyl and 
t-butoxyl radicals were prepared by mixing H2O2 with FeSO4-5H2O and adding catalase as a
peroxide scavenger.   H2O2 and hydroxyl radicals are the only ROS that showed any significant 
fluorophore release, albeit hydroxyl radical released fluorophore at a lower magnitude.  
Figure 2.6. Fluorophore release from acetal 2.21 compared to carbonate 2.23 
Figure 2.7. Comparison of fluorophore release by different oxidants [2.21] =40 µM [oxidant] = 200 µM 
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The in vitro results led us to investigate the fragmentation and release of fluorophore 2.20 
from acetal 2.21 in a biologically relevant environment.  These experiments were performed by 
Yuta Naro in collaboration with the Dieter’s group.  We chose to adapt a protocol from Chang, 
where HeLa cells were incubated with acetal 2.21 for 45 min, then imaged in the presence and 
absence of exogenous H2O2 (100 µM) (Figure 2.8).  In the absence of H2O2, very little fluorophore 
release occurred; however, in the presence of H2O2, a large amount of fluorophore release was 
observed.  These results demonstrate that α-boryl ethers are capable of crossing cell membranes 
and can release their cargo within cells. These studies were also conducted with acetal 2.22, and 
they resulted in no release of the fluorophore in the presence and absence of H2O2; providing 
further evidence for the oxidative release mechanism. 
Since HeLa cells are derived from cancerous tissues, they are expected to contain elevated 
levels of endogenous H2O2 and will therefore have a higher background.99  The same experiment 
was performed in HEK293T cells, derived from noncancerous tissue and the background was 
significantly reduced in the absence of H2O2 for the breakdown of acetal 2.21 (Details in Appendix 
A).  To further provide evidence that α-boryl ethers are excellent scaffold for cargo release under 
biological conditions, we demonstrated oxidative breakdown in the presence of endogenously 
Figure 2.8 Fluorophore release from 2.21 in HeLa cells treated with exogenous H2O2. 
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produced H2O2 (Figure 2.9).  To achieve this, HeLa cells were incubated with 1 µM Phorbol 
myristate acetate (PMA) (which is known to promote intracellular H2O2 generation),100 followed 
by acetal 2.21 (10 µM).  Cells incubated with PMA showed increased fluorescence over cells that 
were not; showcasing the capacity of α-boryl ethers to act as vehicles for H2O2  triggered 
release within cells. 
Thus, the synthesis of α-boryl ethers their effectiveness as vehicles for the release of cargo 
within a biological environment was established.  This advancement represents the first example 
of alkyl boronate esters being used in a cellular environment as triggers for H2O2.   Additionally, 
the release of cargo is not accompanied by the release of cytotoxic quinone-methides.   
Figure 2.9 Cellular oxidative fluorophore release from acetal 2.21 in the presence of endogenously produced H2O2 
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3.0  BISTRAMIDE A 
The Bistramides are a class of bioactive small molecules isolated from the marine ascidian 
Lissoclinum bistraum in 1989.101  Bistramide A, B, C, D, and K all showed broad, potent 
antiproliferative effects towards several tumor cell lines (Figure 3.1).102  In 2005, Kozmin 
discovered that Actin is the primary cellular receptor for Bistramide A.103 Several approaches 
towards its total synthesis and synthesis of potent analogues have been undertaken.  In this section, 
previous strategies towards the synthesis of Bistramide A as well as previous synthesis of 
analogues of Bistramide A will be discussed.  Utilizing a previous 14-step route to the synthesis 
of Bistramide A,104  the author will describe the synthesis and biological activity of five analogues 
of Bistramide A.  
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3.1 PRIOR SYNTHESES OF BISTRAMIDE A 
Retrosynthetically, Bistramide A can be divided into fragment A, fragment B, and fragment 
C by the 2 amide linkages (Scheme 3.1).  The two major syntheses of Bistramide A described in 
this section follow this retrosynthetic pathway 
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Scheme 3.1 Retrosynthesis of Bistramide A 
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3.1.1 Kozmin’s 2004 Synthesis of Bistramide A 
The first total synthesis of Bistramide A was reported by Kozmin in 2004 with a longest 
linear sequence of 15 steps.105  Kozmin’s synthesis of fragment A is presented in Scheme 3.2.  At 
the outset of  Brown crotylation of aldehyde 3.1 gives alcohol 3.2,106 which is protected as a benzyl 
ether then the TBS group is removed with TBAF.  A Mitsunobu reaction with phthalimide gave 
3.3,107 which underwent ring-opening/cross-metathesis with strained cyclopropane acetal 3.4.108  
Deprotection of the resulting acetal with H2SO4 gives dieneone 3.5.   Cross-metathesis with benzyl 
ether 3.6 gives dienone 3.7. Deprotection of the three benzyl ethers via hydrogenolysis and the 
subsequent cyclization forms spiroketal 3.8 as a single diastereomer.  3.8 was oxidized to the 
aldehyde, then underwent Cr-mediated olefination to give enone 3.9.109   Itsuno-Corey 
reduction,110 then deprotection of the phthalimide gives amine 3.10 and completes fragment A.  
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Scheme 3.2 Kozmin's Synthesis of the left fragment of Bistramide A 
Reagents and Conditions
a) Brown Crotylation, 84%, 94% ee.  b-c) KH, BnBr, Bu4NI then TBAF, 59% over 2 steps d) phthalimide, PPh3, DIAD, 94% e) Grubbs Catalyst II, 
Benzene, then H2SO4, MeCN 72% f) Grubbs Cataklyst II, CH2Cl2, 68% g) Pd(OH)2, EtOAc/MeOH, H2, 61% h) DMP, CH2Cl2, 95%, i) 
dibromoketone, CrCl2, THF, 50% j) (R)-2-methyl-CBS-oxazoborolidine, Catecholborane, PhMe, 85% k) MeNH2, MeOH, 65º C, quantitative
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Fragment B is synthesized via brown crotylation of aldehyde 3.11, protection of the 
acetonide and oxidative cleavage of the alkene to give carboxylic acid 3.12 (Scheme 3.3). Acid-
mediated deprotection of the acetonide and protection of the resulting amine gives 3.13  (fragment 
B). 
Fragment C is assembled from Brown crotylation of TBS-protected aldehyde 3.14 gives 
alcohol 3.15 (Scheme 3.4). Acylation with acryloyl chloride, ring-closing metathesis, and Pd/C 
reduction of the double bond gives lactone 3.16.  Reduction/acylation of lactone 3.16 with DIBAL 
then protection of the lactol with acetic anhydride gives acetate 3.17. ZnCl2 mediated substitution 
of the acetal with silyl enol ether 3.18 affords enone 3.19.  Deprotection of the TBS ether, then 
oxidation of the resulting alcohol to the acid followed by DCC-mediated amide coupling with N-
hydroxy succinimide provides activated ester 3.20 (fragment C).  
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Reagents and Conditions
a) Brown Crotylation, 64%, 93% ee b) Me2C(OMe)2, TsOH-H2O, 90% c) NaIO4, RuCl3, 62%
d) 3N HCl, EtOAc, quantitative e) FmocOSu, Na2CO3, 71%
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Reagents and Conditions
a) Brown Crotylation, 63%. 93% ee b) Acryloyl chloride, NEt3, DMAP, 88% c) Grubbs Catalyst II (13 mol%), CH2Cl2, 72% d) H2, Pd/C, EtOAc, 99%
e) DIBAL, CH2Cl2, -78°C f) Ac2O, pyridine, DMAP, 81% over 2 steps g) CH2Cl2, ZnCl2, -78°C h) HF, CH3CN i) H5IO6,CrO3, CH3CN (0.75 % H2O), 
37% over 3 steps j) N-hydroxysuccinimide, DCC, CH3CN, 98%
3.14
3.15 3.16 3.17
3.19
3.18
Scheme 3.3 Kozmin's synthesis of the middle fragment of Bistramide 
Scheme 3.4 Kozmin’s synthesis of the right fragment of Bistramide A 
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Fragment A (3.10) and fragment B (3.13) are coupled via py-BOP condensation, then 
deprotected to afford amine 3.21 (Scheme 3.5).  Deprotection followed by treatment with activated 
ester fragment C (3.20) affords Bistramide A.  This highly convergent enantioselective synthesis 
is achieved in 15 steps. 
3.1.2 Crimmins 2006 Synthesis of Bistramide A 
After the completion of Kozmin’s synthesis, the Crimmins group published their own route 
towards Bistramide A.111 Crimmins’ synthesis differs with respect to all three fragments. 
Fragment A was constructed starting with the alkylation of valine derived oxazolidinone 3.21 with 
benzyloxyacetyl chloride to give benzyl glycolate 3.22 (Scheme 3.6).112  The enolate of imide 3.22 
was alkylated with allyl iodide, then reductively cleaved and oxidized under Swern conditions to 
give aldehyde 3.23. 113 A Julia olefination with sulfone 3.24 gave diene 3.25 as a mixture of 
isomers.114 Cross-metathesis with methyl acrylate, then reduction with Pd/C under H2 and acid 
mediated lactonization give lactone 3.26.  The addition of the lithium acetylide of 3.27 to lactone 
3.26 gives a keto alcohol, which was subsequently reduced under Pd/C and H2 to give spiroketal 
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Scheme 3.5 Kozmin's final coupling to synthesize Bistramide A 
a) PyBOP, DIEA, DMF 88%; (b) Et2NH, DMF; (c) DMF 82% (two steps) 
Reagents and Conditions
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3.28.  The phthalimide was installed under Mitsunobu conditions115 and the TBDPS ether was 
deprotected with HF-pyridine to give an alcohol.  The alcohol was oxidized with Dess-Martin 
Periodinane,116 then subjected to Horner-Wadsworth-Emmons olefination to give enone 3.29.117 
Stereoselective reduction of the alcohol with Corey’s oxazoborolidine gives an alcohol.110 Finally, 
cleavage of the phthalimide group with MeOH and methylamine gives fragment A (3.30).  
To synthesize fragment B, allylic alcohol 3.31 underwent Sharpless assymetric 
epoxidation, then the resulting epoxy alcohol was opened with lithium dimethyl cuprate to give 
1,3 diol 3.32 as a mixture with the corresponding 1,2 diol (Scheme 3.7).  Treatment with NaIO4 
removed the 1,2 diol and gave pure 1,3 diol 3.32.  Protection with TBSOTf gave bis-silyl ether, 
then oxidative removal of PMB with DDQ gave alcohol 3.33.  The azide was installed under 
Mitsunobu conditions, then the TBS ether was cleaved with catalytic camphorsulfonic acid to give 
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Scheme 3.6 Crimmins synthesis of the left fragment of Bistramide A 
Reagents and Conditions
a) n-BuLi, then  98%; benzyloxyacetyl (b) NaHMDS, allyl iodide, THF, PhMe, 81%;  (c) LiBH4, MeOH, Et2O, 98%; (d) Et3N, DMSO, (COCl)2, 
CH2Cl2 3.24, then aldehyde 3.23, 87%;  (e) LiHMDS, chloride, sulfone 86%; (f) Grubbs Catalyst II, methyl acrylate, CH2Cl2, 40 °C, 87%; (g) H2, 
Pd/C, EtOAc; (h) p-TSA, benzene, 80 °C, 70% (two steps); (i) alkyne 3.27, n-BuLi, 3.26; (j) H2, Pd/C, MeOH, EtOAc, 83% (two steps); (k) PPh3, 
DEAD, phthalimide, THF, 0 °C; 58%; (l) HF/pyr., THF, 84% (over 2 steps) (m) Dess-Martin periodinane n) Ba(OH)2, THF, MeCOCH(Me)P(O)
(OEt)2 , 58% o) (R)-CBS, catecholborane. Toluene, 65%; p) MeOH, MeNH2, 99%
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3.34.  Oxidation of the primary alcohol to the carboxylic acid, reduction of the azide with Pd/C 
under H2, and protection of the primary amine gave fragment B (3.35).   
To construct fragment C, aldehyde 3.36 was added to the chlorotitanium enolate of 
thiazolidinethione 3.37 gave aldol adduct 3.38 (Scheme 3.8).118  Reductive cleavage, then a 
Horner-Wadsworth-Emmons olefination gave unsaturated ester 3.39.  Reduction of the alkene on 
Pd/C and H2, then acid-catalyzed lactonization and reductive acylation119 gave acetate 3.40 as a 
mixture of diastereomers (9:1 dr). in situ addition of silyl enol ether 3.41 to acetate 3.40 followed 
by deprotection of the TIPS ether with H2SiF6 gave alcohol 3.42.  Oxidation to the carboxylic aicd 
and amide coupling with N-hydroxy succinimide gives fragment C (3.43).          
Reagents and Conditions
(a) l-(+)-DET, Ti(Oi-Pr)4, t-BuOOH, CH2Cl2, 4 Å sieves, -20 °C, 95%, 98% ee; (b) Me2CuLi, Et2O, -50 °C to 25 °C, 6:1 of 
1,3- to 1,2-diol; NaIO4, H2O, 71%; (c) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C, 97%; (d) DDQ, pH 7 buffer, CH2Cl2, 0 °C, 
98%; (e) DEAD, PPh3, (PhO)2PON3, THF, 0 °C, 90%; (f) CSA, MeOH, CH2Cl2, 0 °C, 85%; (g) NaClO2, TEMPO, 
CH3CN, 35 °C, 95%; (h) HF/pyr., THF, 70%; (i) H2, Pd/C, Fmoc-OSu, THF, 70%.
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(a) TiCl4, NMP, (-)-sparteine, CH2Cl2, -78 °C, 6, 87%; (b) i-Bu2AlH, THF, -78 °C; (c) Ph3PCHCO2Et, CH2Cl2, 78%
(two steps); (d) H2, Raney Ni, EtOH; (e) PPTS, CH2Cl2, 40 °C, 81% (two steps); (f) i-Bu2AlH, pyridine, DMAP,
Ac2O, CH2Cl2, -78 to -20 °C, 96%; (g) Et3N, TMSOTf, 3-penten-2-one, CH2Cl2, 0 °C then -78 °C, then add
acetate 3.40, 87%, 9:1 dr; (h) H2SiF6, CH3CN, 0 °C, 75%; (i) H5IO5/CrO3, CH3CN, 77%; (j) N-
hydroxysuccinimide, EDC·HCl, CH2Cl2, 100%.
OTMS +
3.42
Scheme 3.7 Crimmins Synthesis of the middle fragment of Bistramide A 
Scheme 3.8 Crimmins Synthesis of Fragment C (3.43) 
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Completion of Crimmins’ synthesis of Bistramide A was nearly identical to Kozmin’s 
synthesis.  Overall Crimmins synthesis was 18 steps compared to Kozmin’s 15. 
3.1.3 Floreancig’s 2014 Synthesis of Bistramide A 
The most efficient synthesis to date of Bistramide A was reported by the Floreancig group 
in 2014.104  The retrosynthetic plan put forth by Floreancig was quite similar to those reported by 
Crimmins and Kozmin.  The key component of the synthetic plan was the formation of the 
spiroketal of Fragment A through a one-pot enantioselective Hetero-Diels-Alder (HDA) 
cycloaddition with Cr catalyst A,120 C-H bond cleavage with DDQ,121 and 
protodesilylation/cyclization (Scheme 3.9).122 
Aldehyde 3.44 was synthesized by epoxidation with mCPBA, then oxidation with H5IO6 
in two steps from (+)-β-citronellene.123  To synthesize siloxydiene 3.45 4-chlorobutanol is oxidized 
to the aldehyde using Pahrick-doring conditions,124 then Brown crotylation106 and silyl ether 
protection gives alkene 3.46 (Scheme 3.10).  Suzuki coupling125 with  (E)-4-iodobut-3-en-2-one 
yielded an enone, which was converted into siloxy diene 3.45 in the presence of NEt3 and 
triethysilyltrifluoromethanesulfonate.  An enantioslective HDA reaction, DDQ treatment, and acid 
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mediated ring closure yielded spiroketal 3.47. Spiroketal 3.47 was subjected to a variation of a 
Wolff-Kishner reduction126 to give spirocycle 3.48, which underwent cross-metathesis with 
methacrolein in the presence of Nitro-Grela catalyst to give aldehyde 3.49. A diastereoselective 
addition of Me2Zn into aldehyde 3.49 in the presence of (-)MIB gave alcohol 3.50.  Finally, to 
complete azido fragment A, chloride displacement in the presence of NaN3 gave azide 3.51.   
Scheme 3.10 Floreancigs synthesis of Fragment A (3.51) 
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 Floreancig’s approach towards fragment C begins with Parikh-Doering oxidation of 
monoprotected alcohol 3.52, followed by Brown Crotylation to give homoallylic alcohol 3.53 
(Scheme 3.11). Rhodium catalyzed hydroformylation of homoallylic alcohol 3.53 under high 
pressure H2/CO (Syngas) and Breit’s self-assembling supramolecular ligand (6-DPPon) forms a 
lactol,127-128 which can be protected with acetic anhydride to form acetate 3.54 as an 
inconsequential mixture of diastereomers.  The addition of the in situ formed silyl enol 
ether derived from 3-penten-2-one into 3.54 occurs with desilylation to give alcohol 3.42 (see 
Kozmin synthesis).  Completion of fragment C was performed in a manner identical to 
Kozmin to give succinimide 3.43.  
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atm); then Ac2O Et3N, DMAP, 91%; d) 3-penten-2-one, TMSOTf, Et3N CH2Cl2, -78°C, 57%; e) H5IO6, CrO3,
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Scheme 3.11 Floreancig’s synthesis of Fragment C 
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Succinimide 3.43 and β-amino acid fragment 3.55 (fragment B of Kozmin’s synthesis) 
were coupled together in the presence of diisopropyethylamine, then DCC esterification with N-
hydroxysuccinimide gives succinimide 3.56 (Scheme 3.12). 
 
To complete the Synthesis, Staudinger reduction of azide 3.51, followed by addition into 
succinimide 3.56 gives Bistramide A in 14 steps (Scheme 3.13). 
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Scheme 3.12 Coupling of Fragment B and Fragment C to form BR 
Scheme 3.13 Floreancigs completion of Bistramide A 
Reagents and Conditions
a) THF:H2O 3:1, PME3 b) DMF, 3.56, 61%
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3.2 PREVIOUS ANALOGUES OF BISTRAMIDE A 
Since the  unexpected discovery that Bistramide A’s primary cellular receptor is Actin,103 
several analogues for Bistramide A have been synthesized, primarily to determine its mode of 
action and increase potency.  The rational design of Bistramide A analogues can be inferred from 
the X-ray structure of Bistramide A bound to actin, reported by Kozmin in 2006.129  The central 
amino acid fragment of Bistramide A establishes several polar contacts with its target and the 
spiroketal fragment occupies a hydrophobic pocket (Figure 3.2). 
Figure 3.2 Bistramide A contacts involve with A-Actin recognition 
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3.2.1 Kozmin’s Bistramide Analogues 
Comprehensive characterization of the mode of action of Bistramide A and the structural 
components essential for its potency were reported in 2008 through the synthesis of several 
structural analogues of Bistramide A (Figure 3.3).130  Each analogue reported was evaluated based 
on its ability to bind monomeric actin (Kd) and the compounds ability to inhibit cell growth of 
A549 (nonsmall cell lung cancer) cells (GI50).  
The X-ray crystal structure of Bistramide A bound to Actin suggests that the middle amino 
acid fragment and the left spiroketal fragment played an influential role in establishing a hydrogen 
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Figure 3.3.  Rationally designed analogues of Bistramide A, their growth inhibition (GI50) and their 
dissociation constants (Kd) with monomeric actin 
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bond-network and hydrophobic interactions with its cellular target.  Analogue 3.57 and analogue 
3.58, the spiroketal fragment and the amino acid fragment respectively, showed no activity; 
suggesting that both fragments together are essential.  When the fragments are linked (3.61), actin 
binding was restored to a partial extent; although cellular inhibition is low compared to the 
Bistramide A. Elimination of the two methyl groups on the spiroketal fragment (3.59) led to a 
sharp decrease in actin-binding efficiency, which is consistent with the hypothesis that the 
spiroketal interacts with a hydrophobic pocket in Actin.  Adding in the pyran portion of the right 
fragment (3.60) didn’t have a significant effect on the actin-binding or cell inhibition.  
Incorporation of the enone portion of the right fragment (3.62 and 3.63) dramatically increased 
cell-based activity.  This finding suggests that the enone containing bistramide analogues 3.62 and 
3.63  and Bistramide A suggest that Actin may be covalently modified.  Monitoring the interaction 
of the 3.62, 3.63, and Bistramide A with Actin using MS analysis revealed the presence of high 
molecular weight peaks consistent with covalent modification.  The unprecedented high reactivity 
of Cys-374 on actin 131 suggests that Michael addition of the Cys-374 thiol to the enone portion of 
the Bistramide Analogues contributes significantly to the cytotoxic activity of Bistramide A and 
analogues 3.62 and 3.63.   
This work led to the development of rationally simplified bistramide analogue 3.64 (Figure 
3.4).132  Compound  3.64 contains the lipophilic/hydrophobic spiroketal fragment and the 
hydrophilic middle fragment, both of which are essential for retaining actin-binding activity; 
removal of the enone minimize in vivo toxicity and thus makes 3.64 more appropriate for living 
tissue.  Compared to the dissociation constant (Kd) for Bistramide A with Actin-G of 6.8 nm, 3.64 
has a comparable Kd (9.0 nm).  Analogue 3.64 depolymerizers actin in vitro, inhibits growth of 
cancer cell lines in vitro, and suppresses A549 (nonsmall cell lung cancer) tumor growth in vivo.  
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3.2.2 Panek’s Bistramide A Stereoisomer Library 
35 stereoisomers of Bistramide A were reported and tested by Panek in 2009, a single 
analogue, 3.65 had enhanced potency compared to Bistramide A (Figure 3.5). This work 
showcases the ability of crotylsilane reagents 3.66, 3.67, and 3.68. In a prior synthesis of 
Bistramide A reported by the Panek group,133  these three chiral reagents were used to establish 8 
of the 11 stereoisomers of Bistramide A.  Stereodifferentiation of 3.66 and 3.67 were used to 
provide 8 possible isomers for fragment C in 9 steps (Scheme 3.14).  The key step in the sequence 
was a [4 +2}-annulation with  β-benzyloxyaldehyde with each stereochemical variant of 3.66 and 
3.67.  This forms the required pyran ring and establishes the relative stereochemistry of the methyl 
group relative to the ring junctions.  An 8-step sequence was then used to synthesize the 8 
stereoisomers of the carboxylic acid of fragment C.   
O
O
H
N
O OH
N
H
H
H
O
OMe
Analogue 3.64
Kd = 9.0 nM      GI50
 = 0.065 µM
OH
Figure 3.4 Rationally designed Bistramide Analogue for In vivo studies 
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3.68 and its corresponding enantiomer were used to provide the 4 isomers of amino acid 
fragment B (Scheme 3.15).   This was achieved through a two-step sequence that consisted of 
[3+2]-annulation followed by a SbCl5 mediated E2 elimination to give homoallylic alcohols. SnCl4 
provides the anti relationship and BF3-OEt2 provides the syn relationship.  An 8 step sequence 
provides the four isomers of TIPS protected fragment B. 
Coupling of the 4 diastereomers of TIPS Protected Fragment B and the 8 isomers of 
carboxylic acid Fragment C provides 32 different isomeric fragments of 3.69 (Scheme 3.16).  
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Scheme 3.14 Synthesis of 8 stereoisomers of Fragment C of Bistramide A 
Scheme 3.15 Synthesis of 4 isomers of Fragment B of Bistramide A
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Finally, a sequence of deprotection of the TIPS ester 3.69, followed by coupling with 
spiroketal fragment A and its corresponding epimer; then silyl ether deprotection leads to the 35 
isomer library of Bistramide A analogues. 
   The 35-isomer library of Bistramide Analogues was screened for actin depolymerization 
and cytotoxicity.    Only a single stereochemical isomer, 3.65, was found to be more potent than 
Bistramide A by a factor of two (Figure 3.5).  Surprisingly, 3.65 differs at the ring junction of the 
tetrahydropyran portion of fragment C, which was demonstrated by Kozmin to not have an effect 
on potency as much as fragment B and fragment A.  Additionally, the alcohol epimer of Bistramide 
A, 3.70, exhibited similar potency to Bistramide A, suggesting that the stereochemical 
configuration of the alcohol on fragment A is inconsequential for biological activity. 
Figure 3.5 Most potent stereoisomers of Bistramide A 
Scheme 3.16 Coupling of Fragment B and Fragment C to synthesize 32 isomers of BR 
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3.3 NOVEL ANALOGUES OF BISTRAMIDE A, SYNTHETIC OPTIMIZATION, 
AND BIOLOGICAL ACTIVITY 
Our group currently has the shortest sequence for the synthesis of Bistramide A at 14 
steps.  In the synthesis of fragment A, there is a three step Wolff-Kishner reduction to remove the 
ketone from the spiroketal ring.  We reasoned that since the spiroketal plays a central role in 
determining biological potency; analogues of Bistramide A could easily be synthesized with 
different levels of oxidation in the spiroketal ring in a shorter sequence than the synthesis of the 
natural product. Starting with spiroketal intermediate 3.47, cross-metathesis with methacrolein in 
the presence of Hoveyda-Grubbs metathesis catalysis give di-carbonyl compound 3.71.  
Unfortunately, the addition of Me2Zn in the presence of (-) MIB simply led to decomposition 
(Scheme 3.17). 
We reasoned that the synthesis of our desired analogues could be even further simplified 
by ignoring the secondary alcohol stereocenter of the spiroketal fragment. Prior work on 
bistramide analogues has shown that changes to the alcohol on the spiroketal fragment do not 
dramatically effect biological activity.  We planned to make five bistramide analogues, axial and 
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Scheme 3.17 Attempted dimethyl zinc addition into catbonyl 3.71 
Reagents and conditions
Methacroleine:CH2Cl2 5:1, HG-II, 63% 
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equatorial alcohols 3.72 and 3.73, ketone analogue 3.74, methyl ether analogue 3.75, and fully 
reduced analogue 3.76 to compare to synthetic Bistramide A.  
Figure 3.6 Novel analogues of Bistramide A 
OH
O
O
H
N
O OH
N
H
O
O
H
O
H
Bistramide A
H
H
HO
O
O
H
N
O OH
N
H
O
O
H
O
H
H
H
HO
O
O
H
N
O OH
N
H
O
O
H
O
H
H
H
HO
HO
O
O
H
N
O OH
N
H
O
O
H
O
H
H
H
O
MeO
O
O
H
N
O OH
N
H
O
O
H
O
H
H
H
O
HO
O
O
H
N
O OH
N
H
O
O
H
O
H
H
H
3.72
3.73
3.74
3.75
3.76
HO
82 
3.74 was synthesized by cross-metathesis between alkene 3.47 and methacrolein in the 
presence of HGII (E:Z 10:1). The E and Z isomers were inseparable and thus the synthesis of each 
of the analogues was completed as a mixture.  Results from prior work on Bistramide analogues 
show that the Z isomer will not have a dramatic effect on the potency; with reported GI50 values 
lower than Bistramide A by a factor of five.134  Chemoselective reduction of aldehyde 3.71 with 
a single equivalent of L-selectride (Scheme 3.18) followed by chloride displacement gives azide 
3.77.  Coupling with succinimide 3.56 affords ketone analogue 3.74.  To synthesized methyl ether 
analogue 3.75, azide 3.77 was methylated with methyl triflate and 2,6-ditertbutylpyridine to give 
azide 3.78, which was coupled with succinimide 3.56 to form methyl ether analogue 3.75.  
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Scheme 3.18 Synthesis of Bistramide analogues 3.74 and 3.75 
Reagents and Conditions
a) Methacrolein:CH2Cl2 5:1, HG-II, 68%. b) L-selectride, THF, -78°C, 67% c) NaN3, DMF, 50°C, 92%. d) PMe3, THF:H2O 3:1, then 3.56, DMF, 
41% e) 2,6 ditertbutylpyridine, MeOTf, CH2Cl2, 69% f) PMe3, THF:H2O 3:1, then 3.56, DMF, 31%
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To prepare axial analogue 3.72, dicarbonyl 3.71 was reduced with NaBH4 to give the axial 
alcohol (Scheme 3.19). Chloride displacement with sodium azide in DMF give azide 3.79. 
Staudinger reduction and addition into succinimide 3.56 gives axial alcohol bistramide analogue 
3.72.  
To synthesize the equatorial analogue, alkene 3.47 was subjected to Meerwein-Pondorf-
Verley reduction conditions mediated by Sm in isopropanol delivers the hydride in the axial 
position to give thee equatorial alcohol (Scheme 3.20).  The high selectivity observed in this 
reduction likely results from coordination of Sm to the axial alcohol of the spiroketal ring. Cross-
metathesis, NaBH4 reduction, and chloride displacement gives azide 3.80, which undergoes 
coupling with succinimide 3.56 to give equatorial bistramide analogue 3.73.     
To synthesize the fully reduced analogue, ketone 3.81 was subjected to modified Wolff-
Kishner reduction conditions and the ketone was removed over three steps.  Chloride displacement 
provides azide 3.82, which undergoes coupling with succinimide 3.56 to give bistramide analogue 
3.76. 
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c) PMe3, THF:H2O 3:1, then 3.56, DMF, 43%
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Scheme 3.19 Synthesis of 3.72 
Scheme 3.20 Synthesis of Bistramide analogue 3.73 
Reagents and Conditions
a) Sm, isopropanol, 75% b) Methacroleine:CH2Cl2 5:1, HG-II, 68%.
c) NaBH4, MeOH 0°C, 81%.  d) NaN3, DMF, 50°C, 90%. e) PMe3, THF:H2O 3:1, then 3.56, DMF, 39%
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In collaboration with the Deiter’s group, Yuta Naro tested the five analogues of 
Bistramide A as well as synthetically prepared Bistramide A.  Alcohol containing bistramide 
analogues 3.72 and 3.73 showed dramatically reduced activity compared to Bistramide A.  This 
is perhaps not a surprising result, as Kozmin demonstrated that maintaining the hydrophobicity 
of the spiroketal core is essential for activity. Ketone and methyl ether analogues 3.74 and 
3.75 showed modest decreases in activity compared to Bistramide A; thus the ketone is 
tolerated.  Surprisingly, fully reduced analogue 3.76 showed increased activity compared to 
Bistramide A. 
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Scheme 3.21 Synthesis of bistramide analogue 3.76 
Reagents and Conditions
a) MeOH, TsNHNH2 b) MeOH:THF, NaBH3CN c)  EtOH/H2O 20:1, NaOAc, 47% over 3 
steps d)  NaN3, DMF, 50°C, 81%. e)  PMe3, THF:H2O 3:1, then 3.56, DMF, 54%
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3.73 
GI50 = ND
Bistramide A 
GI50 = 95 ± 9 nM
3.72 
GI50 = 2575 ± 992 nM
3.74 
GI50 = 331 ± 49 nM
3.76 
GI50 = 45 ± 2 nM
3.75 
GI50 = 296 ± 162 nM
Figure 3.7  GI50 curves for Bistramide A, 3.73, 3.72,3.74, 3.76, and 3.75 in small cell lung cancer (A549) cells. 
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Inspired by these results we envisioned a more convergent route towards the synthesis of 
a potent analogue of Bistramide A.  Starting with epoxide (+) β-citronellene, 3.83 was synthesized 
by selective epoxidation of the more electron rich alkene.  Epoxide 3.83 undergoes cross-
metathesis in the presence of 2-methallyl acetate and HG-II to give allyl acetate 3.84 in E:Z ratio 
of 5:1.  Cleavage of epoxide 3.84 in the presence of H5IO6 gives aldehyde 3.85.       
Aldehyde 3.83 and siloxydiene 3.45 undergo a one-pot HDA with Cr catalyst B, DDQ 
oxidation, and acid mediated cyclization to give spirocycle 3.86.  Spirocycle 3.86 can then undergo 
a one-pot acetate deprotection, azide displacement reaction to give 3.77, the precursor to 
bistramide analogue 3.74.    
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Scheme 3.22 Synthesis of aldehyde 3.83 
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Scheme 3.23 A more convergent route towards the synthesis of a potent Bistramide Analogue 
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Thus completion of the synthesis of Bistramide analogue 3.74 can be accomplished in 9 
steps, this is an improvement over the best prior synthesis of Bistramide A which is 14 steps. 
Obviating the need to reduce the ketone removes a three-step sequence and altering the allylic 
alcohol from 2° to 1° greatly expedites the synthesis. 
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APPENDIX A 
Alcohol, Aldehyde, and Ketone Liberation and Intracellular Cargo Release 
through Peroxide Mediated α-boryl ether Fragmentation (Supporting Info) 
1,3-dicyclohexyl-1H-imidazol-3-ium tetrafluoroborate ((ICy)BF4). To a flame 
dried, 2-neck, 500 mL round bottom flask containing a stir bar was added toluene (100 
mL), followed by cyclohexylamine (9.92 g, 100 mmol).  Paraformaldehyde (3.16 g, 100 
mmol) was added, the flask was sealed and allowed to stir under N2 for 30 minutes.  The 
reaction was cooled to 0 °C using an ice-water bath and cyclohexylamine (9.92 mmol, 100 mmol) 
was added dropwise via syringe.  The reaction was allowed to stir for 15 minutes and then 48 wt% 
HBF4 in H2O (12.6 mL, 96.4 mmol) was added dropwise.  The reaction was allowed to stir for 30 
minutes and then glyoxal trimer dihydrate (6.93 g, 33.0 mmol) was dissolved in 20 mL of H2O 
and added via syringe. The reaction was sealed and allowed to stir under N2 at 50 °C for 16 hours. 
The solid precipitate was filtered off and washed with 100 mL of H2O and 100 mL of diethyl ether. 
Recrystallization of the resulting off-white solid in 2:1 ethyl acetate:CH2Cl2 gave (ICy)BF4 (10.8 
g, 33.7 mmol, 33% yield). Characterization data is consistent with that reported in the literature.135 
Data for ICyBF4 
1H NMR  (400 MHz, CDCl3) 
8.93 (s, 1H), 7.44 (d, J = 8.0 Hz, 2H), 4.32 (tt, J = 3.6, 12 Hz, 2H), 2.19-2.16 (m, 4H), 1.92-1.89 
(m, 4H), 1.76-1.66 (m, 6H), 1.52-1.42 (m, 4H), 1.32-1.24 (m, 2H) ppm 
N
N
BF4
-
89 
13C NMR (125 MHz, CDCl3) 
133.18, 120.37, 60.07, 33.29, 24.93, 24.57 ppm 
TLC Rf = .2 (10% Et2O/CH2Cl2) [silica gel, I2 stain] 
2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (2.1). To a flame dried, 
250 mL round bottom flask containing a stir bar was added bis(pinacolato)diboron 
(1.93 g, 7.62 mmol), 1,3-bis(cyclohexyl)imidazolium tetrafluoroborate (0.22 g, 0.69 mmol), 
NaOtBu (0.13 g, 1.39 mmol), and CuCl (0.14 g, 1.4 mmol). Toluene (50 mL) was added, the flask 
was sealed, and the reaction was stirred for 30 min. 2-Butanone (0.50 g, 6.9 mmol) was added via 
syringe followed immediately by MeOH (0.43 g, 14 mmol).  After three h the mixture was loaded 
directly onto a short silica plug pretreated with CH2Cl2.  The column was then washed with copious 
amounts of Et2O and the eluent was removed under reduced pressure.  The resulting residue was 
purified by silica gel column chromatography (Rf = 0.4, 5% Et2O in CH2Cl2) to yield the title 
compound as a colorless oil (1.14 g, 5.68 mmol, 82% yield).  
Data for 2.1 
1H NMR  (500 MHz, CDCl3) 
δ 1.63 (m, 2H), 1.49 (m, 1H), 1.29 (s, 12H), 1.25 (s, 3H), 0.95 (t, J = 6.5 Hz, 3H) 
11B NMR (160 MHz, CDCl3) 
δ 33.1 
13C NMR (125 MHz, CDCl3) 
δ 84.2, 34.0, 25.7, 24.72, 24.71, 9.5 
IR  (thin film, NaCl) 
3400, 2890,1431,1336,1109 cm-1 
90 
HRMS  (FTMS ES+) 
[M+Na]+ Calculated for C10H21BO3Na 223.1476, found 223.1473 
TLC 
Rf = 0.4 (5% Et2O/CH2Cl2) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 2-(2-(Methoxymethoxy)butan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(2.4). To a flame dried, 10 mL round bottom flask containing a stir bar was added 
CH2Cl2 (5 mL), α-boryl alcohol 2.2 (0.083 g, 0.42 mmol), and (iPr)2NEt (0.107 g, 0.457 mmol). 
The flask was sealed, then evacuated and refilled with Ar (3x) using a balloon equipped with a 
needle and a rubber adapter. The solution was cooled to 0 °C using an ice-water bath and then 
ClCH2OMe (0.037 g, 0.46 mmol) was added dropwise via syringe. The reaction was stirred 
overnight, then was quenched with saturated aqueous NaHCO3 (5 mL).  The reaction mixture was 
transferred to a separatory funnel, the two layers were separated and the aqueous layer was 
extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were washed with brine (2 x 10 
mL), dried over Na2SO4, filtered, and concentrated under reduced pressure.  The resulting residue 
was purified by silica gel column chromatography (Rf = 0.7, 20% Et2O in hexanes) to yield the 
title compound as a colorless oil (0.093 g, 0.38 mmol, 92% yield).  
Data for 2.4 
1H NMR  (400 MHz, CDCl3) 
δ 4.69 (dd, J = 12.9 Hz, 12.9 Hz, 2H), 3.36 (s, 3H), 1.63 (m, 2H), 1.26 (s, 12 H), 1.22 (s, 3H), 0.89 
(t, J = 7.48 Hz, 3H)  
11B NMR (128 MHz, CDCl3) 
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δ 32.2  
13C NMR (100 MHz, CDCl3) 
δ 92.6, 83.6, 55.4, 31.2, 24.8, 24.7, 21.4, 21.3, 8.6  
IR  (thin film, NaCl) 
2940, 1456, 1323, 1201 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for  C12H26O4B 245.1918, found 245.1908 
TLC 
Rf = 0.7 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
 Phenyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-yl) 
carbonate (2.3). To a flame dried, 10 mL round bottom flask containing a stir 
bar was added CH2Cl2 (5 mL), α-boryl alcohol 2.2 (0.089 g, 0.45 mmol), and pyridine (0.073 g, 
0.89 mmol). The flask was sealed,  evacuated, and refilled with Ar (3x) using a balloon equipped 
with a needle and a rubber adapter. The solution was cooled to 0 °C using an ice-water bath and 
then PhOC(O)Cl (0.077 g, 0.49 mmol) was added dropwise via syringe. The reaction was stirred 
overnight, then was quenched with saturated aqueous NaHCO3 (5 mL). The reaction mixture was 
transferred to a separatory funnel, the two layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were washed with brine (2 x 10 
mL), dried over Na2SO4, filtered, and then concentrated under reduced pressure. The resulting 
residue was purified by silica gel column chromatography (Rf = 0.3, 20% Et2O in hexanes) to yield 
the title compound as a colorless oil (0.101 g, 0.315 mmol, 71% yield).  
Data for 2.3 
 92 
1H NMR  (400 MHz, CDCl3) 
δ 7.37 (m, 2H), 7.20 (m, 3H), 1.82 (m, 2H), 1.43 (s, 3H), 1.28 (s, 6H), 1.26 (s, 6H), 0.98 (t, J = 7.5 
Hz, 3H) 
11B NMR (128 MHz, CDCl3) 
δ 32.2 ppm 
13C NMR (100 MHz, CDCl3) 
δ 154.1, 151.4, 129.3, 125.7, 121.0, 84.1, 30.2, 24.9, 24.7, 20.4, 8.2 ppm 
IR  (thin film, NaCl) 
3016, 1312, 1246, 1167, 1048, 954, 837, 780, 690 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C17H26O5B 321.1868, found 321.1853 
TLC 
Rf = 0.3 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
 2-(2-((Cyclohexyloxy)methoxy)butan-2-yl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (2.5). To a flame dried, 10 mL round bottom flask containing 
a stir bar was added CH2Cl2 (5 mL), α-boryl alcohol 2.2 (0.10 g, 0.50 mmol), and N(iPr)2Et (0.081 
g, 1.0 mmol). The flask was sealed, evacuated and refilled with Ar (3x) using a balloon equipped 
with a needle and a rubber adapter. The solution was cooled to 0 °C using an ice-water bath and 
then ClCH2OCy (0.129 g, 0.550 mmol) was added dropwise via syringe. The reaction was stirred 
overnight, then was quenched with saturated aqueous NaHCO3 (15 mL). The reaction mixture was 
transferred to a separatory funnel, the two layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (2 x 20 mL).  The combined organic layers were washed with brine (2 x 20 
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mL), dried over Na2SO4, filtered, and then concentrated under reduced pressure. The resulting 
residue was purified by silica gel column chromatography (Rf = 0.8, 20% Et2O in hexanes) to yield 
the title compound as a colorless oil (0.038 g, 0.12 mmol, 24% yield).  
 
Data for 2.5 
1H NMR  (400 MHz, CDCl3) 
δ 4.81 (dd, J = 12.2 Hz, 2H), 3.61 (m, 1H), 1.92 (m, 2H), 1.63 (m, 5H), 1.26 (s, 6H), 1.26 (s, 6H), 
1.24 (s, 3H), 1.22 (m, 5H),  0.90 (t, J = 7.4 Hz, 3H)  
11B NMR (128 MHz, CDCl3) 
δ 32.5 
13C NMR (100 MHz, CDCl3) 
δ 89.3, 83.7, 74.5, 32.9, 32.5, 25.8, 24.8, 24.7, 24.4, 24.3, 22.3, 9.0 ppm 
IR  (thin film, NaCl) 
2932, 1441, 1333, 1465, 1211 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C17H34O4B 313.2550, found 313.2535. 
TLC 
Rf = 0.8 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
 (1S, 2S, 4S)-2-(Chloromethoxy)-1-isopropyl-4-methylcyclohexane (S1). 
Trimethylsilylchloride (5 mL) was added to a flame dried flask containing menthol 
(0.502 g, 3.21 mmol) and paraformaldehyde (0.106 g, 3.53 mmol).   The reaction was stirred for 
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2 h, then was filtered and concentrated under reduced pressure to give S1 0.558 g, 2.73 mmol, 
85%), which was used as is. Characterization data are consistent with that reported in the literature. 
 
2-(2-((((1R, 2S, 5R)-2-Isopropyl-5-methylcyclohexyl)oxy)methoxy)butan-
2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.6). To a flame dried, 10 
mL round bottom flask containing a stir bar was added CH2Cl2 (5 mL), α-boryl alcohol 2.2 (0.200 
g, 1.00 mmol), and N(iPr)2Et (0.322 g, 2.00 mmol). The flask was sealed, evacuated and refilled 
with Ar (3x) using a balloon equipped with a needle and a rubber adapter. The solution was cooled 
to 0 °C using an ice-water bath and then freshly prepared S1 (0.226 g, 1.10 mmol) was added 
dropwise via syringe. The reaction was stirred overnight, then was quenched with saturated 
aqueous NaHCO3 (15 mL). The reaction mixture was transferred to a separatory funnel, the two 
layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were washed with brine (2 x 20 mL), dried over Na2SO4, filtered, and concentrated 
under reduced pressure. The resulting residue was purified by silica gel column chromatography 
(Rf = 0.8, 20% Et2O in hexanes) to yield the title compound as a colorless oil (0.040 g, 0.109 mmol, 
11% yield, 1:1 mixture of diastereomers).  
Data for 2.6 
1H NMR  (400 MHz, CDCl3) 
δ 4.91 (d, J = 7.0 Hz, 0.5H), 4.84 (d, J = 7.0 Hz, 0.5H), 4.76 (d, J = 7.0 Hz, 0.5H), 4.69 (d, J = 7.0 
Hz, 0.5H), 3.47 (m, 2H), 2.20 (m, 2H), 1.62 (m, 4H), 1.25 (m, 18H), 0.88 (m, 12H), 0.76 (d, J = 
6.9 Hz, 3H) 
11B NMR (128 MHz, CDCl3) 
δ 32.5 
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13C NMR (100 MHz, CDCl3) 
δ 90.1, 83.7, 76.9, 48.5, 48.38, 42.0, 41.6, 34.5, 31.7, 31.6, 31.4, 25.1, 25.01, 24.9, 24.8, 24.7, 24.6, 
23.0, 22.4, 22.0, 21.9, 21.2, 15.93, 15.90, 9.21, 9.18 ppm 
IR  (thin film, NaCl) 
2938, 1439, 1341, 1375, 1464, 1210 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H42O4B 369.3171, found 369.3173 
TLC 
Rf = 0.7 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
 4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-2-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)butan-2-ol (2.9). To a flame dried, 250 mL 
round bottom flask containing a stir bar was added bis(pinacolato)diboron 
(0.547 g, 2.16 mmol), 1,3-bis(cyclohexyl)imidazolium tetrafluoroborate (0.058 g, 0.18 mmol), 
NaOtBu (0.035 g, 0.36 mmol), and CuCl (0.036 g, 0.36 mmol). The flask was sealed, then 
evacuated and refilled with Ar (3x) using a balloon equipped with a needle and a rubber adapter. 
Toluene (10 mL) was added to the flask via syringe and the reaction was stirred for 30 min. The 
appropriate ketone (0.500 g, 1.80 mmol) was added via syringe followed immediately by MeOH 
(0.112 g, 3.60 mmol). After three h the mixture was loaded directly onto a short silica plug 
pretreated with CH2Cl2. The column was then washed with copious amounts of Et2O and the eluent 
was removed under reduced pressure. The resulting residue was purified by silica gel column 
chromatography (Rf = 0.5, 5% Et2O in CH2Cl2) to yield the title compound as a colorless oil (0.575 
g, 1.42 mmol, 78% yield).  
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Data for 2.9 
1H NMR  (400 MHz, CDCl3) 
δ 7.04 (d, J = 8.4 Hz, 2H), 6.74 (d, J = 8.4 Hz, 2H), 2.76 (ddd, J = 4.8, 12.8, 12.8 HZ, 1H), 2.49 
(ddd, J = 4.8, 12.8, 12.8 Hz, 1H), 1.89 (ddd, J = 4.8, 13.2, 13.2 Hz, 1H), 1.76-1.68 (m, 1H), 1.75(s, 
1H), 1.28 (s, 12H), 1.27 (s, 3H), 0.98 (s, 9H), 0.18 (s, 9H)  
11B NMR (128 MHz, CDCl3) 
δ 34.3 
13C NMR (100 MHz, CDCl3) 
δ 153.6, 135.3, 129.1, 119.8, 84.4, 53.4, 43.6, 31.0, 26.1, 25.7, 25.7, 25.0, 24.8, 24.7, 18.2, 17.99, 
–4.4  
IR  (thin film, NaCl) 
3456, 3015, 1312, 1439, 1167, 1143, 912, 837, 780, 690 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C22H40BO4Si 407.2784, found 407.2766 
TLC 
Rf = 0.5 (5% Et2O in CH2Cl2) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
tert-Butyl(4-(3-ethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)butyl)phenoxy)dimethylsilane (2.10).  To a flame dried, 25 mL round 
bottom flask containing a stir bar was added silver trifluoromethane 
sulfonate (0.174 g, 0.677 mmol). The flask was sealed, then evacuated and refilled with Ar (3x) 
using a balloon equipped with a needle and a rubber adapter. Alcohol 2.9 (0.250 g, 0.615 mmol) 
in CH2Cl2 (15 mL) was added to the flask via syringe. The solution was cooled to 0 °C using an 
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ice-water bath and 2,6-di-tert-butylpyridine (0.176 g, 0.923 mmol) was added dropwise via syringe 
followed immediately by ethyl iodide (0.115 g, 0.738 mmol).  The mixture was slowly warmed to 
room temperature, stirred for 1 h, filtered through a pad of Celite® 545, and concentrated under 
reduced pressure. The resulting reside was dissolved in diethyl ether (20 mL), washed with H2O 
(3 X 30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure.  The resulting 
oily yellow residue was purified by silica gel column chromatography (Rf = 0.4, 30% Et2O in 
hexanes) to yield the title compound as a yellow oil (0.121 g, 0.279 mmol, 45% yield). 
Data for 2.10 
1H NMR  (400 MHz, CDCl3) 
δ 7.05 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 8.4 Hz), 3.46 (q, J = 7.0 Hz, 2H), 2.58 (m, 2H),  1.84 (m, 
2H), 1.29 (s, 12H), 1.27 (s, 3H), 0.98 (s, 9H), 0.18 (s, 6H)  
11B NMR (128 MHz, CDCl3) 
δ 33.8 
13C NMR (100 MHz, CDCl3) 
δ 153.4, 135.8, 129.1, 119.8, 83.8, 59.6, 39.8, 29.8, 25.7, 24.8, 24.7, 21.4, 18.2, 16.3, –4.4 
IR  (thin film, NaCl) 
3013, 1309, 1434, 1156,1141, 986, 834, 777, 682 cm-1 
HRMS  (TOF MS ES+) 
[M+Na]+ Calculated for C24H43BO4SiNa 457.2921, found 457.2783 
TLC 
Rf = 0.7 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
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Triethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-
yl)oxy)silane (2.11). To a flame dried, 25 mL round bottom flask containing 
a stir bar was added CH2Cl2 (10 mL), α-boryl alcohol 2.2 (0.150 g, 0.750 
mmol), and imidazole (0.102 g, 1.50 mmol). The flask was sealed, then evacuated and refilled with 
Ar (3x) using a balloon equipped with a needle and a rubber adapter. The solution was cooled to 
0 °C using an ice-water bath, and then tritethylsilylchloride (0.150 g, 1.00 mmol) was added 
dropwise via syringe. The reaction was stirred overnight, then was quenched with saturated 
aqueous NH4Cl (15 mL). The reaction mixture was transferred to a separatory funnel, the two 
layers were separated, and the aqueous layer was extracted with CH2Cl2 (2 x 15 mL).  The 
combined organic layers were washed with brine (2 x 15 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The resulting residue was purified by silica gel column 
chromatography (Rf = 0.8, 5% Et2O in hexanes) to yield the title compound as a colorless oil (0.186 
g, 0.592 mmol, 79% yield).  
Data for 2.11 
1H NMR  (400 MHz, CDCl3) 
δ 1.44 (q, J = 7.5 Hz, 2H), 1.18 (s, 12H), 1.13 (s, 3H), 0.87 (t, J = 8.0 Hz, 9H), 0.80 (t, J = 7.5 Hz), 
0.50 (m, 6H)  
11B NMR (128 MHz, CDCl3) 
δ 33.0  
13C NMR (100 MHz, CDCl3) 
δ 83.5, 77.2, 35.0, 25.6, 24.8, 9.3, 7.2, 6.8  
IR  (thin film, NaCl) 
2940, 1456, 1323, 1255, 1201, 1145 cm-1 
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HRMS  (TOF MS ES+) 
[M–C2H5]+ Calculated for C14H30BO3Si 285.2057, found 285.2034 
TLC 
Rf = 0.7 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
2-(2-Isobutoxybutan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane  (2.12).  To a 
10 mL scintillation vial containing a stir bar was added CH3CN (4 mL), compound 
2.11 (0.100 g, 0.318 mmol), and isobutyraldehyde (0.048 g, 0.64 mmol). To the reaction mixture 
was added a solution of BiBr3 dissolved in CH3CN (1.5 g/mL, 0.016 mmol, 53 μL), immediately 
followed by triethylsilane (0.184 g, 1.59 mmol). The vial was sealed and stirred for 2 h, then was 
run through a short plug of celite which was flushed with diethyl ether. The eluent was 
concentrated and the resulting residue was purified by silica gel column chromatography (Rf = 0.8, 
5% Et2O in hexanes) to yield the title compound as a colorless oil (0.063 g, 0.24 mmol, 77% yield).  
Data for 2.12 
1H NMR  (500 MHz, CDCl3) 
δ 3.02 (d, J = 6.7 Hz, 2H), 1.73 (m, J = 6.7 Hz, 1H), 1.51 (m, 2H), 1.19 (s, 6H), 1.18 (s, 6H), 1.09 
(s, 3H), 0.81 (m, 9H)  
11B NMR (160 MHz, CDCl3) 
δ 32.9 
13C NMR (125 MHz, CDCl3) 
δ 83.5, 71.7, 30.6, 29.3, 24.9, 24.7, 20.7, 19.7, 19.6, 8.5 ppm 
IR  (thin film, NaCl) 
2930, 1452, 1325, 1254, 1200 cm-1 
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HRMS  (TOF MS ES+) 
[M+H]+ Calculated for C14H30BO3 257.2288, found 257.2276 
TLC 
Rf = 0.7 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
triethyl(2-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)propoxy)silane (2.13). To a flame dried, 25 mL round bottom flask 
containing a stir bar was added bis(pinacolato)diboron (0.920 g, 3.63 mmol), 
1,3-Bis(cyclohexyl)imidazolium tetrafluoroborate (0.111 g, 0.346 mmol), NaOtBu (0.067 g, 0.692 
mmol), and CuCl (0.069 g, 0.692 mmol). Toluene (15 mL) was added to the flask and the flask 
was sealed, then the reaction was stirred for 30 minutes.  isobutyraldehyde (0.250 g, 3.46 mmol) 
was added via syringe followed immediately by MeOH (0.214 g, 6.92 mmol).  After three hours, 
the reaction was loaded directly onto a short silica plug pretreated with CH2Cl2.  The column was 
then washed with copious amounts of Et2O and the eluent was removed under reduced pressure.  
The resulting residue was dissolved in CH2Cl2 (10 mL) and transferred to a flame dried, 25 mL 
round bottom flask containing a stirbar. Imidazole (0.707 g, 10.4 mmol) was added and the flask 
was sealed, then evacuated and refilled with Ar (3x) using a balloon equipped with a needle and a 
rubber adapter. The solution was cooled to 0 °C using an ice-water bath and then 
tritethylsilylchloride (0.782 g, 5.19 mmol) was added dropwise via syringe.  The reaction was 
allowed to stir overnight, then quenched with saturated aqueous NH4Cl (15 mL).  The reaction 
mixture was transferred to a separatory funnel, the two layers were separated and the aqueous layer 
was extracted with CH2Cl2 (2 x 15 mL).  The combined organic layers were washed with brine (2 
x 15 mL), dried over Na2SO4, gravity filtered, and then concentrated under reduced pressure.  The 
B
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O
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resulting residue was purified by silica gel column chromatography (Rf = 0.7, 5% Et2O:hexanes) 
to yield the title compound as a colorless oil (0.338 g, 0.311 mmol, 31% yield). The column should 
be run as quickly as possible, as the boronate group is prone to degradation when it is left on silica 
gel for too long. 
Data for 2.13 
1H NMR  (400 MHz, CDCl3) 
3.18 (d, J = 6.4 Hz, 1H), 1.76 (m, 1H), 1.20 (s, 6H), 1.19 (s, 6H), 0.87 (m, 15H), 0.52 (m, 6H) ppm 
11B NMR (128 MHz, CDCl3) 
32.44 
13C NMR (100 MHz, CDCl3) 
83.62, 32.74, 25.1, 24.81, 19.43, 19.33, 7.07, 4.82 ppm 
IR (thin film, NaCl) 
2934 1456, 1321, 1253, 1200, 1144 cm-1 
HRMS  (TOF MS ES+) 
[M-29]2+ Calculated for C14H30BO3Si : 285.2057 found 285.2052 
TLC   
Rf = 0.4 (5% Et2O/CH2Cl2) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
2-(1-(Cyclohexyloxy)-2-methylpropyl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (2.14).  To a 10 mL scintillation vial containing a stir bar was added 
CH3CN (4 mL), compound 2.13 (0.018 g, 0.079 mmol), and cyclohexanone (0.008 
g, 0.083 mmol). To the reaction mixture was added a solution of BiBr3 in CH3CN (1.5 g/mL, 0.004 
mmol, 12 μL), immediately followed by triethylsilane (0.028 g, 0.24 mmol). The vial was sealed 
and the reaction mixture was stirred for 2 h. The mixture was run through a short plug of Celite 
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then was flushed with diethyl ether. The eluent was concentrated and the resulting residue was 
purified by silica gel column chromatography (Rf = 0.6, 5% Et2O in hexanes) to yield the title 
compound as a colorless oil (0.018 g, 0.063 mmol, 81% yield).  
Data for 2.14 
1H NMR  (500 MHz, CDCl3) 
δ 3.04 (m, 1H), 2.82 (d, 7.45 Hz), 1.81 (m, 3H), 1.65 (m, 2H), 1.41 (m, 1H), 1.20 (s, 6H), 1.19 (s, 
6H), 1.20-1.07 (m, 18H), 0.88 (d, J = 6.7 Hz, 3H), 0.84 (d, J = 6.7 Hz, 3H) ppm 
11B NMR (128 MHz, CDCl3) 
δ 31.9 ppm 
13C NMR (125 MHz, CDCl3) 
δ 83.5, 33.2, 32.3, 30.9, 25.9, 25.0, 24.5, 24.4, 19.9, 19.4 ppm 
IR  (thin film, NaCl) 
2932, 1465, 1446, 1321, 1252, 1199, 1148 cm-1 
HRMS  (TOF MS ES+) 
[M+H]+ Calculated for C16H32BO3 283.2444 found 283.2431 
TLC 
Rf = 0.4 (5% Et2O in CH2Cl2) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
 2,2,5,7,8-Pentamethylchroman-6-yl carbonochloridate (S2).  To a flame 
dried, 2-neck 25 mL round bottom flask containing a stir bar was added 
triphosgene (1.09 g, 3.70 mmol). The flask was sealed, then evacuated and refilled with Ar (3x) 
using a balloon equipped with a needle and a rubber adapter. A solution of 2,2,5,6,8-
pentamethylchroman-7-ol (2.20 g, 10.0 mmol) dissolved in CH2Cl2 (5 mL) was added to the flask 
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via syringe. The solution was cooled to 0 °C using an ice-water bath and pyridine (0.79 g, 10.0 
mmol) was added dropwise via syringe. The reaction was slowly warmed to rt, stirred for 3 h, and 
then diluted with ethyl acetate (25 mL). The resulting mixture was partitioned with 1M HCl (15 
mL) and the resulting biphasic mixture was placed into a separatory funnel. The organic layer was 
washed with brine (2 X 20 mL) and H2O (2 x 20 mL), dried over Na2SO4, filtered, and concentrated 
under reduced pressure.  The resulting yellow oil (2.14 g, 7.59 mmol, 76% yield) was used as is. 
Data for S2 
1H NMR  (400 MHz, CDCl3) 
δ 2.63 (t, J = 7.2 Hz, 2H), 2.12 (s, 3H), 2.11 (s, 3H), 2.08 (s, 3H), 2.11 (s, 3H), 1.81 (t, J = 7.2 Hz, 
2H), 1.31 (s, 6H)  
13C NMR (100 MHz, CDCl3) 
δ 150.4, 142.7, 126.1, 124.5, 123.6, 117.6, 73.6, 32.5, 26.8, 20.9, 12.8, 12.0, 11.8  
 
4-((tert-Butyldimethylsilyl)oxy)-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)butan-2-yl (2,2,5,7,8-pentamethylchroman-6-yl) 
carbonate (2.7). To a flame dried, 5 mL round bottom flask containing 
a stir bar was added the appropriate boryl alcohol (0.200 mg, 0.550 mmol) in CH2Cl2 (5 mL) and 
pyridine (0.087 g, 1.1 mmol). The flask was sealed, then evacuated and refilled with Ar (3x) using 
a balloon equipped with a needle and a rubber adapter. The solution was cooled to 0 °C using an 
ice-water bath, and freshly prepared chloroformate (0.310 g, 1.1 mmol) was added dropwise via 
syringe. The reaction was stirred for 1 h, then was quenched with saturated aqueous NH4Cl (5 
mL). The reaction mixture was transferred to a separatory funnel, the two layers were separated 
and the aqueous layer was extracted with CH2Cl2 (2 x 5 mL). The combined organic layers were 
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washed with brine (2 x 5 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The resulting residue was purified by silica gel column chromatography (Rf = 0.5, 20% 
Et2O in hexanes) to provide the desired compound as a yellow oil (0.210 g, 0.370 mmol, 67% 
yield).  
Data for 2.7 
1H NMR  (400 MHz, CDCl3) 
δ 3.81 (ddd, J = 6.0, 6.0, 10.0 Hz, 2H), 2.61 (t, J = 6.8 Hz, 2H), 2.12-2.02 (m, 2H), 2.09 (s, 6H), 
2.05 (s, 3H), 1.78 (t, J = 6.4 Hz, 2H), 1.47 (s, 3H), 1.30 (s, 6H), 1.24 (s, 6H), 1.23 (s, 6H), 0.90 (s, 
9H), 0.07 (s, 9H)  
11B NMR (128 MHz, CDCl3) 
δ 32.8  
13C NMR (100 MHz, CDCl3) 
δ 154.5, 149.5, 141.2, 126.9, 125.2, 122.9, 117.0, 84.0, 73.0, 59.0, 40.2, 32.7, 26.9, 25.96, 24.9, 
24.8, 21.6, 20.9, 18.3, 12.7, 11.9, 11.8, –5.26, –5.28  
IR  (thin film, NaCl) 
3023, 1739, 1446, 1288, 1368, 1165, 1217, 1091, 894, 834, 775, 638 cm-1 
HRMS  (TOF MS ES+) 
[M+H]+ Calculated for C31H54BO7Si 577.3752, found 577.3732 
TLC 
Rf = 0.5 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-yl benzoate (2.15). 
To a flame dried, 10 mL round bottom flask containing a stir bar was added 
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CH2Cl2 (5 mL), α-boryl alcohol 2.2 (0.050 g, 0.25 mmol), and pyridine (0.023 g, 0.30 mmol). The 
flask was sealed, then evacuated and refilled with Ar (3x) using a balloon equipped with a needle 
and a rubber adapter. The solution was cooled to 0 °C using an ice-water bath, then PhC(O)Cl 
(0.039 g, 0.27 mmol) was added dropwise via syringe.  The reaction was stirred overnight, then 
was quenched with saturated aqueous NaHCO3 (5 mL).  The reaction mixture was transferred to a 
separatory funnel, the two layers were separated and the aqueous layer was extracted with CH2Cl2 
(2 x 10 mL). The combined organic layers were washed with brine (2 x 10 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel 
column chromatography (Rf = 0.2, 20% Et2O in hexanes) to yield the title compound as a colorless 
oil (0.051 g, 0.17 mmol, 67% yield).  
Data for 2.15 
1H NMR  (400 MHz, CDCl3) 
δ 8.03 (d, J = 7.1 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.9 Hz, 2H) 1.88 (dq, J = 7.6, 14.8 
Hz, 1H), 1.76 (dq, J = 7.6, 14.8 Hz, 1H), 1.39 (s, 3H), 1.28 (s, 6H), 1.27 (s, 3H), 1.01 (t, J = 7.5 
Hz). 
11B NMR (128 MHz, CDCl3) 
δ 27.0  
13C NMR (100 MHz, CDCl3) 
δ 169.5, 133.6, 130.6, 129.9, 129.0, 128.3, 82.9, 24.9, 24.8, 20.6, 8.2  
IR  (thin film, NaCl) 
3012, 1720, 1333, 1246, 1167, 1043, 952, 834, 777, 681 cm-1 
HRMS  (TOF MS ES+) 
[M+H]+ Calculated for C17H26BO4 305.1924 found 305.1910 
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TLC 
Rf = 0.7 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
4-((4-methoxybenzyl)oxy)butan-2-one (S3).  To a flame dried, wide neck 
100 mL round bottom flask containing a stir bar was added 4-hydroxy-2-
butanone (4.12 g, 46.5 mmol), p-methoxybenzyl bromide (8.00 g, 51.1 mmol), and iPrNEt (13.2 
g, 102 mmol). A flame dried reflux condender was attached, and the reaction mixture was refluxed 
under N2 for 6 h. The reaction mixture was cooled to rt, then was diluted with ethyl acetate (100 
mL). A saturated aqueous solution of sodium bisulphate was added to the reaction mixture 
dropwise via pipette (40 mL). The resulting biphasic mixture was transferred to a separatory funnel 
the two layers were separated and the aqueous layer was extracted with ethyl acetate (3 x 50 mL). 
The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The resulting yellow oil was purified by silica gel column chromatography (Rf = 0.5, 
20% ethyl acetate in hexanes) to yield the title compound as a colorless oil (4.21 g, 20.2 mmol, 
40% yield). Characterization data are consistent with those reported in the literature. 
Data for S3 
1H NMR  (400 MHz, CDCl3) 
δ 7.30-7.20 (m, 5H), 4.46 (s, 2H), 3.68 (t, J = 6.4 Hz, 2H), 2.67 (t, J = 6.0 Hz, 2 H), 2.12 (s, 3H)  
TLC 
Rf = 0.5 (20% ethyl acetate in hexanes) [silica gel, p-anisaldehyde stain] 
 
 4-((4-Methoxybenzyl)oxy)-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)butan-2-ol (2.17). To a flame dried, 100 mL round 
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bottom flask containing a stir bar was added bis(pinacolato)diboron (2.92 g, 11.5 mmol), 1,3-
bis(cyclohexyl)imidazolium tetrafluoroborate (0.319 g, 0.960 mmol), NaOtBu (0.184 g, 1.92 
mmol), and CuCl (0.188 g, 1.92  mmol). The flask was sealed, then evacuated and refilled with Ar 
(3x) using a balloon equipped with a needle and a rubber adapter. Toluene (25 mL) was added to 
the flask via syringe and the reaction was stirred for 30 min. Ketone 27 (2.00 g, 9.60 mmol) was 
added via syringe followed immediately by MeOH (0.595 g, 19.2 mmol). After three h, the mixture 
was loaded directly onto a short silica plug pretreated with CH2Cl2. The column was washed with 
copious amounts of Et2O and the eluent was removed under reduced pressure. The resulting 
residue was purified by silica gel column chromatography (Rf = 0.6, 10% Et2O in CH2Cl2) to yield 
the title compound as a colorless oil (2.71 g, 8.06 mmol, 84% yield).  
Data for 2.17 
1H NMR (400 MHz, CDCl3) 
δ 7.28 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 4.46 (d, J = 12.0 Hz, 2H), 3.81 (s, 3H), 3.63 
(m, 1H), 3.45 (m, 1H), 2.37 (s, 1H), 1.96 (ddd, J = 5.6, 5.9, 14.0 Hz, 1H), 1.71 (dt, J = 5.6, 5.6, 
14.0 Hz), 1.26 (s, 3H), 1.25 (s, 12H) ppm 
11B NMR (400 MHz, CDCl3) 
δ 33.2  
13C NMR (125 MHz, CDCl3) 
δ 159.2, 130.4, 129.3, 113.8, 84.1, 72.7, 67.1, 55.3, 40.1, 26.1, 24.7, 24.7  
IR  (thin film, NaCl) 
3446, 3015, 1312, 1433, 1145, 910, 834, 779, 686 cm-1 
HRMS  (TOF MS ES+) 
[M+H]+ Calculated for C18H30BO5 337.2180, found 337.2175 
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TLC 
Rf = 0.6 (5% Et2O in CH2Cl2) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
2-((2S,4R)-2-(4-Methoxyphenyl)-4-methyl-1,3-dioxan-4-yl)-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane (2.18).  To a flame dried, 10 mL round 
bottom flask containing a stir bar was added CH2Cl2 (5 mL) and α-boryl alcohol 
2.17 (0.100 g, 0.297 mmol). The reaction flask was cooled to 0 °C using an ice-
water bath, then 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.067 g, 0.30 
mmol) was added.  The reaction was stirred for 1 h at 0 °C, then for 30 min at rt. The reaction was 
quenched with saturated aqueous NaHCO3 (5 mL) then was transferred to a separatory funnel. The 
two layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The 
combined organic layers were washed with brine (2 x 10 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The resulting residue was purified by silica gel column 
chromatography (Rf = 0.4, 20% Et2O in hexanes) to yield the title compound as a white solid 
(0.079 g, 0.23 mmol, 78% yield).  
Data for 2.18 
1H NMR  (400 MHz, CDCl3) 
δ 7.44 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 5.56 (s, 1H), 4.18 (m, 1H), 3.88 (m, 1H), 3.80 
(s, 3H), 1.79 (m, 2H), 1.33 (s, 3H), 1.31 (s, 12H)  
11B NMR (128 MHz, CDCl3) 
δ 33.3  
13C NMR (100 MHz, CDCl3) 
δ 159.8, 132.0, 127.5, 113.5, 100.1, 84.2, 77.2, 68.8, 55.3, 35.2, 25.4, 24.9, 24.6  
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IR  (thin film, NaCl) 
3011, 1314, 1434, 1097, 913, 837, 781, 698 cm-1 
HRMS  (FTMS ESI) 
[M+H]+ Calculated for C18H28BO5 335.2024, found 335.2023 
TLC 
Rf = 0.4 (20% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
 4,4,5,5-Tetramethyl-2-(4-methyl-2,2-diphenyl-1,3-dioxan-4-yl)-1,3,2-
dioxaborolane (2.19). To a flame dried, 25 mL Schlenk flask containing a stir bar 
was added Pd/C (0.096 g, 0.090 mmol), then small amounts of CH2Cl2 were run 
down the sides of the flask. α-Boryl alcohol 2.17 (0.200 g, 0.594 mmol) was dissolved in 10 mL 
of methanol and added to the flask. The flask was sealed, then evacuated and refilled with H2 (3x).  
The reaction was stirred under H2 for 8 h, then the mixture was run through a short plug of Celite, 
washed with copious amounts of ethyl acetate, and concentrated under reduced pressure to yield 
the crude diol.  The crude product was used without further purification. To a flame dried, 10 mL 
round bottom flask containing a stir bar was added the crude alcohol in CHCl3 (1 mL) followed by 
benzophenone dimethyl ketal (0.134 g, 0.594 mmol).  A trace amount of pyridinium p-toluene 
sulfonate was added to the flask and the flask was sealed. The reaction was stirred for 12 h, then 
wasquenched with saturated aqueous NaHCO3 (10 mL). The reaction mixture was transferred to a 
separatory funnel, the two layers were separated, and the aqueous layer was extracted with CH2Cl2 
(2 x 15 mL). The combined organic layers were washed with brine (2 x 15 mL), dried over Na2SO4, 
filtered, and then concentrated under reduced pressure. The resulting residue was purified by silica 
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gel column chromatography (Rf = 0.2, 10% Et2O in hexanes) to yield the title compound as a white 
solid (0.112 g, 0.291 mmol, 49 % yield over two steps). 
Data for 2.19 
1H NMR  (400 MHz, CDCl3) 
δ 7.59 (d, J = 7.3 Hz, 2H), 7.51 (d, J = 7.3 Hz, 2H), 7.23 (m, 6H), 4.19 (ddd, J = 4.4, 10.9, 10.9 
Hz, 1H), 4.00 (ddd, J = 3.1, 5.5, 10.9 Hz, 1H), 1.89 (ddd, J = 4.4, 4.4, 7.5 Hz, 1H), 1.70 (ddd, J = 
5.6, 10.9 Hz, 12.8 Hz, 1H), 1.40 (s, 3H), 1.10 (s, 6H), 0.92 (s, 6H) 
11B NMR (128 MHz, CDCl3) 
δ 33.1  
13C NMR (100 MHz, CDCl3) 
δ 146.1, 143.0, 127.9, 127.9, 127.8, 127.4, 127.2, 125.9, 100.2, 83.7, 77.2, 60.5, 33.9, 26.4, 25.1, 
23.8  
IR  (thin film, NaCl) 
3111, 1314, 1431, 1108, 918, 826, 797, 712 cm-1 
HRMS  (FTMS ESI) 
[M+H]+ Calculated for C23H30BO4 381.2232, found 381.2230 
TLC 
Rf = 0.2 (10% Et2O in hexanes) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
 
4-((tert-butyldimethylsilyl)oxy)butan-2-one (S4). To a flame 
dried, 500 mL round bottom flask containing a stir bar was added CH2Cl2 
(200 mL), followed by 4-hydroxy-2-butanone (10.0 g, 114 mmol) and imidazole (9.30 g, 137 
mmol).  The reaction was allowed to stir until all the imidazole had dissolved, and then tert-
O
OTBS
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butyldimethylsilyl chloride (18.0 g, 119 mmol) was added.  The flask was sealed and allowed to 
stir under N2 for 1.5 hours.  The reaction was quenched with saturated aqueous NH4Cl (80 mL). 
The mixture was transferred to a separatory funnel, the two layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (2 x 50 mL).  The combined organic layers were washed with 
brine (2 x 100 mL) and H2O (2 x 100 mL), dried over MgSO4, gravity filtered, and concentrated 
under reduced pressure to yield the title compound as a colorless oil (22.5 g, 111 mmol, 98% 
yield). Characterization data is consistent with that reported in the literature.  
Data for S4 
1H NMR  (400 MHz, CDCl3) 
3.89 (t, J = 6.4 Hz, 2H), 2.62 (t, J = 6.4 Hz, 2 H), 0.88 (s, 9H), .06 (s, 6H) ppm   
TLC  Rf = .9 (20% Et2O/Hexanes) [silica gel, p-anisaldehyde stain] 
 
4-((tert-butyldimethylsilyl)oxy)-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)butan-2-ol (2.8). To a flame dried, 250 mL round 
bottom flask containing a stir bar was added bis(pinacolato)diboron 
(0.690 g, 2.72 mmol), 1,3-Bis(cyclohexyl)imidazolium tetrafluoroborate (0.082 g, 0.245 mmol), 
NaOtBu (0.474 g, 0.494 mmol), and CuCl (0.489 g, 0.494 mmol). The flask was sealed, then 
evacuated and refilled with Ar (3x) using a balloon equipped with a needle and a rubber adapter.  
Toluene (10 mL) was added to the flask via syringe and the reaction was stirred for 30 minutes.  
Ketone S6 (0.500 g, 2.47 mmol) was added via syringe followed immediately by MeOH (0.153 g, 
4.94 mmol).  After three hours, the reaction was loaded directly onto a short silica plug pretreated 
with CH2Cl2.  The column was then washed with copious amounts of Et2O and the eluent was 
removed under reduced pressure.  The resulting residue was purified by silica gel column 
B OTBS
HO
O
O
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chromatography (Rf = 0.6, 10% Et2O:CH2Cl2) to yield the title compound as a colorless oil (0.646 
g, 1.96 mmol, 79% yield). The column should be run as quickly as possible, as the boronate group 
is prone to degradation when it is left on silica gel for too long.  
Data for 2.8 
1H NMR  (400 MHz, CDCl3) 
3.89-3.85 (m, 2H), 3.23 (s, 1H), 1.87 (ddd, J = 5.6, 5.6, 14.2 Hz, 1H), 1.73 (ddd, J = 6.8, 6.8, 13.6 
Hz), 1.27 (s, 12H), 1.26 (s, 3H), .90 (s, 9H), .08 (s, 6H) ppm 
11B NMR (128 MHz, CDCl3) 
33.39 ppm  
13C NMR (100 MHz, CDCl3) 
83.99, 61.98, 41.47, 25.89, 25.54, 25.02, 24.75, 24.69, 18.14, -5.52 ppm 
IR  (thin film, NaCl)  
3503, 3012, 1367, 1436, 1228, 1084, 1005, 834, 773 cm-1 
HRMS  (TOF MS ES+) 
[M+H]+ Calculated for C16H36BO4Si: 331.2476, found 331.2478 
TLC   
Rf = 0.6 (5% Et2O/CH2Cl2) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
7-(Diethylamino)-3-(4-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)-1,3-dioxan-2-yl)-2H-chromen-2-one (2.21). To a flame dried, 10 mL round 
bottom flask containing a stir bar was added CH2Cl2 (5 mL), TBS protected boryl 
alcohol 2.8 (0.050 g, 0.151 mmol), and aldehyde 2.20 (0.025 g, 0.102 mmol). The 
flask was sealed, then evacuated and refilled with Ar (3x) using a balloon equipped with a needle 
and a rubber adapter. The solution was cooled to –78 °C using an acetone-dry ice bath and then a 
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single drop of trimethylsilyl triflouromethane sulfonate diluted in CH2Cl2 (1 mL) was added 
dropwise via syringe, followed by .025 mL of methanol. The reaction was allowed to warm to 
room temperature, and then was quenched with triethylamine (0.5 mL), then concentrated under 
reduced pressure.  The resulting crude oil purified by silica gel column chromatography (Rf = 0.2, 
40% hexanes in Et2O) to yield the title compound as a pale yellow solid (0.033 g, 0.73 mmol, 73% 
yield).  
Data for 2.21 
1H NMR (500 MHz, CD3CN) 
δ 7.88 (s, 1H), 7.41 (d, J = 8.9 Hz, 1H), 6.69 (dd, J = 2.5, 8.9 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 
5.61 (s, 1H), 4.07 (ddd, J = 1.6, 4.7, 11.6 Hz, 1H), 3.84 (ddd, J = 2.9, 11.6, 11.6 Hz, 1H), 3.46 (q, 
J = 7.1 Hz, 4H), 1.73 (m, 2H), 1.31 (s, 12H), 1.29 (s, 3H), 1.19 (t, J = 7.1 Hz, 6 H) 
11B NMR (128 MHz, CDCl3) 
δ 34.1 
13C NMR (125 MHz, CDCl3) 
δ 161.1, 156.5, 150.8, 141.1, 129.5, 118.8, 108.7, 108.3, 97.1, 95.2, 84.5, 66.9, 44.7, 35.2, 25.4, 
24.9, 24.5, 12.5 ppm 
IR  (thin film, NaCl) 
3101, 3021, 1751, 1432, 1316, 1302, 1102, 912, 860 cm_1 
HRMS  (TOF MS ES+) 
[M+H]+ Calculated for C24H35BO6N 444.2552, found 444.2537 
TLC 
Rf = 0.2 (40% hexanes in Et2O) [silica gel, p-anisaldehyde stain] [silica gel, curcumin stain] 
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7-(Diethylamino)-3-(4-methyl-1,3-dioxan-2-yl)-2H-chromen-2-one (2.22). To a 
flame dried, 10 mL round bottom flask containing a stir bar was added CH2Cl2 (5 mL), 
1,3 butanediol (0.50 mL), and the dimethyl acetal of the 2.20 (0.100 g, 0.343 mmol). A 
trace amount of pyridinium p-toluenesulfonate was added and the flask was sealed, 
stirred under argon for 6 hours, and quenched with saturated aqueous NaHCO3 (5 mL). The 
reaction mixture was transferred to a separatory funnel, the two layers were separated and the 
aqueous layer was extracted with CH2Cl2 (2 x 10 mL).  The combined organic layers were washed 
with brine (2 x 10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The 
resulting residue was purified by silica gel column chromatography (Rf = 0.8, 40% ethyl acetate 
in hexanes) to yield the title compound as a white solid (0.102 g, 0.316 mmol, 92% yield). 
Data for 2.22 
1H NMR  (400 MHz, CDCl3) 
δ 7.83 (s, 1H), 7.19 (s, 1H), 6.47 (dd, J = 2.4, 8.8 Hz, 1H), 6.40 (d, J = 2.4 Hz, 1H), 5.57 (s, 1H), 
4.14 (dd, J = 4.6, 11.5 Hz, 1H), 3.91 (m, 2H), 3.32 (q, J = 7.1 Hz, 4H), 1.69 (dddd, J = 5.1, 13.0, 
13.0, 13.0 Hz, 1H), 1.45 (dd, J = 1.1, 13.4 Hz, 1H), 1.23 (d, J = 6.2 Hz, 3H), 1.13 (t, J = 7.1 Hz, 
6H) 
13C NMR (100 MHz, CDCl3) 
δ 161.2, 156.5, 150.9, 141.0, 118.4, 108.9, 108.3, 97.2, 96.4, 73.6, 67.2, 44.8, 33.1, 21.8, 12.4  
IR  (thin film, NaCl) 
3103, 3011, 1749, 1302, 1104, 916, 890 cm_1 
HRMS  (TOF MS ES+) 
[M+H]+ Calculated for C18H24O4N 318.1699, found 318.1721 
TLC 
 115 
Rf = 0.8 (40% ethyl acetate in hexanes) [silica gel, UV] 
 
 
 
 
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl 
carbonochloridate (S5).   A flask containing Na2CO3 (3.51 g, 33.0 
mmol) and a stir bar was flame dried then allowed to cool to room 
temperature in a dessicator.  The flask was cooled to 0°C under a 
positive pressure of N2, then triphosgene (2.20 g, 7.42 mmol)  dissolved in toluene (15 mL) was 
added via syringe.  The reaction was stirred at 0°C for 30 minutes, then the (4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenyl)methanol (0.87 g, 3.72 mmol) dissolved in toluene was added via 
syringe.  The reaction was allowed to warm to room temperature and stirred for three hours.  The 
reaction was filtered and concentrated under reduced pressure to give the crude chloroformate 
which was used as is (0.651 g, 2.13 mmol, 59 % yield).  Characterization data is consistent with 
that reported in the literature.  
Data for S5 
 
1H NMR  (500 MHz, CDCl3) 
 
7.83 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2 H), 5.31 (s, 2H), 1.35 (s, 12H) ppm   
 
TLC   
 
Rf = 0.7 (20% ethyl acetate/Hexanes) [silica gel, p-anisaldehyde stain] 
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4-methyl-2-oxo-2H-chromen-7-yl (4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)benzyl) carbonate (2.23). 4-
methyl umbelliferone (0.100 g, 0.56 mmol), was added to a 
flame dried flask containing a stir bar.  Dichloromethane (15 
mL) was added to the flask, followed by pyridine (0.27 g, 3.36 mmol). The reaction was sealed, 
cooled to 0°C, and placed under a positive pressure of N2.  Chlororoformate S5 (0.33 g, 1.12 mmol) 
was added dropwise via syringe.  The reaction was allowed to stir for three hours at room 
temperature, then was quenched with saturated aqueous NaHCO3 (10 ml).  The reaction was 
transferred to a separatory funnel, and the organic layer was washed with brine (2 x 10 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure to give a crude residue.  The residue 
was purified by column chromatography on silica gel (20% ethyl acetate/hexanes) to give the 
product (0.036 g, .083 mmol, 15 % yield) as a white solid.  
Data for 2.23 
1H NMR  (500 MHz, CDCl3) 
7.85 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 8.7 Hz, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 2.3 Hz, 
1H), 7.16 (dd, J = 2.3, 8.7 Hz, 1H), 6.28 (d, J = 1.2 Hz, 1H), 5.31 (s, 2H), 2.43 (d, J = 1.2 Hz, 3H), 
1.35 (s, 12H).  
11B NMR (160 MHz, CDCl3) 
30.47 ppm  
13C NMR (125 MHz, CDCl3) 
160.40, 154.15, 153.26, 152.78, 151.79, 137.22, 135.18, 127.83, 127.61, 125.49, 118.02, 117.39, 
114.70, 109.96, 83.97, 70.66, 24.88, 18.75 ppm 
HRMS  (TOF MS ES+) 
B
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[M+H]+ Calculated for C24H26BO7: 437.1766, found 437.1766 
TLC   
Rf = 0.3 (20% ethyl acetate/Hexanes) [silica gel, KMnO4 stain, UV] 
Fluorophore release response of 2.21 to H2O2.   
The same procedure was used to monitor fluorophore release response of 2.21. The results of these 
release studies are shown in Figure 1. 
 
 
 
The above procedure was followed except that the 25 μM solution of 2.21 was treated with 2 μL 
of a 1 M aqueous solution of H2O2 to provide a final [H2O2] of 10 mM. The results of these release 
studies are shown in Figure 2. 
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Fluorophore release response of 2.21 to Reactive Oxygen Species.  
4 mL of a 40 μM solution of 2.21 was prepared by diluting a 8 mM DMSO stock solution of 2.21 
with PBS (pH 7.4).  Experiments employed a final concentration of 10 mM O2 and 200 μM for all 
other ROS. Superoxide (O2-) was added as solid KO2. Hydrogen peroxide (H2O2), tert-butyl 
hydroperoxide (TBHP), and hypochlorite (OCl-) were delivered from commercially available 
solutions of 30%, 70%, and 5% aqueous solutions, respectively. Hydroxyl radical (•OH) and tert-
butoxy radical (•OtBu) were generated by reaction of 1 mM Fe2+ with 200 μM H2O2 or 200 μM 
TBHP, respectively (prior to administration of these solutions to 2.21, 200 units of catalase was 
also added as a scavenger for any remaining H2O2).  Fluorescence was measured using a plate 
reader (λex = 448 nm, λem = 499 nm) every minute.  Temperature was maintained at 27 °C.  
 
 
 
Cell culture 
HeLa cells were grown at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium (Hyclone), 
supplemented with 10% fetal bovine serum (Seradigm). Dulbecco’s phosphate buffered saline 
(DPBS) solution was formulated according to manufacturer’s protocol (Sigma-Aldrich) at pH 7.3. 
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Ultra pure dimethylsulfoxide (DMSO) was purchased from Sigma-Aldrich, hydrogen peroxide 
(37%) was purchased from Fisher Scientific, and phorbol 12-myristate 13-acetate (PMA) was 
purchased from Acros Organics. 
 
Fluorophore release from 2.21 in HeLa cells with exogenous H2O2 
HeLa cells were plated at 35,000 cells/well in a black 96-well plate (Greiner Bio-one) and 
incubated overnight. Media was replaced with 2.21 (10 µM, 0.5% DMSO) diluted in DPBS (100 
µL). Cells were incubated with 2.21 for 45 min at 37 °C, before removing treatment and washing 
cells with DPBS (2 x 50 µL). Fresh DPBS was added (90 µL), and initial fluorescence (Fi) was 
imaged on a Zeiss Axio Observer Z1 microscope using a 20x objective and GFP (Set 38 HE) filter 
(ex. 470 nm, em. 525 nm). Next, 10 µL of aq. hydrogen peroxide (1 mM) or 10 µL of water 
(vehicle) was added and cells were incubated for an additional 45 min at 37 °C before imaging 
final fluorescence (F). Next, fresh DPBS containing 2 µM Hoeschst 33258 (100 µL) was added to 
cells and incubated for 15 min before imaging using a DAPI (Set 68) filter (ex. 377 nm, em. 464 
nm). 
 
 
 
Fluorophore 2.21 in HeLa cells with exogenous H2O2 
HeLa cells were plated at 35,000 cells/well in a black 96-well plate (Greiner Bio-one) and 
incubated overnight. Media was replaced with 2.21 (25 µM, 0.5% DMSO) diluted in DPBS (100 
µL). Cells were incubated with 2.21 for 45 min at 37 °C, before removing treatment and washing 
cells with DPBS (2 x 50 µL). Fresh DPBS was added (90 µL), and initial fluorescence (Fi) was 
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imaged on a Zeiss Axio Observer Z1 microscope using a 20x objective and GFP (Set 38 HE) filter 
(ex. 470 nm, em. 525 nm). Next, 10 µL of aq. hydrogen peroxide (1 mM) or 10 µL of water 
(vehicle) was added and cells were incubated for an additional 45 min at 37 °C before imaging 
final fluorescence (F). 
 
Fluorophore release from 2.21 in HeLa cells by endogenous PMA-stimulated H2O2 
generation 
HeLa cells were plated at 35,000 cells/well in a black 96-well plate (Greiner Bio-one) and 
incubated overnight. Media was refreshed with PMA-treated DMEM (1 µM, 0.1% DMSO) or 
DMSO (0.1%) and cells were incubated for 1 h before removing treatment and washing cells with 
DPBS (2 x 50 uL). Fresh DPBS (100 µL) containing 2.21 (10 µM, 0.5% DMSO) was added to the 
wells and cells were imaged for initial fluorescence (Fi) on a Zeiss Axio Observer Z1 microscope 
using a 20x objective and GFP (Set 38 HE) filter (ex. 470 nm, em. 525 nm). Cells were 
subsequently incubated for an additional 60 min before imaging final fluorescence (F), then fresh 
DPBS containing 2 uM Hoeschst 33258 (100 µL) was added to cells and incubated for 15 min 
before imaging using a DAPI (Set 68) filter (ex. 377 nm, em. 464 nm). 
 
 
 
Fluorescence intensity calculations and statistical analysis 
ImageJ software (National Institutes of Health) was utilized for image analysis and quantification. 
A region-of-interest (ROI) was selected around individual HeLa cells (n = 3) and mean fluorescent 
intensity of each cell was calculated using the ImageJ “Measure” tool. ROIs containing no cells 
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were used to calculate background mean fluorescent intensity and were subsequently background 
subtracted from the mean fluorescent intensities of cell. For each condition, three cells were 
quantified and the final fluorescence (F) was set relative to the initial fluorescence (Fi) for each 
individual cell (F/Fi). Statistical analysis was conducted via an unpaired t-test in the GraphPad 
Prism software. 
 
 
 
 
 
 
Figure 3. Control fluorophore acetal 2.22 in HeLa cells. Cells were treated with 25 µM 2.22 in 
DPBS buffer for 45 min at 37 °C, followed by replacement with fresh DPBS containing vehicle or 
100 µM H2O2. Following 30 min incubation, cellular fluorescence was imaged on a Zeiss Axio 
Observer Z1 microscope using a 20x objective and GFP (Set 38 HE) filter (ex. 470 nm, em. 525 
nm). Mean fluorescence intensities were calculated from individual HeLa cells (n = 3) and set 
relative to vehicle control. Error bars denote SD. 
 
 
General procedure for monitoring alcohol release via 1H NMR spectroscopy. 
The NMR spectrometer was programmed to acquire a spectrum every 32 scans (3 minutes, 24 
seconds) with a relaxation time of 2 seconds to ensure accurate integration values. Buffer solutions 
were prepared according to and using D2O instead of H2O. 
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Representative procedure for sample preparation. 
Compound 2.3 (2.9 mg, 0.012 mmol) was dissolved in CD3CN (475 μL) and D2O (50 μL) was 
added followed by pH 8.00 phosphate buffer (25 μL, 0.1 M, D2O) and dimethoxy ethane (internal 
standard, 25 μL, 1.5 M, CD3CN). The resulting solution was transferred to an NMR tube.  This 
sample preparation is modeled after Phillip’s Protocol. 
 
Representative procedure for alcohol release in response to H2O2. 
The release of butanone from 2.3 was monitored via 1H NMR spectroscopy at 300 K. NMR 
samples were prepared according to the representative procedure for sample preparation. An initial 
1H NMR scan was taken to obtain baseline integration values relative to the internal standard (1,2-
dimethoxyethane). The NMR sample was treated with a solution of H2O2•urea (3.0 M, 25 μL, 6.25 
equivalents), and mixing was achieved by inverting the NMR tube three times. The final 
concentration of 2.3 was 20 mM and the final concentration of H2O2 was 125 mM.  The release of 
alcohol was either directly measured by integration of alcohol or measured based on integration of 
the known ketone or aldehyde by products. 
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APPENDIX B 
Novel Analogues of Bistramide A, synthetic Optimization, and Biological 
Activity (Supporting Info) 
 
 
 
 
(2R,4R,6S,8S)-8-(3-chloropropyl)-2-((S)-3-methylpent-4-en-1-yl)-
1,7-dioxaspiro[5.5]undecan-4-ol (S6).  To a flame dried, 10 mL schlenck 
flask containing a stir bar was added samarium (0.15 g, 1.00 mmol) and I2 (6 mg, 0.039 mmol).  
The flask was back filled with Ar (3x), then degassed, dry, isopropanol (3 mL) was added via 
syringe.  The reaction was stirred for 30 minutes, then ketone 3.47 (40  mg, 0.11 mmol) dissolved 
in isopropanol (1 mL) was added via syringe and allowed to stir overnight. The reaction was 
quenched with 1M HCl (5 mL) and extracted with diethyl ether (3x).  The combined organic layers 
were dried over Na2SO4, filtered, and concentrated under reduced pressure.  The resulting residue 
was purified by silica gel chromatography (Rf = 0.3, 20% ethyl acetate in hexanes) to give alcohol 
S6 (31 mg, 0.086 mmol, 75% yield). 
Data for S6 
Optical Rotation  (c = 0.14, CHCl3) 
[α]25D = -9.3  
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a) Sm, isopropanol, 75% b) Methacroleine:CH2Cl2
 5:1, HG-II, 68%.
c) NaBH4, MeOH 0°C, 81%.  d) NaN3, DMF, 50°C, 90%.
e) PMe3, THF:H2O 3:1, then 3.56, DMF, 39%
a-d e
3.47
3.80 3.73
H
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1H NMR  (500 MHz, CDCl3) 
δ 5.72 (ddd, J = 7.5, 10.3, 17.5 Hz, 1H), 4.99-4.93 (m, 2H), 4.12-4.07 (m, Jtot = 26 Hz, axial, 1H), 
3.62-3.52 (m, 2H), 3.49-3.43 (m, 1H), 3.13 (t, 1H, J = 9.7 Hz), 2.15 (sep, J = 5.6 Hz, 1H), 2.05-
2.12 (m, 1H), 2.05-1.92 (m, 3H), 1.83-1.67 (m, 3H), 1.47-1.11 (m, 12H), 1.02 (d, J = 6.8 Hz, 3 H), 
0.85 (d, J = 6.6 Hz, 3H). 
Meerwein-Pondorf-Verley reduction of similar cyclic ketones is known to give the alcohol in the 
equatorial position.136 
13C NMR (125 MHz, CDCl3) 
δ 144.51, 112.68, 97.18, 74.38, 68.01, 65.02, 45.46, 44.99, 41.05, 37.61, 35.77, 34.70, 33.48, 
32.64, 30.54, 29.09, 27.89, 20.15, 17.88 
IR  (ATR) 
3416, 2911, 1493, 1361, 1321, 1249, 1093, 1081, 1033, 981, 911 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C19H34O3Cl 345.2191, found 345.2204 
TLC 
Rf = 0.3, 20% ethyl acetate in hexanes [silica gel, anisaldehyde stain] 
 
(S,E)-6-((2R,4R,6R,8R,9S)-8-(3-chloropropyl)-4-hydroxy-9-methyl-
1,7-dioxaspiro[5.5]undecan-2-yl)-2,4-dimethylhex-2-enal (S7).  To a 
flame dried, 25 mL round bottom flask containing a stir bar was added alkene S7 (20 mg, 0.056 
mmol) dissolved in CH2Cl2 (1 mL).  Methacrolein (5 mL) was added, then Nitro-Grela catalyst 
(3.8 mg, 5.6 µmol) and the flask was sealed and placed under an argon balloon.  The reaction was 
heated at 40 °C for 4 hours, then concentrated under reduced pressure.  The resulting residue was 
O
O
H
H
HO
Cl
O
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purified by silica gel chromatography (Rf = 0.3, 40% ethyl acetate in hexanes) to give aldehyde S7 
(.014 g, 0.037 mmol, 67%, E:Z (10:1)). 
Data for S7 
Optical Rotation  (c = 0.28, CHCl3) 
[α]25D = +11.82 
1H  NMR (500 MHz, CDCl3) 
δ 9.42 (s, 1H), 6.28 (dd, J = 1.1, 9.9 Hz), 4.12-4.08 (m, 1H), 3.61-3.52 (m, 2H), 3.48-3.45 (m, 1H),  
3.10 (td, J = 2.3, 9.7 Hz, 1H), 2.73-2.69 (m, 1H), 2.08-1.98 (m, 2H), 1.94-1.91 (m, 1H), 1.83-1.78 
(m, 1H), 1.77 (d, J =1.2 Hz, 3H),  1.75-1.59 (m, 3H), 1.54-1.15 (m, 10 H), 1.11 (d, J = 5.8 Hz, 
3H), 0.85 (d, J = 6.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) 
δ 195.63, 159.98, 138.20, 97.25, 77.23, 74.45, 67.78, 64.88, 60.42, 45.47, 40.92, 35.68, 34.67, 
33.79, 33.59, 32.83, 30.52, 29.15, 27.87, 19.93, 17.95, 14.21, 9.49 
IR  (ATR) 
3412, 2901, 1681, 1632, 1493, 1361, 1316, 1243, 1099, 1074, 1011, 979, 907 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H36O4Cl 387.2296, found 345.2304 
TLC 
Rf = 0.3, 40% ethyl acetate in hexanes [silica gel, anisaldehyde stain] 
 
(2R,4R,6R,8R,9S)-8-(3-chloropropyl)-2-((S,E)-6-hydroxy-3,5-
dimethylhex-4-en-1-yl)-9-methyl-1,7-dioxaspiro[5.5]undecan-4-ol (S8). 
To a flame dried, 10 mL round bottom flask, containing stir bar was added aldehyde S8 (15 mg, 
O
O
H
H
HO
Cl
OH
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0.040 mmol) dissolved in MeOH (3 mL).  The reaction was cooled to 0°C using an ice-water bath, 
then NaBH4 (5 mg, 0.14 mmol) was added in a single portion. The reaction stirred at 0°C for 30 
minutes, then quenched with H2O and extracted with diethyl ether (3x). The combined organic 
layers were dried over Na2SO4, filtered, and concentrated under reduced pressure.  A column was 
run on the resulting residue (Rf = 0.15, 40% ethyl acetate in hexanes) to give diol S8 (12  mg, 
0.032 mmol, 81%). 
Data for S8 
Optical Rotation  (c = 0.18, CHCl3) 
[α]25D = +10.0 
1H NMR  (500 MHz, CDCl3) 
δ 5.20 (dd, J = 1.0, 9.4 Hz, 1H), 4.16-4.07 (m, 1H), 4.01 (s, 2H), 3.61-3.52 (m, 2H), 3.47-3.43 (m, 
1H), 3.13 (td, J = 2.3, 9.7 Hz, 1H), 2.44-2.37 (m, 1H), 2.06-1.98 (m, 2H), 1.94-1.91 (m, 1H), 1.83-
1.71 (m, 2H), 1.68 (d, J = 1 Hz, 3H), 1.59-1.25 (m, 12 H), 0.97 (d, J = 6.7 Hz, 3H), 0.85 (d, J = 
6.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3) 
δ 133.6, 132.37, 97.19, 74.40, 68.97, 67.95, 65.02, 45.44, 44.98, 41.06, 35.76, 34.71, 33.75, 33.52, 
31.99, 30.53, 29.13, 27.88, 21.03, 17.89, 13.91 
IR  (ATR) 
3407, 2877, 1490, 1332, 1211, 1076, 1062, 1001, 986, 907 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H38O4Cl 389.2453, found 389.2462 
TLC 
Rf = 0.15, 40% ethyl acetate in hexanes [silica gel, anisaldehyde stain] 
 127 
 
(2R,4R,6R,8R,9S)-8-(3-azidopropyl)-2-((S,E)-6-hydroxy-3,5-
dimethylhex-4-en-1-yl)-9-methyl-1,7-dioxaspiro[5.5]undecan-4-ol 
(3.80). To a flame dried, 1 dram vial mL containing stir bar was added diol 3.80 (9.0 mg , 0.023 
mmol) in DMF (1 mL). Sodium azide (15 mg, 0.23 mmol) was added in a single portion and the 
reaction was sealed then heated to 50°C and stirred overnight.  The reaction was allowed to cool 
to room temperature, then diluted with H2O and extracted with diethyl ether (3x).  The combined 
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure.  A 
column was run on the resulting residue (Rf = 0.15, 40% ethyl acetate in hexanes) to give diol 3.80 
(8.1 mg, 0.020 mmol, 88%). 
Data for 3.80 
Optical Rotation  (c = 0.21, CHCl3) 
[α]25D = +10.1 
1H NMR  (500 MHz, CDCl3) 
δ  5.20 (d, J = 9.5, 1H), 4.16-4.07 (m, 1H), 4.02 (s, 2H), 3.47-3.43 (m, 1H), 3.39-3.26 (m, 2H), 
3.13 (td, J = 2.2, 9.7 Hz, 1H),  2.43-2.35 (m, 1H), 1.99 (dd, J = 4.6, 12.3 Hz, 1H),  1.95-1.91 (m, 
1H), 1.88-1.81 (m, 2H),  1.77-1.26 (m, 15H),  0.97 (d, J = 6.7 Hz, 3H),  0.84 (d, J = 6.6 Hz, 3H) 
13C NMR (100 MHz, CDCl3) 
δ 133.61, 132.37, 97.20, 74.47, 68.97, 67.99, 65.02, 51.87, 44.98, 41.05, 35.76, 34.70, 33.76, 
33.55, 32.02, 30.19, 29.68, 27.87, 25.32, 17.89, 13.89  
IR  (ATR) 
3419, 2873, 2080, 1487, 1331, 1307, 1215, 1077, 1064, 999, 981, 900 cm-1 
HRMS  (FTMS ES+) 
O
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[M+H]+ Calculated for C21H38O4N3 396.2857, found 396.2860 
TLC 
Rf = 0.15, 40% ethyl acetate in hexanes [silica gel, anisaldehyde stain] Note: Staring material and 
product have identical Rf 
 
(2S,3R)-3-hydroxy-N-(3-((2R,3S,6R,8R,10R)-10-
hydroxy-8-((S,E)-6-hydroxy-3,5-dimethylhex-4-en-
1-yl)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl)propyl)-2-methyl-4-(2-((2S,3S)-3-methyl-6-
((E)-2-oxopent-3-en-1-yl)tetrahydro-2H-pyran-2-yl)acetamido)butanamide (3.73).  To a 
flame dried 5 mL flask containing a stir bar was added azide 3.80 (7.0 mg, 0.018 mmol) dissolved 
in THF (1mL), then H2O (0.3 mL) was added.  The reaction was sealed under Ar, then PMe3 (1.00 
M in THF, 0.10 mL, 0.10 mmol) was added via syringe.The reaction was stirred for 1 hour, then 
diluted with diethyl ether and H2O. The resulting mixture was extracted with diethyl ether (3x) 
and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced 
pressure.  The resulting reside was then dissolved in dimethylformamide (1 ml) and sealed under 
argon. Succinimide 3.56 (5.1 mg, 0.011 mmol) dissolved in dimethylformamide (0.3 ml) was 
added via syringe.  The reaction was stirred at room temperature overnight, then diluted with 
CH2Cl2 and H2O.  The resulting mixture was extracted with CH2Cl2 (3x), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. A column was run on the resulting residue (Rf 
= 0.15, 5% methanol in CH2Cl2) to give bistramide analogue 3.73 (3.1 mg, 0.0044 mmol, 39%). 
Data for 3.73 
Optical Rotation  (c = 0.12, CHCl3) 
[α]25D = +2.1 
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1H NMR  (500 MHz, CDCl3) 
δ 7.30 (br.t, 1H), 6.99 (br. t, 1H),  6.91 (dd, 1H, J = 6.8, 15.7 Hz), 6.12 (dd, 1H, J = 1.6, 15.8 Hz), 
5.21 (d, 1H, J =  9.4 Hz), 4.58 (br. d, 1H), 4.22-4.19 (m, 1H), 4.11-4.09 (m, 1H), 4.05-4.04 (m, 
1H), 3.99 (s, 2H), 3.81-3.77 (m, 1H), 3.72 (q, 1H, J = 5.2 Hz), 3.45 (dd, 1H, J = 5.3, 14 Hz), 3.37-
3.22 (m, 4H), 2.90 (dd, 1H, J = 8.75, 16.9 Hz), 2.75 (dd, 1H, J = 11.7, 15.2 Hz), 2.54 (dd, 1H, J = 
3.15, 16.9 Hz), 2.42-2.36 (m, 2H), 2.15 (d, 1H, J = 15.1 Hz), 1.92 (dd, 3H, J = 1.6, 6.8 Hz), 1.85-
1.74 (m, 3H), 1.68 (s, 3H), 1.57-1.19 (m, 24H), 0.96 (d, 3H, J = 6.7 Hz), 0.86 (d, 3H, J = 7 Hz), 
0.83 (d, 3H, J = 6.5 Hz)       
13C NMR (125 MHz, CDCl3) 
δ 198.98, 174.97, 173.71, 144.68, 135.58, 132.32, 132.06, 97.12, 74.98, 74.45, 74.07, 68.90, 68.04, 
64.63, 45.25, 44.90, 43.63, 40.91, 39.18, 35.79, 34.62, 33.65, 33.49, 33.32, 32.31, 31.99, 31.91, 
30.82, 30.02, 29.69, 27.89, 26.53, 25.87, 20.93, 18.39, 17.92, 17.15, 15.64, 13.95 
IR  (ATR) 
3600-3200 (brs), 2937, 2861, 1651, 1549, 1379, 1298, 1201, 986, 731 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C39H67O9N2 707.4841, found 707.4821 
TLC 
Rf = 0.15 5% methanol in dichloromethane [silica gel, p-anisaldehyde stain] 
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(S,E)-6-((2R,6S,8S)-8-(3-chloropropyl)-4-oxo-1,7-
dioxaspiro[5.5]undecan-2-yl)-2,4-dimethylhex-2-enal (3.71).  To a 
flame dried, 25 mL round bottom flask containing a stir bar was added alkene 3.47 (0.040 g, 0.11 
mmol) dissolved in CH2Cl2 (1 mL).  Methacrolein (5 mL) was added, then Nitro-Grela catalyst 
(.014 g, .021 mmol) and the flask was sealed and placed under an argon balloon.  The reaction was 
heated at 40 °C for 4 hours, then concentrated under reduced pressure.  The resulting residue was 
purified by silica gel chromatography (Rf = 0.3, 20% ethyl acetate in hexanes) to give aldehyde 
3.71 (.031 g, 0.083 mmol, 68% E:Z 20:1). 
Data for 3.71 
Optical Rotation  (c = 0.41, CHCl3) 
[α]25D = +12.2 
1H NMR  (400 MHz, CDCl3) 
δ 9.43 (s, 1H), 6.30 (d, J = 9.8 Hz, 1H), 3.75 (m, 1H), 3.58-3.46 (m, 2H), 3.13 (t, J = 9.4 Hz, 1H), 
2.73 (m, 1H), 2.58-2.42 (m, 1H), 2.39 (s, 2H), 2.36-2.32 (m, 1H),  2.18 (t, J = 13.8 Hz, 1H), 1.86-
1.81 (m, 2H),  1.78 (s, 3H), 1.69-1.36 (m, 10H), 1.13 (d, J = 6.4 Hz, 3H), 0.86 (d, J = 6.2 Hz, 3H) 
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Reagents and conditions
a) Methacroleine:CH2Cl2
 5:1, HG-II, 68%.
b) L-selectride, THF, -78°C, 67%.  c) NaN3, DMF, 50°C, 92%.
d) PMe3, THF:H2O 3:1, then 3.56, DMF, 41% e) 2,6 ditertbutylpyridine, MeOTf, CH2Cl2, 69% 
f) PMe3, THF:H2O 3:1, then 3.56, DMF, 31%
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13C NMR (100 MHz, CDCl3) 
δ 205.71, 195.48, 159.41, 138.41, 99.03, 75.43, 68.67, 51.83, 47.05, 45.51, 35.23, 34.10, 33.87, 
33.56, 32.57, 30.27, 28.52, 27.90, 19.55, 17.82, 9.53 
IR  (ATR) 
2901, 1701, 1681, 1626, 1498, 1349, 1316, 1241, 1099, 1052, 1000, 976 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H34O4Cl 385.2140, found 385.2144 
TLC 
Rf = 0.3 20% ethyl acetate in hexanes [silica gel, p-anisaldehyde stain]  
 
(2R,6S,8S)-8-(3-chloropropyl)-2-((S,E)-6-hydroxy-3,5-dimethylhex-4-
en-1-yl)-1,7-dioxaspiro[5.5]undecan-4-one (3.81).  To a flame dried flask 
containing a stir bar was added aldehyde 3.71 (0.051 g, 0.13 mmol) 
dissolved in THF (10 ml).  The flask was placed under argon, cooled to -78 °C, then L-selectride 
(1M in THF, 0.17 ml, 0.17 mmol) was added dropwise.  The reaction was stirred for 30 minutes 
at -78 °C then cooled to room temperature.  The reaction was quenched with H2O and extracted 
with diethyl ether (3x).  The combined organic layers were dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The resulting residue was purified by silica gel column 
chromatography (Rf =0.15, 30% ethyl acetate in hexanes) to give title compound 3.81 (0.031 g, 
.081 mmol, 62%) as well as diol S8 (0.015 g, .039 mmol, 30%). 
Data for 3.81 
Optical Rotation  (c = 0.18, CHCl3) 
[α]25D = +10.4 
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1H NMR  (500 MHz, CDCl3) 
δ 5.20 (dd, J = 9.5, 1.1 Hz, 1H), 4.03 (s, 2H), 3.74 (ddt, J = 11.4, 8.5, 3.2 Hz, 1H), 3.58-3.47 (m, 
2H), 3.15 (td, J = 9.4, 2.4 Hz, 1H), 2.43-2.40 (m, 1H), 2.39 (s, 2H), 2.36-2.32 (m, 1H), 2.34 (dd, J 
= 13.7, 1.7 Hz, 1H),  2.18 (dd, J = 14.1, 11.5 Hz, 1H), 1.99-1.93 (m, 1H), 1.87-1.76 (m, 2H), 1.68 
(d, J = 1 Hz, 3H), 1.66-1.26 (m, 13H), 0.98 (d, J = 6.7 Hz, 3H), 0.87 (d, J = 5.6 Hz, 3H) 
13C NMR (125 MHz, CDCl3) 
δ 205.71, 133.87, 131.90, 98.96, 75.29, 68.86, 68.82, 51.86, 47.19, 45.53, 35.30, 34.08, 33.90, 
33.22, 31.97, 30.27, 28.52, 27.89, 21.11, 17.79, 13.96 
IR  (ATR) 
3311, 2901, 1701, 1640, 1498, 1349, 1299, 1254, 1081, 1042, 999, 979, 652 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H36O4Cl 387.2297, found 387.2298 
TLC 
Rf = 0.15 30% ethyl acetate in hexanes) [silica gel, p-anisaldehyde stain]  
 
(2R,6R,8R,9S)-8-(3-azidopropyl)-2-((S,E)-6-hydroxy-3,5-
dimethylhex-4-en-1-yl)-9-methyl-1,7-dioxaspiro[5.5]undecan-4-one 
(3.77). To a flame dried, 1 dram vial mL containing stir bar was added 
ketone 3.81 (12 mg , 0.030 mmol) in DMF (1 mL). Sodium azide (30 mg, 0.46 mmol) was added 
in a single portion and the reaction was sealed then heated to 50°C and stirred overnight.  The 
reaction was cooled to room temperature, then diluted with H2O and extracted with diethyl ether 
(3x).  The combined organic layers were dried over Na2SO4, filtered, and concentrated under 
O
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reduced pressure.  The resulting residue was purified by silica gel column chromatography (Rf = 
0.15, 30% ethyl acetate in hexanes) to give azide 3.77 (9.0 mg, 0.023 mmol, 75%). 
Data for 3.77 
Optical Rotation  (c = 0.10, CHCl3) 
[α]25D = +3.5 
1H NMR  (500 MHz, CDCl3) 
δ 5.20 (d, J = 9.2 Hz, 1H), 4.02 (s, 2H), 3.77-3.73 (m, 1H), 3.32-3.21 (m, 2H), 3.17-3.13 (m, 1H), 
2.43-2.40 (m, 1H), 2.38 (s, 2H), 2.36-2.33 (m, 1H), 2.19 (dd, J = 14.1, 11.5 Hz, 1H), 1.87-1.82 (m, 
2H), 1.78-1.36 (m, 15H), 0.99 (d, J = 6.7 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H) 
13C NMR (125 MHz, CDCl3) 
δ 205.96, 133.88, 131.90, 98.96, 75.40, 68.84, 61.89, 51.84, 47.17, 45.91, 35.32, 34.06, 33.91, 
33.24, 31.97, 30.15, 29.68, 27.89, 24.92, 21.06, 17.78, 13.91, 8.61 
IR  (ATR) 
3211, 2899, 2121, 1699, 1630, 1498, 1356, 1278, 1243, 1077, 1045, 976 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H36O4N3 394.2700, found 394.2697 
 TLC 
Rf = 0.15 30% ethyl acetate in hexanes [silica gel, p-anisaldehyde stain] 
 
 
 (2S,3R)-3-hydroxy-N-(3-
((2R,3S,6R,8R)-8-((S,E)-6-
hydroxy-3,5-dimethylhex-4-en-1-
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yl)-3-methyl-10-oxo-1,7-dioxaspiro[5.5]undecan-2-yl)propyl)-2-methyl-4-(2-((2S,3S)-3-
methyl-6-((E)-2-oxopent-3-en-1-yl)tetrahydro-2H-pyran-2-yl)acetamido)butanamide (3.74). 
To a flame dried 5 mL flask containing a stir bar was added azide 3.77 (7.0 mg, 0.018 mmol) 
dissolved in THF (1mL), then H2O (0.3 mL) was added.  The reaction was sealed under Ar, then 
PMe3 (1.00 M in THF, 0.10 mL, 0.10 mmol) was added via syringe.The reaction was stirred for 1 
hour, then diluted with diethyl ether and H2O. The resulting mixture was extracted with diethyl 
ether (3x) and the combined organic layers were dried over Na2SO4, filtered, and concentrated 
under reduced pressure.  The resulting reside was then dissolved in dimethylformamide (1 ml) and 
sealed under argon. Succinimide 3.56 (5.0 mg, 0.011 mmol) dissolved in dimethylformamide (0.3 
ml) was added via syringe.  The reaction was stirred at room temperature overnight, then diluted 
with CH2Cl2 and H2O.  The resulting mixture was extracted with CH2Cl2 (3x), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. A column was run on the resulting residue (Rf 
= 0.20, 5% methanol in CH2Cl2) to give bistramide analogue 3.74 (3.2 mg, 0.0045 mmol, 41%). 
Data for 3.74 
Optical Rotation  (c = 0.10, CHCl3) 
[α]25D = +3.6 
1H NMR  (500 MHz, CDCl3) 
δ  7.29 (br.t, 1H), 6.91 (dd, 1H, J = 6.85, 15.9 Hz),  6.82 (br.t, 1H), 6.13 (dd, 1H, J = 1.5, 15.8 Hz), 
5.21 (d, 1H, J = 9.35 Hz), 4.21 (m, 1H),  4.10 (m, 1H), 4.01 (s, 2H), 3.77 (m, 1H), 3.72 (d, 1H J = 
5.25 Hz), 3.51-3.46 (m, 1H), 3.25-3.22 (m, 2H), 3.14 (t, 1H, J = 10 Hz), 2.91 (dd, 1H, J = 8.75, 
16.9 Hz), 2.76 (dd, 1H, J = 11.9, 15.0 Hz), 2.55 (dd, 1H, J = 3.05, 17 Hz), 2.38 (s, 2 H), 2.41 (m, 
1H), 2.37-2.33 (m, 1H), 2.20-2.13 (m, 3H), 1.92 (dd, 3H, J = 1.4, 6.8 Hz), 1.85-1.81 (m, 1H), 1.67-
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1.31 (m, 19H), 1.29- 1.22 (m, 8H), 0.98 (d, 3H, J = 6.7 Hz), 0.86 (d, 3H, J = 7.05 Hz), 0.83 (d, 
3H, J = 6.6 Hz)        
13C NMR (125 MHz, CDCl3) 
δ 206.32, 198.91, 175.27, 173.34, 144.40, 133.92, 132.16, 131.78, 98.92, 98.89, 75.32, 74.77, 
73.73, 70.60, 68.92, 68.75, 51.96, 47.13, 45.29, 44.57, 43.31, 39.13, 35.35, 33.96, 33.80, 33.32, 
33.15, 32.48, 31.98, 30.74, 29.76, 27.93, 26.54, 25.21, 20.98, 18.37, 17.80, 17.05, 15.49, 13.97. 
IR  (ATR) 
3600-3200 (brs), 2937, 2861, 1721, 1650, 1520, 1386, 1298, 1201, 977, 722 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C39H65O9N2 705.4685, found 705.4667 
TLC 
Rf = 0.20 5% methanol in dichloromethane [silica gel, p-anisaldehyde stain] 
 
(2R,8R,9S)-8-(3-azidopropyl)-2-((S,E)-6-methoxy-3,5-dimethylhex-4-
en-1-yl)-9-methyl-1,7-dioxaspiro[5.5]undecan-4-one (3.78). To a flame 
dried, 5 mL round bottom flask containing a stir bar was added azide 3.77 
(6.0 mg , 0.015 mmol) in CH2Cl2 (1 mL). The flask was sealed under Ar and 2,6-ditertbutylpyridine 
(0.2 mL) and methyl trifluoromethanesulfonate (0.1 mL) were added via syringe sequentially.  The 
reaction was allowed to stir at room temperature overnight, then concentrated under reduced 
pressure.  The resulting residue was purified by silica gel column chromatography (Rf = 0.6, 20% 
ethyl acetate in hexanes) to give methyl ether 3.78 (4.1 mg, 0.010 mmol, 69% yield). 
Data for 3.78 
Optical Rotation  (c = 0.071, CHCl3) 
O
O
H
H
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[α]25D = -11.3 
1H NMR  (500 MHz, CDCl3) 
δ 5.20 (d, J = 9.6 Hz, 1H), 3.81 (s, 2H), 3.71-3.73 (m, 1H), 3.33-3.21 (m, 2H), 3.29 (s, 3H), 3.14 
(t, J = 9.2 Hz 1H), 2.44-2.41 (m, 1H), 2.38 (s, 2H), 2.36-2.32 (m, 1H), 2.18 (dd, J = 14.05, 11.4 
Hz, 1H), 1.86-1.73 (m, 4H), 1.65 (s, 3H), 1.63-1.26 (m, 10 H), 0.99 (d, J = 6.6 Hz, 3H), 0.86 (d, J 
= 6.5 Hz, 3H) 
13C NMR (125 MHz, CDCl3) 
δ 205.97, 133.98, 131.12, 98.94, 78.62, 75.39, 68.82, 57.33, 51.84, 47.16, 35.32, 34.06, 33.89, 
33.19, 32.07, 30.12, 29.98, 27.88, 24.92, 21.03, 17.77, 14.02  
IR  (ATR) 
2890, 2119, 1715, 1640, 1490, 1353, 1279, 1247, 1099, 1049, 966 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C22H37N3O4 408.2857, found 408.2864 
TLC 
Rf = 0.6, 20% ethyl acetate in hexanes [silica gel, anisaldehyde stain] 
 
(2S,3R)-3-hydroxy-N-(3-((2R,3S,8R)-8-((S,E)-6-
methoxy-3,5-dimethylhex-4-en-1-yl)-3-methyl-10-
oxo-1,7-dioxaspiro[5.5]undecan-2-yl)propyl)-2-
methyl-4-(2-((2S,3S,6R)-3-methyl-6-((E)-2-oxopent-3-en-1-yl)tetrahydro-2H-pyran-2-
yl)acetamido)butanamide (3.76).  To a flame dried 5 mL flask containing a stir bar was added 
azide 3.78 (4.0 mg, 0.0098 mmol) dissolved in THF (1mL), then H2O (0.3 mL) was added.  The 
reaction was sealed under Ar, then PMe3 (1.00 M in THF, 0.10 mL, 0.10 mmol) was added via 
O
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syringe.The reaction was stirred for 1 hour, then diluted with diethyl ether and H2O. The resulting 
mixture was extracted with diethyl ether (3x) and the combined organic layers were dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  The resulting reside was then dissolved 
in dimethylformamide (1 ml) and sealed under argon. Succinimide 3.56 (8.0 mg, 0.018 mmol) 
dissolved in dimethylformamide (0.3 ml) was added via syringe.  The reaction was stirred at room 
temperature overnight, then diluted with CH2Cl2 and H2O.  The resulting mixture was extracted 
with CH2Cl2 (3x), dried over Na2SO4, filtered, and concentrated under reduced pressure. A column 
was run on the resulting residue (Rf = 0.20, 5% methanol in CH2Cl2) to give bistramide analogue 
3.76 (1.8 mg, 0.0025 mmol, 31% yield). 
Data for 3.76 
Optical Rotation (c = 0.053, CHCl3) 
[α]25D = +1.3   
1H NMR  (700 MHz, CDCl3) 
δ  7.42 (br. t, 1H), 6.91 (dd, 1H, J = 6.9, 15.8 Hz), 6.82 (br.t, 1H), 6.13 (dd, 1H, J = 1.4, 15.6 Hz), 
5.20 (d, 1H, J = 9.4 Hz), 4.21 (m, 1H), 4.10 (m, 1H), 3.81 (m, 2H), 3.77-3.67 (m, 2H), 3.53-3.49 
(m, 1H), 3.29 (s, 3H), 2.72-3.19 (m, 2H), 3.13 (t, 1H, J = 8.8 Hz), 2.95-2.88 (m, 1H), 2.77 (dd, 1H, 
J = 11.6, 15.0 Hz), 2.58-2.54 (m, 1H), 2.42-2.40 (m, 1H), 2.38 (s, 2H), 2.34-2.33 (m, 1H), 2.20-
2.12 (m, 2H), 1.92 (s, 3H), 1.85-1.83 (m, 1H), 1.65 (s, 3H), 1.69-1.52 (m, 6H), 1.48-1.44 (m, 2H), 
1.40-1.30(m, 6H), 1.29-1.18 (m, 6H), 0.98 (d, 3H, J = 6.7 Hz), 0.87 (d, 3H, J = 6.8 Hz), 0.83 (d, 
3H, J = 6.5 Hz)           
13C NMR (175 MHz, CDCl3) 
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δ 206.55, 199.00, 175.31, 173.35, 144.54, 134.20, 132.05, 130.97, 98.96, 78.66, 75.45, 74.79, 
73.66, 68.84, 57.32, 51.96, 47.20, 45.27, 44.52, 43.25, 39.30, 35.29, 34.16, 33.62, 33.32, 33.11, 
33.13, 32.17, 30.79, 29.86, 29.71, 27.87, 26.51, 25.17, 21.22, 18.47, 17.82, 17.14, 15.52, 14.07   
IR  (ATR) 
3600-3200 (brs), 2941, 2731, 1660, 1391, 1301, 1200, 976, 721 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C40H67O9N2 719.4841, found 719.48476 
TLC 
Rf = 0.35 5% methanol in dichloromethane [silica gel, p-anisaldehyde stain] 
 
 
 
 
(2R4S,6R,8R,9S)-8-(3-chloropropyl)-2-((S,E)-6-hydroxy-3,5-
dimethylhex-4-en-1-yl)-9-methyl-1,7-dioxaspiro[5.5]undecan-4-ol (S8). 
To a flame dried, 10 mL round bottom flask, containing stir bar was added aldehyde 3.71 (21 mg, 
0.050 mmol) dissolved in MeOH (3 mL).  The reaction was cooled to 0°C using an ice-water bath, 
then NaBH4 (5 mg, 0.14 mmol) was added in a single portion. The reaction stirred at 0°C for 30 
minutes, then quenched with H2O and extracted with diethyl ether (3x). The combined organic 
layers were dried over Na2SO4, filtered, and concentrated under reduced pressure.  A column was 
run on the resulting residue (Rf = 0.25, 40% ethyl acetate in hexanes) to give diol S8 (18  mg, 
0.045 mmol, 88%). 
Data for S8 
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Reagents and conditions
a) NaBH4, MeOH 0°C, 88%.  b) NaN3, DMF, 50°C, 63%.
c) PMe3, THF:H2O 3:1, then 3.56, DMF, 43%
a-b c
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Optical Rotation  (c = 0.14, CHCl3) 
[α]25D = +14.3 
1H NMR  (500 MHz, CDCl3) 
δ 5.21 (dd, J = 9.5, 1.2 Hz, 1H), 4.07-4.04 (m, Jtot = 15.2 Hz, 1H), 4.02 (s, 1H), 4.01 (s, 1H), 3.95 
(d, J = 9.7 Hz, 1H), 3.80-3.76 (m, 1H), 3.59-3.56 (m, 2H), 3.34-3.39 (m, 1H), 2.44-2.39 (m, 1H), 
1.97-1.90 (m, 1H), 1.86-1.75 (m, 4H), 1.68 (d, J = 1.2 Hz, 3H), 1.65-1.57 (m, 4H), 1.54-1.31 (m, 
10H), 0.98 (d, J = 6.7 Hz, 3H), 0.87 (J = 6.5 Hz, 3H)  
13C NMR (125 MHz, CDCl3) 
\δ 133.65, 132.34, 97.98, 75.39, 69.95, 65.21, 63.94, 45.30, 40.27, 38.30, 35.76, 33.96, 33.78, 
33.41, 32.07, 30.06, 28.56, 27.32, 21.11, 17.89, 13.93  
IR  (ATR) 
3300-3200 (brs), 2899, 1643, 1496, 1359, 1301, 1243, 1076, 1039, 999, 652 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H38O4Cl 389.2453, found 389.2456 
TLC 
Rf = 0.25, 40% ethyl acetate in hexanes [silica gel, anisaldehyde stain] 
 
(2R,4S,6R,8R,9S)-8-(3-azidopropyl)-2-((S,E)-6-hydroxy-3,5-
dimethylhex-4-en-1-yl)-9-methyl-1,7-dioxaspiro[5.5]undecan-
4-ol (3.79). To a flame dried, 1 dram vial mL containing stir bar was 
added diol 3.79 (14 mg , 0.036 mmol) in DMF (1 mL). Sodium azide (23 mg, 0.36 mmol) was 
added in a single portion and the reaction was sealed then heated to 50°C and stirred overnight.  
The reaction was cooled to room temperature, then diluted with H2O and extracted with diethyl 
O
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H
H
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ether (3x).  The combined organic layers were dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  A column was run on the resulting residue (Rf = 0.25, 40% ethyl acetate in 
hexanes) to give azide 3.79 (9  mg, 0.023 mmol, 63%). 
 Data for 3.79 
Optical Rotation  (c = 0.11, CHCl3) 
[α]25D = +28.2 
1H NMR  (500 MHz, CDCl3) 
δ 5.21 (dd, J = 1.05 Hz, 1H), 4.06-4.04 (m, 1H), 4.01 (s, 2H), 3.94 (d, J = 9.6 Hz, 1H), 3.80-3.77 
(m, 1H), 3.36-3.29 (m, 3H), 2.45-2.37 (m, 1H), 1.86-1.73 (m, 4H), 1.67 (d, J = 1 Hz, 3H), 1.65-
1.34 (m, 14H), 0.98 (d, J = 6.7 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H) 
13C NMR (125 MHz, CDCl3) 
δ 133.60, 132.22, 97.98, 75.47, 68.94, 65.20, 63.97, 57.17, 40.27, 38.29, 35.76, 34.00, 33.78, 
33.44, 32.08, 29.91, 29.68, 27.31, 25.06, 17.91, 13.91 
IR  (ATR) 
3300-3200 (brs), 2877, 2111, 1641, 1498, 1361, 1299, 1243, 1077, 1041, 978 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H38O4N3 396.2856, found 396.2856 
TLC 
Rf = 0.25, 40% ethyl acetate in hexanes [silica gel, anisaldehyde stain] 
 
(2S,3R)-3-hydroxy-N-(3-((2R,3S,6R,8R,10S)-10-hydroxy-8-((S,E)-6-hydroxy-3,5-
dimethylhex-4-en-1-yl)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl)propyl)-2-methyl-4-(2-
((2S,3S)-3-methyl-6-((E)-2-oxopent-3-en-1-yl)tetrahydro-2H-pyran-2-
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yl)acetamido)butanamide (3.72).  To a flame dried 5 
mL flask containing a stir bar was added azide 3.79 (6.2 
mg, 0.016 mmol) dissolved in THF (1mL), then H2O (0.3 mL) was added.  The reaction was sealed 
under Ar, then PMe3 (1.00 M in THF, 0.10 mL, 0.10 mmol) was added via syringe.  The reaction 
was stirred for 1 hour, then diluted with diethyl ether and H2O. The resulting mixture was extracted 
with diethyl ether (3x) and the combined organic layers were dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The resulting reside was then dissolved in 
dimethylformamide (1 ml) and sealed under argon. Succinimide 3.56 (5.9 mg, 0.013 mmol) 
dissolved in dimethylformamide (0.3 ml) was added via syringe.  The reaction was stirred at room 
temperature overnight, then diluted with CH2Cl2 and H2O.  The resulting mixture was extracted 
with CH2Cl2 (3x), dried over Na2SO4, filtered, and concentrated under reduced pressure. A column 
was run on the resulting residue (Rf = 0.15, 5% methanol in CH2Cl2) to give bistramide analogue 
3.72 (5.1 mg, 0.0072 mmol, 55%). 
Data for 3.72 
Optical Rotation  (c = 0.07, CHCl3) 
[α]25D = +14.3 
\1H NMR  (500 MHz, CDCl3) 
δ 7.31 (br. t, 1H), 6.97 (br. t, 1H), 6.91 (dd, 1H, J = 6.8, 15.8 Hz), 6.14 (dd, 1H, J = 1.7, 15.9 Hz), 
5.21 (d, 1H, J = 9.5 Hz), 4.57 (d, 1H, J = 4.3 Hz), 4.22-4.18 (m, 1H), 4.15-4.09 (m, 1H), 4.05 (m, 
2H), 4.00 (s, 2H), 3.80-3.78 (m, 1H), 3.73 (m, 1H), 3.75 (dt, 1H, J = 6.3, 14 Hz), 3.39-3.22 (m, 
3H), 2.90 (dd, 1H, J = 8.8, 17 Hz), 2.76 (dd, 1H, J = 6.0, 15.0 Hz), 2.54 (dd, 1H, J = 3.0, 16.8 Hz), 
2.41-2.37 (m, 2H), 2.15 (d, 1H, J = 15.2 Hz), 1.93 (dd, 3H, J = 1.5, 6.8 Hz), 1.84-1.72 (m, 3H),  
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1.69-1.28 (m, 18H), 1.68 (s, 3H), 1.26-1.19 (m, 6H), 0.97 (d, 3H, J = 6.7 Hz), 0.87 (d, 3H, J = 7.0 
Hz), 0.83 (d, 3H, J = 6.5 Hz)      
13C NMR (125 MHz, CDCl3) 
δ 197.92, 174.31, 172.30, 143.40, 132.60, 131.28, 131.18, 96.80, 74.45, 73.76, 73.67, 72.62, 67.85, 
64.19, 62.93, 44.30, 43.51, 42.22, 39.36, 38.10, 37.22, 34.80, 32.97, 32.73, 32.38, 32.30, 31.47, 
31.10, 29.77, 28.74, 26.37, 25.54, 24.63, 20.01, 17.36, 16.91, 16.06, 14.51, 12.97   
IR  (ATR) 
3600-3200 (brs), 2937, 2861, 1651, 1519, 1382, 1295, 1200, 977, 724 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C39H67O9N2 707.4841, found 707.4842 
TLC 
Rf = 0.20 5% methanol in dichloromethane [silica gel, p-anisaldehyde stain] 
 
 
(S,E)-6-((2S,6S,8R,9S)-8-(3-chloropropyl)-9-methyl-1,7-
dioxaspiro[5.5]undecan-2-yl)-2,4-dimethylhex-2-en-1-ol (S9). To a 
solution of ketone S9 (.031 g, .078 mmol) in MeOH (1.2 mL) was added TsNHNH2 (0.029 g, 0.16 
mmol) in one portion.  The resulting solution was stirred at room temperature for 6 hours then was 
concentrated under reduced pressure.  The residue was diluted with 30% ethyl acetate in hexanes 
and filtered through a short silica plug.  The filtrate was concentrated and re-dissolved in MeOH 
and THF (1:1, 3 ml). A solution of NaBH3CN (6.3 mg, 0.10 mmol) in MeOH (0.10 ml) was added 
dropwise via syringe at 0°C.  To the resulting solution was carefully added a 1 M HCl stock 
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Reagents and conditions a) MeOH, TsNHNH
2, b) MeOH:THF, NaBH3CN 
c) EtOH/H2O 20:1, NaOAc, 47% over 3 steps
d) NaN3, DMF, 50°C, 81%.
e) PMe3, THF:H2O 3:1, then 3.56, DMF, 54%
a-d e
HO
3.81 3.82 3.76
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solution in EtOH dropwise at 0°C until TLC analysis indicated completion (0.5 mL).  The reaction 
was diluted with diethyl ether and washed with H2O, saturated aqueous NaHCO3, and brine.  The 
organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure.  The 
residue was dissolved in EtOH (4 mL), the NaOAc (0.161 g, 1.94 mmol) was added followed by 
H2O (0.20 ml). The reaction was heated to 75°C for 1 hour, cooled to room temperature, diluted 
with diethyl ether, and washed with H2O and brine.  The organic layer was dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  The resulting residue was purified by silica gel 
column chromatography (Rf = 0.5, 20% ethyl acetate in hexanes) to give alcohol S9 (.021 g, 0.055 
mmol, 47% yield over 3 steps).   
Data for S9 
Optical Rotation  (c = 0.10, CHCl3) 
[α]25D = +20.4 
1H NMR  (500 MHz, CDCl3) 
δ 5.20 (d, J = 9.4 Hz, 1H), 4.01 (s. 2H), 3.65-3.54 (m, 2H), 3.43 (m, 1H), 3.17 (t, J =  9.7 Hz, 1H), 
2.39-2.34 (m, 1H), 2.16-2.09 (m, 1H), 1.87-1.73 (m, 4H), 1.68 (s, 3H), 1.64-1.29 (m, 10H), 1.20-
1.11 (m, 15H), 0.96 (d, J = 6.6 Hz, 3H), 0.85 (d, J = 6.5 Hz, 3H) 
13C NMR (125MHz,CDCl3) 
δ 133.44, 132.65, 95.50, 74.11, 69.12, 69.05, 45.61, 35.10, 35.47, 35.01, 34.19, 33.53, 32.05, 
31.39, 30.69, 29.69, 29.29, 27.91, 21.03, 19.20, 17.94, 13.91 
IR  (ATR) 
3412, 2929, 2863, 1451, 1381, 1269, 1221, 1175, 1090, 1032, 986, 676 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H38O3Cl 373.2504, found 373.2512 
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TLC 
Rf = 0.5 20% ethyl acetate in hexanes [silica gel, p-anisaldehyde stain]  
 
(S,E)-6-((2S,6S,8R,9S)-8-(3-azidopropyl)-9-methyl-
1,7-dioxaspiro[5.5]undecan-2-yl)-2,4-dimethylhex-2-en-1-ol 
(3.82). To a flame dried, 1 dram vial mL containing stir bar was 
added compound 3.82 (10 mg , 0.026 mmol) in DMF (1 mL). Sodium azide (30 mg, 0.46 mmol) 
was added in a single portion and the reaction was sealed then heated to 50°C and stirred overnight.  
The reaction was cooled to room temperature, then diluted with H2O and extracted with diethyl 
ether (3x).  The combined organic layers were dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The resulting residue was purified by silica gel column chromatography (Rf = 
0.50, 20% ethyl acetate in hexanes) to give azide 3.82 (8.0 mg, 0.021 mmol, 81%). 
Data for 3.82 
Optical Rotation  (c = 0.11, CHCl3) 
[α]25D = +27.3 
1H NMR  (500 MHz, CDCl3) 
δ 5.19 (d, J= 9.4 Hz, 1H), 4.00 (s, 2H), 3.47-3.44 (m, 1H), 3.38-3.27 (m, 2H), 3.17 (td, J = 9.7, 1.9 
Hz, 1H), 2.39-2.32 (m, 1H), 1.97-1.90 (m, 2H), 1.84-1.72 (m, 4H), 1.67 (s, 3H), 1.63-1.28 (m, 
10H), 1.22-1.14 (m, 15H), 0.96 (d, J = 6.7 Hz, 3H), 0.85 (d, J = 6.5 Hz, 3 H) 
13C NMR (125 MHz, CDCl3) 
δ 133.43, 132.64, 95.51, 74.18, 69.17, 69.02, 51.94, 36.09, 35.46, 35.02, 34.20, 33.57, 32.07, 
31.38, 30.33, 29.69, 27.90, 25.46, 21.02, 19.20, 17.95, 13.89 
IR  (ATR) 
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3425, 2929, 2863, 2121, 1443, 1377, 1267, 1219, 1089, 1029, 984 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C21H38O3N3 380.2908, found 380.2909 
TLC 
Rf = 0.5 20% ethyl acetate in hexanes [silica gel, p-anisaldehyde stain]  
(2S,3R)-3-hydroxy-N-(3-((2R,3S,6S,8S)-8-
((S,E)-6-hydroxy-3,5-dimethylhex-4-en-1-
yl)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-
yl)propyl)-2-methyl-4-(2-((2S,3S)-3-methyl-6-((E)-2-oxopent-3-en-1-yl)tetrahydro-2H-
pyran-2-yl)acetamido)butanamide (3.78). To a flame dried 5 mL flask containing a stir bar was 
added azide 3.82 (7.0 mg, 0.018 mmol) dissolved in THF (1mL), then H2O (0.3 mL) was added.  
The reaction was sealed under Ar, then PMe3 (1.00 M in THF, 1.5 mL, 0.15 mmol) was added via 
syringe.The reaction was stirred for 1 hour, then diluted with diethyl ether and H2O. The resulting 
mixture was extracted with diethyl ether (3x) and the combined organic layers were dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  The resulting reside was then dissolved 
in dimethylformamide (1 ml) and sealed under argon. Succinimide 3.56 (5.0 mg, 0.011 mmol) 
dissolved in dimethylformamide (0.3 ml) was added via syringe.  The reaction was stirred at room 
temperature overnight, then diluted with CH2Cl2 and H2O.  The resulting mixture was extracted 
with CH2Cl2 (3x), dried over Na2SO4, filtered, and concentrated under reduced pressure. A column 
was run on the resulting residue (Rf = 0.20, 5% methanol in CH2Cl2) to give bistramide analogue 
3.78 (4.1 mg, 0.0059 mmol, 54%). 
Data for 3.78 
Optical Rotation  (c = 0.21, CHCl3) 
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[α]25D = +1.5 
1H NMR  (500 MHz, CDCl3) 
δ  7.32 (br.t, 1H), 6.96 (br.t, 1H),  6.91 (dd, 1H, J = 6.95, 13.8 Hz), 6.15 (dd, 1H, J = 1.5, 15.9 Hz), 
5.20 (d, 1H, J = 9.1 Hz),  4.20 (m, 1H), 4.07 (dd, 1H, J = 4.75, 11.5 Hz), 3.99 (s, 2H), 3.72 (d, 1H, 
J = 4.55 Hz), 3.53-3.46 (m, 2H), 3.35-3.21 (m, 3H), 3.18 (t, 1H, J = 8.0 Hz), 2.91 (dd, 1H, J = 9.0 
Hz , 17.1 Hz), 2.76 (dd, 1H, J = 11.6 Hz, 15.1 Hz), 2.53 (dd, 1H, J = 2.8, 17.0 Hz), 2.38 (m, 2H), 
2.14 (d, 1H, J = 15 Hz), 1.92 (dd, 3H, J = 1.35, 6.8 Hz), 1.84-1.81 (m, 4H), 1.66-1.56 (m, 13H), 
1.47-1.10 (m, 25H), 0.95 (d, 3 H, J = 6.7 Hz), 0.86 (d, 3H, J = 6.9 Hz), 0.81 (d, 3H, J = 6.4 Hz)  
13C NMR (175 MHz, CDCl3) 
δ 198.98, 175.20, 173.53, 144.59, 133.43, 132.42, 132.11, 95.49, 74.85, 74.17, 73.85, 69.21, 68.87, 
45.27, 44.68, 43.31, 39.40, 36.11, 35.51, 34.96, 34.09, 33.52, 33.33, 32.06, 31.32, 30.33, 29.71, 
27.93, 26.51, 25.85, 22.70, 20.97, 19.24, 18.44, 18.02, 17.18, 15.59, 14.14, 13.97   
 IR  (ATR) 
3600-3200 (brs), 2927, 2857, 1651, 1545, 1455, 1367, 1299, 1219, 988, 733 cm-1 
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C39H67O8N2 691.4892, found 691.4904 
TLC 
Rf = 0.30 5% methanol in dichloromethane [silica gel, p-anisaldehyde stain] 
 
 
 
 
a b
AcO
O
AcO
c
AcO O
2-methylallyl acetate
Reagents and Conditions
a) mCPBA, CH2Cl2, 0
°
C, 73% dr 1:1
b) 5:1 2-methylallyl acetate:CH2Cl2, HG-II (3 mol%), 52%, E:Z 5:1
c) H5IO6, THF, 0
°
C, 51%, E:Z 5:1
O
(+) β-citronellene 3.83 3.84 3.85
 147 
 (4S,E)-6-(3,3-dimethyloxiran-2-yl)-2,4-dimethylhex-2-en-1-yl 
acetate (3.84).  To a flame dried, 250 mL round bottom flask, was 
added (+)-β-Citronellene (4.04 g, 29.3 mmol), followed by CH2Cl2 (150 mL).  The reaction was 
cooled to 0°C using an ice bath, then meta-Chloroperoxybenzoic acid (50%, 11.2 g, 32.3 mmol) 
was added portion wise over 30 minutes.  The reaction was allowed to warm to room temperature 
and then was stirred for 1 hour.  The reaction was filtered through a celite plug eluting with CH2Cl2, 
then the filtrate was concentrated under reduced pressure.  The resulting residue was dissolved in 
diethyl ether (150 mL), then washed with saturated aqueous NaHCO3 (3 x 100 mL) and brine (2 x 
100 mL).  The organic layer was dried over Na2SO4 filtered and concentrated.  The resulting oil 
was purified by silica gel chromatography (Rf = 0.5, 10% ethyl acetate in hexanes) to give epoxide 
3.83 (3.61 g, 26.1 mmol, 79%, dr 1:1).  To a flame dried, 25 mL round bottom flask containing a 
stir bar was added epoxide 3.83 (2.01 g, 13.05 mmol) dissolved in CH2Cl2 (2 mL). 2-methylallyl 
acetate (10 mL) was added then HG-II catalyst (0.254 g, 0.405 mmol).   The flask was sealed under 
an argon balloon and heated to 90°C overnight.  The reaction was cooled to room temperature, 
then concentrated under reduced pressure.  The resulting brown oil was purified by silica gel 
column chromatography (Rf = 0.3, 10% ethyl acetate in hexanes) to give acetate 3.84 (1.63 g, 6.78 
mmol, 51%, E:Z 5:1, d.r. 1:1). 
Data for 3.84 
Optical Rotation  (c = 0.6, CHCl3) 
[α]25D = +35.2 
1H NMR  (500 MHz, CDCl3) 
δ 5.26-5.22 (m, 1H, E isomer), 5.19-5.16 (m, 1H, Z isomer), 4.66-4.56 (m, 2H, Z isomer), 4.46 (s, 
2H, E isomer), 2.72-2.69 (m, 1H), 2.53-2.40 (m, 1H), 2.09-2.08 (m, 3H), 1.77 (d, J = 1 Hz, 3H, E 
AcO
O
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isomer), 1.67 (s, 3H, E isomer), 1.61-1.41 (m, 4H), 1.32 (s, H), 1.26 (d, J = 3.6 Hz), 0.99 (d, J = 
6.7 Hz, 3H) 
13C NMR (100 MHz, CDCl3) 
δ 170.91, 135.42, 135.38, 129.25, 129.14, 70.20, 70.17, 64.48, 64.27, 63.34, 58.22, 58.14, 34.08, 
33.85, 32.21, 32.05, 26.92, 26.74, 24.88, 20.97, 20.91, 20.83, 20.64, 20.97, 20.92, 20.83, 20.64, 
18.63, 18.61, 14.15 
IR  (ATR) 
3083, 2866, 1721, 1644, 1245, 1055, 981 cm-1  
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C14H25O3 241.1798, found 241.1838 
TLC 
Rf = 0.3 10% ethyl acetate in hexanes [silica gel, p-anisaldehyde stain]  
(E)-2,4-dimethyl-7-oxohept-2-en-1-yl acetate (3.85). To a 
flame dried, 50 mL round bottom flask containing a stir bar was 
added epoxide 3.84 (0.502 g, 2.02 mmol) dissolved in THF (10 mL).  The reaction was cooled to 
0°C using an ice bath and placed under argon.   H5IO6 (0.915 g, 4.03 mmol) dissolved in THF (5 
mL) was added dropwise via syringe.  The reaction was allowed to warm to room temperature and 
stirred for 2 hours.  The reaction was (slowly) quenched with saturated aqueous NaHCO3 (5 mL), 
then the mixture was transferred to a separatory funnel and extracted with diethyl ether (3 x 20 
mL).  The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure.  The resulting oil was purified by silica gel column chromatography (Rf = 0.25, 
10% ethyl acetate in hexanes) to give aldehyde 3.85 (0.227 g, 1.15 mmol, 56%, E:Z 5.5:1) 
Data for 3.85 
AcO O
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Optical Rotation  (c = 0.9, CHCl3) 
[α]25D = +21.0 
1H NMR  (400 MHz, CDCl3) 
δ 9.77 (bt, 1H, Z isomer), 9.75 (bt, 1H, E isomer), 5.18 (d, J = 9.7 Hz, 1H, E isomer), 5.11 (d, J = 
10.1 Hz, Z isomer), 4.58-4.52 (m, 2H, Z isomer), 4.47-4.42 (m, 2H, E isomer), 2.48-2.36 (m, 3H), 
2.08 (s, 3H, E isomer), 2.07 (s, 3H. Z isomer),  1.79-1.65 (m, 1H), 1.64 (s, 3H, E isomer), 1.60-
1.47 (m, 1H), 1.00-0.98 (m, 3H) 
13C NMR (100 MHz, CDCl3) 
δ  202.40, 202.34, 170.86, 135.92, 134.24, 130.03, 129.84, 69.92, 63.20, 42.02, 41.95, 31.97, 
31.74, 29.48, 29.37, 21.49, 21.35, 20.97, 20.89, 20.76, 14.15 
IR  (ATR) 
3079, 2721, 1752, 1731, 1043, 991 cm-1  
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C11H19O3 199.1329, found 199.1334 
TLC 
Rf = 0.20 10% ethyl acetate in hexanes [silica gel, p-anisaldehyde stain]  
 
 
 
AcO O
3.85
OSiEt3
OSiEt3
Cl
3.45
1) Cr Cat. B 4 Å sieves
2) CH2Cl2, DDQ
3) TsOH•Η2Ο
61%
AcO
O
O
O
Cl
H
H
+
AcO
O
O
O
Cl
H
H
DMF, NaN3, K2CO3
HO
O
O
O
N3
H
H
79%
N
O
O
Ad
Cr Cl
B
7 Steps
3.86
3.86
3.77
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(4S,E)-6-((2R,8R,9S)-8-(3-chloropropyl)-9-methyl-4-oxo-1,7-
dioxaspiro[5.5]undecan-2-yl)-2,4-dimethylhex-2-en-1-yl acetate 
(3.86). A flame dried 10 mL Schlenck tube containing a stir bar was 
charged with Cr catalyst B (0.030 g, 0.060 mmol) and 4 Å molecular sieves (0.050 g) then sealed 
and back filled with Ar (3x).  Aldehyde (0.303 g, 1.53 mmol) was added via syringe and the 
reaction was allowed to stir for 5 minutes, then diene 3.45 (0.203 g, 0.44 mmol) was added via 
syringe and the reaction was allowed to stir for 3 days.  An additional aliquot of aldehyde 3.85 
(0.101 g, 0.51 mmol) was added via syringe and the reaction was allowed to stir another 3 days.  
The reaction was diluted with CH2Cl2 (5 mL) then 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
(0.0990 g, 0.44 mmol) was added.   The reaction was stirred for 1 hour, then TsOH-H2O (0.151 g, 
0.880 mmol) was added.  The reaction was stirred for 2 hours then was quenched with NEt3 (1 
mL) and filtered through a silica plug eluting with a copious amount of ethyl acetate.  The filtrate 
was concentrated under reduced pressure, then purified by silica gel column chromatography (Rf 
= 0.4, 20% ethyl acetate in hexanes) to give acetate 3.86 (0.112 g, 0.261 mmol, 61% yield) 
Data for 3.86 
Optical Rotation  (c = 0.14, CHCl3) 
[α]25D = +14.3 
1H NMR  (500 MHz, CDCl3) 
δ 5.25 (d, 1H, J = 9.5 Hz), 4.47 (s, 2H), 3.76-3.72 (m, 1H), 3.57-3.47 (m, 2H), 3.15 (td, 1H, J = 
2.45, 9.55 Hz), 2.43-2.40 (m, 1H), 2.38 (s, 2H), 2.34 (dd, 1H, J = 14.05, 2.00 Hz),  2.19 (dd, 1H, 
J = 14.05, 11.3, Hz), 2.08 (s, 3H), 1.99-1.92 (m, 1H), 1.87-1.74 (m, 3H), 1.66 (d, 3H J = 1Hz), 
1.59-1.32 (m, 7H), 0.99 (d, 3H, J = 6.65), 0.87 (d, 3H, J = 6.55 Hz)  
O
O
H
H
O
Cl
OAc
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 13C NMR (100 MHz, CDCl3) 
δ 205.97, 170.91, 135.40, 129.24, 98.94, 75.30, 70.21, 68.74, 51.84, 47.15, 45.48, 35.31, 33.95, 
33.88, 33.03, 32.08, 30.29, 28.52, 27.89, 21.01, 20.82, 17.77, 14.19   
IR  (ATR) 
3211, 2901, 1749, 1701, 1622, 1501, 1352, 1289, 1247, 1091, 1032, 989, 652  
HRMS  (FTMS ES+) 
[M+H]+ Calculated for C23H38O5Cl 429.2402, found 429.2423 
TLC 
Rf = 0.40 20% ethyl acetate in hexanes [silica gel, p-anisaldehyde stain] 
One Pot Acetate Deprotection/Chloride Displacement Deprotection Protocol 
To a flame dried, 1 dram vial mL containing stir bar was added compound 3.86 (10 mg , 
0.026 mmol) in DMF (1 mL) and MeOH (0.1 mL). K2CO3 (25 mg, 0.18 mmol) and Sodium azide 
(30 mg, 0.46 mmol) was added in a single portion and the reaction was sealed then heated to 50°C 
and stirred overnight.  The reaction was cooled to room temperature, then diluted with H2O and 
extracted with diethyl ether (3x).  The combined organic layers were dried over Na2SO4, filtered, 
and concentrated under reduced pressure.  The resulting residue was purified by silica gel column 
chromatography (Rf = 0.50, 20% ethyl acetate in hexanes) to give azide 3.77 (8.0 mg, 0.023 mmol, 
79%). 
Cell culture. Experiments were performed using A549 (ATCC) cells cultured in Dulbecco’s 
Modified Eagle Medium (DMEM; Gibco). All media was supplemented with 10% Fetal Bovine 
Serum (FBS; Sigma-Adrich) and 5% penicillin/streptomycin (VWR) and maintained at 37 °C in a 
5% CO2 atmosphere. Cell line is tested for mycoplasma contamination every three months. 
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Cell viability assays. A549 cells were seeded at 500 cells per well in white, clear-bottom, 
384-well plates (Greiner). After overnight incubation, cells were treated with increasing 
concentrations of compounds or a DMSO control (0.1% DMSO final concentration) in triplicate 
followed by incubation for an additional 48 h. After incubation, cell viability was measured using 
a luminescence-based kit (CellTiter-Glo, Promega) according to manufacturers protocol. 
Luminescence was measured using a Tecan M1000 plate reader. To determine growth inhibition, 
cell viability assays were performed at the time of initial treatment (T0) and after 48 h incubation 
(T48). Data was normalized to DMSO control (C) and growth inhibition (GI) was calculated using 
the equation GI = (T48 - T0)/(C - T0). Data was fit to a sigmoidal plot using GraphPad Prism in 
order to determine GI50 values. Errors bars represent standard deviations from three independent 
experiments.     
Fluorescent visualization of actin in cells. A549 cells were seeded at 10,000 cells per 
well in black, clear-bottom, 96-well plates (Greiner). After overnight incubation, cells were treated 
with either DMSO control (0.1% DMSO) or 400 nM compound for 2 h. Following incubation, 
media was removed and cells were fixed with 5% formaldehyde in PBS buffer for 10 minutes at 
room temperature and permeabilized with 0.1% Triton X-100 in PBS buffer at room temperature 
for 20 minutes. After thorough washing with PBS buffer, cells were co-stained with Rhodamine 
Phalloidin (Invitrogen) and Hoechst 33342 (Sigma Aldrich) stains according to manufacturers 
protocols and visualized on an Axio Observer Z1 microscope (Zeiss).  
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APPENDIX C 
1H, 13C, an 11B NMR Spectra for 2.1  
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APPENDIX D 
1H and 13C NMR Spectra for 3.3 
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